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ABSTRACT 
 
Pneumocystis jirovecii is a significant contributor to the burden of disease in 
immunocompromised patients. The polymerase chain reaction (PCR) is more 
sensitive and specific than microscopy. Cotrimoxazole prophylactic breakthrough and 
treatment failures have been reported, and associated with mutations at codons 55 
and 57 of P. jirovecii dihydropteroate synthase (DHPS). No phylogenetic or 
population genetic models have been successful in elucidating P. jirovecii 
intraspecies strain relatedness.  
 
Aims: 1) Compare detection rates of nine PCR techniques and immunofluorescence 
microscopy (IF); 2) Determine the extent of co-infecting pathogens associated with 
Pneumocystis Pneumonia (PcP); 3) Determine local P. jirovecii ITS1-5.8S-ITS2 rDNA 
strain types, and model lineage evolution employing a coalescent-theory based 
statistical parsimony network analysis; 4) Investigate the possible emergence of 
cotrimoxazole-resistant strains  
 
Methods: PCR was evaluated on clinical specimens employing: ITS nested; DHPS 
single and nested; DHFR nested; major surface glycoprotein (MSG) heminested; 
mitochondrial large subunit rRNA (mtLSUrRNA) single and nested; 18S rRNA one-
tube nested, and real-time 5S rRNA PCR. Retrospective analysis of co-infecting 
pathogens seen in PcP patients was conducted. ITS regions were amplified, cloned 
and sequenced. Statistical parsimony was applied for coalescence based network 
genotype analysis. DHPS genome walking was attempted and DHPS and DHFR 
primer annealing sites explored. Amplified DHPS and DHFR genes were cloned and 
sequenced. 
 
Results: Most sensitive PCR technique was mtLSUrRNA nested followed by 5S real-
time PCR. A poor correlation exist between mtLSUrRNA PCR and IF. Review of 
clinical records suggested a high rate of false-positive IF results. P. jirovecii was 
detected in 4.3% M. tuberculosis-positive HIV-positive, and 2.5% M. tuberculosis-
positive HIV-negative patients. P. jirovecii was detected in 45% HIV-negative 
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patients. The most prevalent ITS type was Eg. Four new combinations: Eo, Je, Ge, 
No; 11 new ITS1 and 13 new ITS2 sequences were identified. A new ITS2 type was 
detected in three patients and designated u. More than one strain type was detected 
in 15/19 patients. Analysis of 5.8SrDNA region revealed 13 clones containing 1-2 
nucleotide polymorphisms. Of 85 mtLSUrRNA PCR-positive specimens, currently 
employed primers amplified DHPS and DHFR genes from 53 and 27 specimens, 
respectively. Newly designed DHPS primers increased detection in 3 / 28 previously 
DHPS-negative mtLSUrRNA-positive specimens. Of 56 DHPS genes amplified and 
sequenced, one contained the double mutation (Thr55Aa; Pro57Ser). DHFR 
Ala67Val was detected in three specimens and a new DHFR genotype (Arg59Gly; 
C278T) was demonstrated.   
 
Conclusions: The study emphasises the need to evaluate PCR primers against local 
strains. It is recommended that mtLSUrRNA PCR be performed in parallel to IF and 
discordant results resolved with clinical evaluation. Co-infection with P. jirovecii and 
M. tuberculosis occurs in South Africa, and treatment for both pathogens is 
recommended when demonstrated by the laboratory. ITS genotyping employing 
statistical parsimony network analysis suggests type Eg as major ancestral 
haplotype, and supports recombination contributing to strain diversity worldwide. 
DHPS mutations may signal emergence of resistance to cotrimoxazole in South 
Africa, however, low sensitivity of primers limits surveillance efforts. 
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OPSOMMING 
 
P. jirovecii dra grootendeels by tot die morbiditeit van imuunonderdrukte pasiënte. 
Die polimerase ketting reaksie (PKR) is meer sensitief en spesifiek as mikroskopie. 
Mutasies in dihidropteroaat sintase (DHPS) by kodons 55 en 57, word geassosieer 
met deurbraak van profilakse en onsuksesvolle behandeling met cotrimoxazole. 
Geen filogenetiese of populasie genetiese modelle was al suksesvol om P. jirovecii 
intraspesie verwantskappe aan te toon nie. 
 
Doelwitte: 1) Vergelyk die deteksie syfers van nege PKR tegnieke en 
immunofluoressensie mikroskopie (IF); 2) Bepaal die omvang van ko-infektiewe 
patogene op Pneumocystis pneumonie; 3) Bepaal die plaaslike P. jirovecii ITS1-
5.8S-ITS2 rDNA stam tipes, en ontleed dié evolusie deur samevloei gebaseerde 
statistiese enkelvoudige netwerk analise; 4) Ondersoek die moontlike ontwikkeling 
van cotrimoxazole weerstandbiedendheid. 
 
Metodes: PKR was ge-evalueer op kliniese monsters deur: ITS dubbel; DHPS 
dubbel en enkel; DHFR dubbel; MSG halfdubbel; mtLSUrRNA enkel en dubbel; 18S 
rRNA enkelbuis dubbel; en in-tyd 5S rRNA PKR. Ko-infektiewe patogene was 
retrospektief beskryf. ITS gebiede was geamplifiseer, gekloneer en onderwerp aan 
DNA volgorde bepaling. Statisties enkelvoudige samevloei gebaseerde netwerk 
genotiep analise was onderneem. DHPS genomiese wandeling was onderneem en 
DHPS en DHFR peiler aanhegtings ondersoek. Geamplifiseerde DHPS en DHFR 
gene was gekloneer en DNA volgordes bepaal. 
 
Resultate: Die mees sensitiewe PKR tegniek was mtLSUrRNA dubbel, gevolg deur 
5S in-tyd PKR. ŉ Swak korrelasie was gesien tussen mtLSUrRNA PKR en IF. 
Ondersoek van kliniese verslae het ŉ hoë voorkoms van fals positiewe IF resultate 
getoon. P. jirovecii was opgespoor in 4.3% M. tuberculosis-positiewe MIV-positiewe, 
en 2.5% M. tuberculosis-positiewe MIV-negatiewe pasiënte. P. jirovecii was 
geïdentifiseer in 45% MIV-negatiewe pasiënte. Die mees prevalente ITS stam tipe 
was Eg. Vier nuwe kombinasies: Eo, Je, Ge, No; 11 nuwe ITS1 en 13 nuwe ITS2 
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tipes was geïdentifiseer. ŉ Nuwe ITS2 tipe, genoem “u”, was ontdek in drie pasiënte. 
Meer as een ITS stam tipe was opgespoor in 15/19 pasiënte. Dertien nuwe 
5.8SrDNA DNA volgordes was ontdek. DHPS was geamplifiseer uit slegs 53/85 
mtLSUrRNA-positiewe monsters. So ook was DHFR uit slegs 27/85 mtLSUrRNA-
positiewe monsters geamplifiseer. Drie van 28 monsters wat mtLSUrRNA-positief 
maar DHPS-negatief was, is deur nuwe DHPS peilers geamplifiseer. Van 56 DHPS 
gene is slegs een monster met die dubbel mutasie (Thr55Ala; Pro57Ser) 
geïdentifiseer. Die DHFR Ala67Val mutasie was in drie pasiënte geïdentifiseer. ŉ 
Nuwe DHFR genotipe (Arg59Gly; C278T) was ontdek. 
 
Gevolgtrekkings: Hierdie studie beklemtoon die noodsaaklikheid om PKR peilers 
teen plaaslike stamme te ondersoek. Dit word aanbeveel dat mtLSUrRNA PKR saam 
met IF uitgevoer word, en dat onversoenbare resultate deur kliniese gegewens beslis 
word. Ko-infeksie van P. jirovecii en M. tuberculosis kom voor en behandeling vir 
albei patogene word aanbeveel indien dit deur die laboratorium aangedui word. ITS 
genotipering en aanwending van statistiese enkelvoudige netwerk analise dui aan 
dat Eg die hoof voorganger stam tipe is. Die analise ondersteun die voorkoms van 
rekombinasie wat kan bydra tot stam diversiteit. Die identifisering van DHPS 
mutasies verteenwoordig die ontwikkeling van weerstandbiedendheid tot 
cotrimoxazole in Suid-Afrika, maar die lae sensitiwiteit van huidige peilers beperk die 
ondersoek daarvan. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
_______________________________ 
 
1.1  PNEUMOCYSTIS JIROVECII PATHOGENESIS AND  EPIDEMIOLOGY 
 
1.1.1 Historical overview 
 
The first description of what turned out to be Pneumocystis was by Carlos Ribeiro 
Justiniano Chagas [Chagas, 1909, cited in Dutz, 1970]. In 1909, while working at the 
Oswaldo Cruz Institute, Rio de Janeiro, he investigated a new disease of railroad 
workers which was subsequently called Chagas’ disease. While working on this 
disease Chagas, as part of his investigations, examined the lungs of a 3-month-old 
child and described what he thought was the sexual form (schizont) of 
Schizotrypanosoma, containing 8 ‘leishmanial’ bodies within one capsule [Chagas, 
1909, cited in Dutz, 1970]. Subsequent investigations of rats, monkeys and other 
free-living species in Africa and South America initially confirmed Chagas’ findings of 
the presence of this so-called schizont of Schizotrypanosoma [Carini, et al., 1910, 
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cited in Dutz, 1970]. Slides of infected material were requested by Mesnil and 
Laversan at the Institute Pasteur in Paris, from Carini at the Institute Pasteur in 
Brazil.  At the Paris Instritute, Dr. and Mrs. Delanoe reviewed Carini’s slides, and 
together with their own investigations on sewer rats at the time, concluded in 1912 
that the entity identified as a sexual form of Schizotrypanosoma was in fact an 
entirely different organism. As they received their original slides from Carini they 
proposed the name Pneumocystis carinii [Delanoe & Delanoe, 1912, cited in Dutz, 
1970]. Maciel and Carini confirmed this [Carini & Maciel, 1914, cited in Dutz, 1970], 
so did Chagas who withdrew his original claim of the reported schizont [Chagas, 
1913, cited in Dutz, 1970]. However, the question of human pathogenicity of 
Pneumocystis carinii rested for a generation. 
 
In 1938 Ammich differentiated a plasmacellular pneumonia from the conventional 
“pneumonia alba” and “syphilitic lung”, with peculiar honeycombed exudates in the 
alveoli [Ammich, 1938, cited in Dutz, 1970]. This type of pneumonia was associated 
with P. carinii for the first time in 1942 in the Netherlands by Van der Meer and Brug, 
however, an aetiologic relationship was not established [van der Meer & Brug, 1942, 
cited in Dutz, 1970]. The first epidemics of Pneumocystis were reported in countries 
of central Europe in the late 1940’s where marasmic and premature infants in 
orphanages were infected [Vaněk & Jirovec, 1952, cited in Dutz, 1970]. It was from 
these epidemics that, in 1952, Jirovec and Vaněk established the aetiologic 
relationship of P. carinii / P. jirovecii (section 1.1.2) to interstitial plasmacellular 
pneumonia of premature or marasmic orphans. [Vaněk & Jirovec, 1952, cited in Dutz, 
1970]. The European orphanage epidemics abated when food rationing was 
abolished, and life returned to normal. However, after 1954, sporadic infections 
caused by Pneumocystis were reported from countries all over the world [Burke & 
Good, 1973]. The association of infections with Pneumocystis in 
immunocompromised patients became known in 1964 [Hill, et al., 1964], and by 1973 
a high index of suspicion of Pneumocystis infection was advised in the following 
categories of patients with pneumonia: premature infants, marasmic and 
malnourished children, patients with congenital immunodeficiency (humoral and cell 
mediated) or acquired immunodeficiency such as diseases related to malignancies, 
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immunosuppressive therapies (particularly adrenocorticosteroids, methotrexate), and 
transplant recipients [Burke & Good, 1973]. 
 
In the early 1980s reports of a syndrome characterized by opportunistic infections, 
uncommon in the general population emerged. This was the emergence of acquired 
immunodeficiency syndrome (AIDS). Pneumocystis pneumonia (PcP) became the 
most prevalent opportunistic disease in patients with AIDS, and lethal if not treated 
correctly [Gottlieb, et al., 1981; Anon., 1983]. In 1983 PcP was responsible for the 
death of the first two patients diagnosed with AIDS in South Africa [Ras, et al., 1983]. 
Since the introduction of highly active antiretroviral therapy (HAART) the incidence of 
PcP in the developed world seems to be declining, however, in the developing world 
it is on the increase.  
 
 
1.1.2 Taxonomy 
 
Classification of the organism was debated for many years. The proponents for 
protozoa argued that the structure of the merozoites, inability to grow on fungal 
media, absence of ergosterol, clinical response to antiprotozoan drugs such as 
pentamidine, and insensitivity to antifungal agents indicated that it was a protozoan 
[Dutz, 1970]. The proponents of the fungal theory based their arguments on staining 
characteristics and electron microscopic appearance of the capsule [Dutz 1970]. 
Most authors considered Pneumocystis to be a protozoan until 1988. Phylogenetic 
analysis of the 16S, 5.8S and 26S ribosomal RNA (rRNA) and other gene sequences 
revealed Pneumocystis to be a member of the Fungi [Edman, et al., 1988; Liu, et al., 
1992] and related to the Ascomycetes with its nearest extant relative being 
Scizosaccharomyces pombe [Ma, et al., 2001; Cushion, 2004]. However, analysis of 
the 5S rRNA placed Pneumocystis closer to the Amoeba or Myxomycota, rather than 
Ascomycota [Watanabe, et al., 1989]. Pneumocystis also possesses a fungal 
characteristic in that the dihydrofolate reductase (DHFR) gene is neither physically 
nor genetically linked to thymidylate synthase (TS). Absence of the bifunctional 
DHFR-TS supports the fungal argument as protozoa have the bifunctional enzyme 
CHAPTER 1  INTRODUCTION 
_________________________________________________________________ 
 
4
[Edman, et al., 1989b]. It is now widely accepted that Pneumocystis is classified 
within the Fungal kingdom [Edman, et al., 1988; Liu, et al., 1992; Ma, et al., 2001]. 
  
Pneumocystis has been identified in a variety of mammals including old and new 
world monkeys, rodents, domestic dogs, and lagomorphs [Botha & van Rensburg, 
1979; Guillot, et al., 1999; Laakkonen, et al., 1999; Furuta, et al., 2001; Guillot, et al., 
2001; Laakkonen, et al., 2001; Hugot, et al., 2003]. As isolates from different host 
species appeared stenoxenic and failed to cross-infect different hosts [Durand-Joly, 
et al., 2002], it prompted classification to be based on the host species. Thus came 
about the trinomial nomenclature such that Pneumocystis carinii was divided into 
“formae speciales” or f. sp. followed by an indication of the host species: P. carinii f. 
sp hominis for the human derived pathogen, P. carinii f. sp carinii and P. carinii f. sp 
ratti, both for distinct rat isolates. This was done in accordance to the International 
Code of Botanical Nomenclature (since the realisation of it being a fungus) [Anon, 
1994]. With the progress in genetic analysis of these special forms, it was decided 
that the isolates from the various host species differ from one another sufficiently to 
warrant the award of species status to the host specific isolates [Stringer, et al., 
1997; Stringer, et al., 2001]. Because the Czech parasitologist Otto Jirovec was 
credited for associating Pneumocystis with plasmacellular pneumonia [Vaněk & 
Jirovec, 1952, cited in Dutz, 1970], the human pathogen is now named P. jirovecii 
and one of the two distinct rat isolates retained the name P. carinii in recognition of 
Carini’s original work [Stringer, et al., 2002; Cushion, 2004]. P. jirovecii has been in 
published use since 1999 [Frenkel, 1999; Stringer, et al., 2002] and its continuation 
will be decided in 2005 at a conference to be convened by the International Code of 
Botanical Nomenclature. For the purposes of international conformity, the name P. 
jirovecii will be used throughout this dissertation. 
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1.1.3  Life cycle and pathogenesis 
 
Three morphologic stages of Pneumocystis have been observed in the mammalian 
lung: the primary proliferative form is known as the trophic stage and the intermediary 
between the trophic form and the cyst is the precyst. Haploid trophic forms can 
undergo either binary fission to yield more haploid daughter cells, or such haploid 
trophic forms can mate, resulting in diploid trophic forms. Synaptonemal complexes 
have been observed in these diploid stages and suggest meiosis. Such meiotic 
divisions (two meiotic cycles) lead to the formation of a precyst that undergoes 
mitosis, with the resultant eight haploid spores contained in a cyst. Spores actively 
exit the cyst (spore case), and continue the cycle [Yoshida, et al., 1989; Cushion, et 
al., 1997; Cushion, 2004]. 
 
P. jirovecii  trophic forms attach to type I alveolar epithelial cells. The Pneumocystis 
major surface glycoprotein (MSG) binds to fibronectin [Nakamura, et al., 1998] and 
epithelial cell surface glycoproteins via a mannose-dependent mechanism [Limper, et 
al., 1991]. Vitronectin and laminin bind in a similar manner [Limper, et al., 1993]. As 
the infection evolves and progresses, the alveolar-epithelial membrane barrier 
becomes disrupted, resulting in epithelial cell death [Nakamura, et al., 1998]. In 
addition, Pneumocystis releases degradative enzymes such as serine proteases that 
add to cellular disruption [Breite, et al., 1993]. The result of the tissue destruction is a 
reduced forced vital capacity, forced expiratory volume in one second, and diffusing 
capability for carbon monoxide [Nelsing, et al., 1995]. Pathogenesis is enhanced by 
type II alveolar epithelial cells as they secrete surfactant proteins (particularly 
surfactant protein A) which bind to MSG and in so doing mask Pneumocystis 
antigens from immunological recognition [Sternberg, et al., 1993]. 
 
 
1.1.4 Clinical disease manifestations 
 
P. jirovecii infection in debilitated infants presents with an interstitial plasma cell 
pneumonia. The disease begins insidiously with symptoms of poor feeding and 
CHAPTER 1  INTRODUCTION 
_________________________________________________________________ 
 
6
progresses gradually to overt respiratory distress and cyanosis. In the compromised 
adult patient PcP is associated with shortness of breath, fever, and a nonproductive 
cough. Sputum is produced occasionally but haemoptysis is rare. PcP in human 
immunodefiency virus (HIV)-positive patients usually occurs as a more subtle disease 
with symptoms lasting weeks to months before acute disease presents. On physical 
examination of patients with PcP, tachypnoea and tachycardia is found in the 
severely ill. Children may become cyanosed with flaring of the nasal alae. 
Radiologically a diffuse bilateral infiltrate is observed extending from the perihilar 
regions [Walzer, 2000]. Clinical presentation differs between HIV-positive and –
negative patients. PcP in HIV-negative patients has been associated with a shorter 
duration of symptoms (5 days vs. 28 days), the patients are more likely to be febrile 
(92% vs. 76%), have a higher median respiratory rate (30 vs. 23.4 breaths/min), 
lower median room arterial oxygen tension (52 vs. 69 mmHg), and a higher room air 
alveolar-arterial oxygen gradient (59 vs. 41 mmHg) [Kovacs, et al., 1984]. 
 
 
1.1.5  Epidemiology 
 
The environmental reservoir of P. jirovecii has not been identified; however questions 
have been raised concerning possible human carriers as the reservoir. Employing 
DNA amplification techniques, P. jirovecii has been detected in some 10% - 51% of 
HIV-positive and 5.8% - 32% of HIV-negative patients without clinical evidence of 
pneumonia [Nevez, et al., 1997; Nevez, et al., 1999b; Sing, et al., 1999; Hauser, et 
al., 2000; Nevez, et al., 2001; Vargas, et al., 2001; Wakefield, et al., 2003; Morris, et 
al., 2004]. In addition to these sensitive techniques, P. jirovecii have been detected 
by immunofluorescence in post mortem lung biopsies of HIV-positive and –negative 
patients diagnosed with diseases other than pneumonia. [Nevez, et al., 1999a]. 
Vargas et al. reported detecting P. jirovecii DNA in 24 of 74 HIV-negative infants 
presenting with upper or lower respiratory tract infections (excluding PcP), implicating 
infants as a reservoir in the transmission cycle [Vargas, et al., 2001]. Further 
implication of infants has been the detection of P. jirovecii DNA in 25% of 
immunocompetent infants presenting with bronchiolitis [Nevez, et al., 2001]. Patients 
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with cystic fibrosis may also add to the human reservoir pool as 7.5% have had P. 
jirovecii DNA detected by the polymerase chain reaction (PCR) [Sing, et al., 2001]. 
However, HIV-positive patients seem to have the highest rates of colonisation (42 / 
91); HIV-positive patients from San Francisco and Cincinnati appear to be at greater 
risk for carriage compared to similar patients in Los Angeles, suggesting a 
geographic association with risk of colonisation [Morris, et al., 2004]. Molecular 
epidemiologic studies have indicated that P. jirovecii strains identified in adults with 
active PcP can be found a) in paediatric PcP patients and b) as transient colonisers 
in immunocompetent infants; again lending support to the possibility that infants may 
constitute a major reservoir of infectious Pneumocystis [Totet, et al., 2003a; Totet, et 
al., 2003b]. 
 
The precise mode of transmission and infectivity of P. jirovecii is not clear. There 
have been reports of transmission of P. jirovecii from a mother to her 4.5-week-old 
infant [Miller, et al., 2002] and from PcP patients to health care workers [Vargas, et 
al., 2000; Miller, et al., 2001]. These, and reports of outbreaks in transplant units, 
suggest possible airborne transmission of the fungus [Hennequin, et al., 1995]. 
Analysis of rural air by spore traps in rural Oxfordshire (far removed from hospitals or 
laboratories), air samples collected from animal facilities housing P. carinii-infected 
rats, air filtrations collected in wards housing PcP patients, and air samples collected 
in ward corridors 25m from the patient rooms have yielded DNA of P. carinii, P. ratti 
and P. jirovecii [Wakefield, 1996; Ollson, et al., 1998]. Studies on the survival and 
infectivity of P. carinii have established that the airborne form of the fungus trapped in 
airblower prefilters retains viability and infectivity for at least 5 months between -80 
ºC and room temperature. It was suggested that at least one life cycle stage of P. 
carinii is dormant and survives outside the mammalian host, and that infection can be 
initiated by a form that remains viable and infective for long periods in the 
environment [Kaneshiro & Maiorano, 1996]. 
  
Seroepidemiological investigations in the USA and Chile have shown that more than 
85% of infants under 2½ years of age have antibodies to Pneumocystis, 20% of 
whom had no evidence of clinical disease [Peglow, et al., 1990; Vargas, et al., 2001]. 
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Serologic studies have shown that Pneumocystis has a worldwide distribution 
although prevalence to specific antigens has geographic variability [Smulian, et al., 
1993]. 
 
With the emergence of AIDS, P. jirovecii has become the most prevalent pulmonary 
pathogen and causes the most common life-threatening infection (52% primary 
diagnoses) in these patients [Anon., 1983]. Even with the introduction of highly active 
antiretroviral therapy (HAART) and chemoprophylaxis P. jirovecii remains a major 
cause of infection in immunocompromised patients in industrialised countries 
[Wallace, et al., 1997; Calderón, et al., 2004], accounting for up to 35% of all cases of 
pneumonia in HIV-positive patients admitted to hospital  [Rimland, et al., 2002]. 
 
PcP in AIDS patients in Africa was initially described as being rare [Elvin, et al., 
1989]. Total absence or incidences of less than 10% have been reported [Elvin, et 
al., 1989; Carme, et al., 1991; Abouya, et al., 1992]. Based on these findings 
recommendations were made to stop cotrimoxazole prophylaxis in HIV-positive 
patients in Cote d’Ivoire [Abouya, et al., 1992]. Either through advances in diagnostic 
strategies or a real increase in incidence, recent reports claim a much higher 
incidence of PcP, particularly in HIV-positive children. Since 1999, incidence rates in 
HIV-positive patients of between 43% and 48% have been reported from African 
studies. [Mahomed 1999, et al.; Ruffini, et al., 2002].  
 
 
1.1.6 Co-infection 
 
Worldwide, PcP and pulmonary tuberculosis (TB), caused by Mycobacterium 
tuberculosis, are the primary lung infections associated with HIV. Their respective 
prevalence, however, varies geographically. P. jirovecii is the most frequent cause of 
opportunistic pneumonia in the USA and Europe, while M. tuberculosis seems to be 
the main pulmonary pathogen in African HIV-positive patients [Orlovic, et al., 2001]. 
Dual pulmonary infections with these pathogens have been reported in up to 66% of 
cases from Africa [Atzori, et al., 1993]. It has been suggested that a surprisingly high 
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frequency of such co-infections may occur in TB hyper-endemic areas [Orlovic, et al., 
2001].  Orlovic et al. reported the co-existence of PcP and TB in 9.9% of induced 
sputum specimens obtained from HIV-positive patients [Orlovic, et al., 2001]. 
Similarly, Aderaye et al. reported the detection of P. jirovecii in Ethiopian patients 
with proven TB in 13.5% HIV-positive and 4.3% HIV-negative patients, respectively. 
These investigators reported a prevalence of PcP in 30.3% of HIV-positive patients 
with suspected TB [Aderaye, et al., 2003]. 
 
Earlier reports of low incidences of PcP in African countries may have been the result 
of a low index of suspicion, and poor laboratory techniques. Clinical differentiation 
between PcP and TB can be difficult as the clinical presentation and radiological 
appearances may be similar [Hargreaves, et al., 2001; Rennert, et al., 2002]. Malin et 
al. reported pulmonary tuberculosis to be the diagnosis most frequently given to HIV-
infected patients with abnormal chest radiography findings consistent with PcP 
[Malin, et al., 1995].  
 
In addition to TB, rates of co-infection with other pathogens range from 20 – 70% 
[McLeod, et al., 1989; Hsiao, et al., 1997]. It has been reported that patients with PcP 
living in developing countries are at high risk of developing co-infections with various 
pathogens, notably Cytomegalovirus (CMV), Streptococcus pneumoniae, 
Staphylococcus aureus, and Cryptococcus neoformans [McLeod, et al., 1989; Hsiao, 
et al., 1997].  
 
 
1.2 LABORATORY DIAGNOSIS 
 
1.2.1 Microscopic detection 
 
Culture confirmation of the presence of P. jirovecii is still not possible and diagnosis 
relies on the microscopic detection of the cysts or trophic forms of the fungus in 
respiratory fluids such as bronchoalveolar lavage fluids (BAL), tracheal aspirates, 
induced sputum or from tissues obtained from transbronchial or open lung biopsies. 
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Staining techniques can be classified as either specific for the sporecase wall such 
as methenamine silver, immunofluorescence and calcofluor white, and stains that are 
specific for the trophic forms such as Giemsa and Diff-Quick [Blumenfeld, et al., 
1988; Beselski, et al., 1990]. Grocott’s methenamine silver stain has traditionally 
been used to identify the cystic stage while Giemsa is used to stain the trophic stage. 
These staining techniques are inherently nonspecific. Newer generation stains such 
as Diff-Quick and Fungifluor have a higher specificity than the older generation stains 
[Procop, et al., 2004] but immunofluorescence (IF) has subsequently increased the 
specificity and sensitivity of diagnostic staining [Stratton, et al., 1991; Alvarez, et al., 
1997]. Besides the lack of sensitivity and specificity of staining techniques, these 
tests have other inadequacies such as inability of a single stain to detect all the 
morphologic stages of the fungus, and observer skill. In addition, it has been shown 
that staining procedures, which rely on the presence of the cyst wall, lack the ability 
to differentiate viable cysts from cysts that are empty remnants after successful 
antibiotic treatment or clearance [Leigh, et al., 1993; Roux, et al., 1994; Armbruster, 
et al., 1995; Liebovitz, et al., 1995]. Immunofluorescent stains are unable to identify 
trophic stages of the fungus that lack the antigens present on the cyst wall [Leigh, et 
al., 1993]. It has been shown that staining methods specific for the cyst wall are not 
effective when patients are treated with inhaled pentamidine because the structure of 
the organism may be changed and are therefore missed  [Armbruster, et al., 1995].  
 
 
1.2.2  Polymerase chain reaction 
 
Early diagnosis of PcP in immunocompromised patients, a life threatening 
complication if not treated correctly, may lower associated morbidity and mortality. 
The PCR has been reported to be superior in the detection of P. jirovecii as it has 
been shown to be more sensitive (104 – 106 times as sensitive) and more specific 
than staining methods [Leigh, et al., 1993]. A number of reports have been published 
on the PCR for the detection of P. jirovecii in clinical samples [Wakefield, et al., 
1990a; Wakefield, et al., 1990b; Kitada, et al., 1991; Tamburrini, et al., 1993; Honda, 
et al., 1994; Lee, et al., 1994; Chouaid, et al., 1995; Moonens, et al., 1995; Skøt, et 
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al., 1995; Mathis, et al., 1997; Rabodonirina, et al., 1997; Ribes, et al., 1997; Huang, 
et al., 1999; Sandhu, et al., 1999; Sing, et al., 2000; Torres, et al., 2000; Helweg-
Larsen, et al., 2002; Kasolo, et al., 2002; Lishimpi, et al., 2002]. The major 
advantages of the PCR are the ability to detect low numbers of organisms 
(sensitivity) and method specificity. Studies have indicated that the PCR can rapidly 
convert from positive to negative once specific treatment for PcP is initiated, and 
could be a good indicator of treatment response. Pertaining to this, anomalous 
results were demonstrated on comparing IF with PCR [Armbruster, et al., 1995]. 
 
The first report of a PCR for clinical detection of P. jirovecii in BAL was by Wakefield 
et al., who employed primers directed at the mitochondrial large subunit ribosomal 
RNA (mtLSUrRNA) [Wakefield, et al., 1990a]. The sensitivities of various PCR 
techniques have been reported to be very high, with detection limits for a single 
round PCR reported as 0.5 – 10 cysts / reaction, and nested PCR 1 – 3 cysts / 
reaction, depending on the primers used [Tamburrini, et al., 1993; De Luca, et al., 
1995; Lu, et al., 1995; Rabodonirina, et al., 1997; Ribes, et al., 1997]. A number of 
loci on P. jirovecii chromosomes have been characterised and evaluated for potential 
PCR diagnostic purposes. They include: dihydropteroate synthase (DHPS), 
dihydrofolate reductase (DHFR), thymidylate synthase (TS), internal transcribed 
spacer regions of the rRNA (ITS), 5S rRNA, 18S rRNA, major surface glycoprotein 
(MSG), mitochondrial large subunit rRNA (mtLSUrRNA) and mitochondrial small 
subunit rRNA  (mtSSUrRNA) [Wakefield, et al., 1990a; Kitada, et al., 1991; 
Tamburrini, et al., 1993; Honda, et al., 1994; Lee, et al., 1994; Chouaid, et al., 1995; 
De Luca, et al., 1995; Moonens, et al., 1995; Lu, et al., 1995; Skøt, et al., 1995; Lane, 
et al., 1997; Mathis, et al., 1997; Rabodonirina, et al., 1997; Ribes, et al., 1997; 
Huang, et al., 1999; Sandhu, et al., 1999; Sing, et al., 2000; Torres, et al., 2000; 
Helweg-Larsen, et al., 2002; Kasolo, et al., 2002; Lishimpi, et al., 2002]. More 
recently real-time PCR has been described as being a sensitive and specific 
technique with the potential for quantitative analysis to differentiate colonisation from 
infection [Kaiser, et al., 2001; Palladino, et al., 2001; Larsen, et al., 2002a; Larsen, et 
al., 2002b; Larsen, et al., 2004]. On employing different PCR primers and gene 
targets varying sensitivities and specificities have been reported [De Luca, et al., 
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1995; Lu, et al., 1995]. Lu et al. investigated different PCR reactions targeting 6 
regions: ITS nested, 18S ribosomal RNA nested, mtLSUrRNA single, TS single, 5S 
rRNA single, and DHFR single. The nested PCR reactions (ITS and 18S rRNA) both 
yielded sensitivities of 100%, however, 18S rRNA PCR amplified DNA from 
Saccharomyces cerevisiae and Cryptococcus neoformans. Of the single round PCR 
reactions mtLSUrRNA yielded a sensitivity of 87%, TS 60%, 5S rRNA 33% and 
DHFR 23%. TS primers also amplified DNA from Candida albicans and C. 
neoformans. The reason for the varying sensitivity of the primers / targets was 
suggested to be target copy number and ease of denaturation [Lu, et al., 1995]. 
Huang et al. developed a heminested PCR targeting the multicopy MSG gene and 
reported superior sensitivity to that of mtLSUrRNA single PCR [Huang, et al., 1999]. 
For the various PCR methods, results indicate sensitivities ranging from 50% - 100% 
and specificities from 79.3% - 100% [De Luca, et al., 1995; Moonens, et al., 1995; 
Skøt, et al., 1995; Mathis, et al., 1997; Ribes, et al., 1997; Huang, et al., 1999]. 
 
Although PCR based methods are considered generally more sensitive and specific 
than staining, results may not be available for several hours. Cytochemical staining 
on the other hand does provide a rapid diagnosis. Recently, real-time PCR has been 
reported as being a rapid PCR technique with significantly reduced cycling times and 
without the need for post-amplification detection of amplicons by time-consuming 
agarose gel electrophoresis. A closed system is ensured and the risk of amplicon 
contamination dramatically reduced [Palladino, et al., 2001]. 
 
Real-time PCR studies employing P. jirovecii MSG directed primers have been 
associated with reports of sensitivities and specificities of between 88% - 100% and 
85% - 98.6%, respectively [Flori, et al., 2004; Larsen, et al., 2004]. Real-time PCR 
employing the DHFR gene primers have resulted in the detection of <5 copies of a 
DHFR-plasmid construct standard / tube [Larsen, et al., 2002b]. Quantitative 
interpretations have led to cut-off values being introduced in order to differentiate 
between colonisation and active infection [Larsen, et al., 2002b; Flori, et al., 2004; 
Larsen, et al., 2004]. Larsen et al., employing P. jirovecii MSG real-time PCR on oral 
washings suggested a cut-off value of 50 copies / tube; ≥50 copies being diagnostic 
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of active infection and <50 copies supportive of diagnosis but further investigations 
required [Larsen, et al., 2004]. Flori et al. however, suggested a cut-off value of 103 
copies / tube; >104 copies being diagnostic of infection with 103 – 104 considered a 
“grey zone” and <103 copies being considered chronic carrier / at an early stage of 
infection development [Flori, et al., 2004]. Both these studies, employing the same 
PCR targets (MSG) and their characteristic cut-off values, have been able to increase 
real-time PCR specificity values from 85% to 100% and from 84.9% to 98.6%, 
respectively [Flori, et al., 2004; Larsen, et al., 2004]. However, Flori et al. 
demonstrated for both mtLSUrRNA single-round standard PCR and MSG real-time 
PCR 100% sensitivity but 84.9% specificity for real-time PCR vs. 87% specificity for 
standard PCR [Flori, et al., 2004]. 
 
 
1.3 GENOTYPING AND COALESCENT PHYLOGENETIC ANALYSIS 
  
1.3.1  Strain typing 
 
To establish a genotyping technique to differentiate strains among infected 
individuals various genomic regions of P. jirovecii have been investigated for possible 
polymorphisms. Seven housekeeping genes have been investigated for potential use 
in strain typing. The TS gene showed no genetic diversity in 13 specimens collected 
from patients with PcP. However, this locus could be of use for differentiating strains 
from different hosts [Latouche, et al., 1997a]. 5S rRNA variations have been detected 
to the extent that 6 variants were obtained from 20 specimens collected from patients 
with PcP [Latouche, et al., 1997a]. The aromatic aminoacid synthesis (AROM) locus 
yielded only two nucleotide polymorphic positions and therefore has limited use for 
strain differentiation [Tsolaki, et al., 1998]. Similarly, the mtSSUrRNA yielded only few 
variants [Tsolaki, et al., 1998]. Single strand conformational polymorphism (SSCP) 
analysis of the β-tubulin and intron of the 26S rRNA genes displayed a limited 
number of patterns, again suggestive of low genetic diversity [Hauser, et al., 1997; 
Nahimana, et al., 2000]. MtLSUrRNA has been reported to have sufficient variation 
for strain typing [Lee, et al., 1993; Latouche, et al., 1997a; Tsolaki, et al., 1998]. Of 
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18 specimens collected from patients with PcP, 4 groups were identified and it was 
noted that more than one mtLSUrRNA type could be present per patient specimen 
[Latouche, et al., 1997a; Latouche, et al., 1997b; Tsolaki, et al., 1998]. The most 
informative locus displaying the highest degree of polymorphisms is the ITS, making 
it the most sensitive DNA region for detecting intraspecies biodiversity [Latouche, et 
al., 1997a; Latouche, et al., 1997b, Tsolaki, et al., 1998]. High degrees of strain 
diversity have been detected in many studies. Strain diversity, calculated as the 
number of different strains detected as a percent of the number of specimens 
analysed, has been reported to be between 27 % (4 strains / 15 specimens) and  
82 % (14 strains / 17 specimens) [Lu, et al., 1994; Tsolaki, et al., 1996; Latouche, et 
al., 1997a; Latouche, et al., 1997b, Lee, et al., 1998; Miller, et al., 1999; Atzori, et al., 
2001; Nevez, et al., 2001a; Volpe, et al., 2001; Matos, et al., 2003; Nevez, et al., 
2003].  
 
Typing, employing ITS nucleotide sequence variations, has become an important tool 
for epidemiological studies of PcP. Various authors have used different methods for 
naming ITS types, but Lee et al. constructively established a consensus ITS1 
sequence of 161 bp and ITS2 of 192 bp. Fifteen ITS1 sequevars were named with 
capitals A through O and fourteen ITS2 sequevars were named in lowercase a 
through n [Lee, et al., 1998]. 
 
Since ITS strain typing has been applied to P. jirovecii, globally prevalent types have 
been identified, along with investigations into geographical variations, distribution in 
infected lungs, recurrent infections, and strain transmissibility. ITS type Eg (23 – 86% 
prevalence) and Ne (11.6 – 56% prevalence) have been found to be the most 
prevalent types with a worldwide distribution [Tsolaki, et al., 1996, Lee, et al., 1998, 
Miller, et al., 1999, Tsolaki, et al., 1999; Helweg-Larsen, et al., 2001; Nimri, et al., 
2002; Matos, et al., 2003]. Types Be, Hh, Nb and Nc have only been detected in the 
USA [Lee, et al., 1998]. Types Ne and Na have been reported to be the most 
frequent types obtained from second and subsequent episodes of PcP and it was 
suggested that they could represent more transmissible or persistent strains [Miller, 
et al., 1999; Tsolaki, et al., 1999]. Uncertainty exists as to the genetic stability of the 
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ITS locus and whether presentation of PcP is due to reactivation of latent strains or 
de novo acquisition from the environment. Studies have reported the persistence of a 
specific type over short periods during the same episode of PcP, as well as 
persistence of the same type during subsequent episodes, suggesting either failure 
to clear the fungus or reacquisition of the same strain from the environment 
[Latouche, et al., 1997b; Tsolaki, et al., 1999]. These observations have been used to 
suggest that genotypes are stable in vivo and validate the reproducibility of the 
technique [Latouche, et al., 1997b]. However, apparent genotype switching (the 
detection of different genotypes at different time points during one episode of PcP) 
has been observed frequently [Tsolaki, et al., 1996; Helweg-Larsen, et al., 2001; 
Matos, et al., 2003]. Helweg-Larsen et al. reported genotype switching in 6 / 10 
patients with recurrent PcP and in 10 / 19 patients who had repeat bronchoscopy 
investigations within the same episode of PcP. It was noted that such genotype 
changes were found only in samples obtained after an interval of >6 days in the latter 
group [Helweg-Larsen, et al., 2001a]. Keely et al., on sequencing two distinct genes, 
the ITS regions encoded by nuclear chromosomes and the mtLSUrRNA gene located 
in the mitochondrion, reported that changes in the ITS types correlated to changes 
seen in the mtLSUrRNA. They concluded that the coincidence of changes in the 
sequence of these genes, one nuclear and the other mitochondrial encoded, 
excluded mutation as the cause of the genetic differences between P. jiroveci strains 
isolated during different episodes of PcP and supported the hypotheses that 
recurrent PcP is caused by re-infection rather than by reactivation of latent organisms 
[Keely & Stringer, 1997]. Co-infection with more than one ITS genotype per PcP 
episode has been demonstrated in up to 60% of specimens, 17% have been 
reported to harbour three genotypes, 3% four genotypes and one study found 2 / 207 
specimens containing 6 genotypes. [Lu, et al., 1994; Lee, et al., 1998, Tsolaki, et al., 
1998; Miller, et al., 1999; Tsolaki, et al., 1999; Nevez, et al., 2001a]. There seems to 
be a geographic tendency to co-infection frequency as 75% patients from Atlanta 
were seen to harbour significantly more strain co-infections than San Francisco 
(6.7%) and Seattle (8.3%) [Nimri, et al., 2002]. Finding multiple strains per PcP 
episode has been supported by genotyping employing different genes / techniques. 
Genotyping with mtLSUrRNA has also shown co-infection with different strains 
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[Latouche, et al., 1997a; Latouche, et al., 1997b, Tsolaki, et al., 1998]. In support of 
DNA sequence variation data as described above, Nahimana et al. and Hauser et al. 
using single strand conformational polymorphism (SSCP) of 4 genomic regions 
reported up to 65% of patients co-infected with different strain types [Hauser, et al., 
1997; Nahimana, et al., 2000]. Discrepancies have been detected on comparison of 
either ITS or mtLSUrRNA types obtained from post-mortem lung biopsies and other 
specimens [Atzori, et al., 2001]. In addition, compartmentalisation of mtLSUrRNA and 
ITS types were observed in discrete sections of lung, suggesting that it cannot be 
assumed a priori that from one specimen strain types are fully representative of the 
whole organ [Ambrose, et al., 2001; Atzori, et al., 2001; Helweg-Larsen, et al., 
2001a]. Based on such observations it was suggested that P. jiroveci infection is not 
a clonal infection, and that repeated de novo acquisition of the opportunistic 
pathogen is likely to occur [Tsolaki, et al., 1996]. 
 
 
1.3.2 Coalescent statistical parsimony network analysis 
 
1.3.2.1  P. jirovecii ribosomal DNA 
The nuclear rRNA is encoded by an operon consisting of the 18S, 5.8S, and 26S 
rRNA genes occurring in tandem. Between the 18S and 5.8S and between the 5.8S 
and 26S rRNA are the internal transcribed spacers 1 and 2 (ITS1 and ITS2), 
respectively. The 18S and 26S rRNA genes are flanked by the 5’ external transcribed 
spacer (5’ ETS) and 3’ external transcribed spacer (3’ ETS), respectively (Figure 1.1). 
The operon is referred to as ribosomal DNA (rDNA). During transcription by RNA 
polymerase I, a 35S pre-rRNA transcript is created that contains the above 
mentioned elements. During maturation of the pre-rRNA, the transcribed spacers are 
removed in a series of processing steps carried out by endo- and exonucleases 
[Venema, et al., 1995]. The pre-rRNA folds into a cruciform-like structure which 
directs maturation by providing targets for RNA binding, and bringing cleavage sites 
into closer proximity. Initial cleavage occurs within ITS1 followed by maturation of the 
3’ 18S termini and 5’ 5.8S termini. Subsequent cleavage reactions yield the matured 
18S, 5.8S and 26S rRNA’s without transcribed spacers [Good, et al., 1997]. Analysis 
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of ITS1 has suggested that it has always functioned as a spacer between the 
prokaryotic unlinked 16S and 23S rRNA genes. ITS2 however, is considered to have 
evolved from a former expansion segment (ES), elements that cause length 
variations in eukaryotic 25/28S rRNA, which at the base of the eukaryotic tree 
separated the 5’ part from the rest of the eukaryotic analogue to the 23S rRNA of 
Escherichia coli [Torres, et al., 1990].   
 
 
 
 
 
 
 
 
Figure 1.1 P. jirovecii ribosomal DNA structure 
  Redrawn from Edman et al. [Edman, et al., 1989] 
 
 
1.3.2.2  ITS based phylogenetic reconstruction 
The ITS gene sequences have been used for phylogenetic reconstruction in many 
orders and genera, particularly plants and lower eukaryotes [Torres, et al., 1990; 
O’Donnel & Cigelnik, 1997; Hijri, et al., 1999; Pélandakis, et al., 2000; Marcilla, et al., 
2001; Marcilla, et al., 2002; Rodriguez-Lanetty, 2003]. Ribosomal DNA, and 
particularly ITS sequences, have been reported to be useful markers for resolving 
supra specific, specific, subspecific, strain and population-level relationships in 
organisms [Marcilla, et al., 2001; Marcilla, et al., 2002]. Since spacer regions evolve 
under fewer constraints than protein coding genes, the rate of spacer evolution is 
very fast. This makes inferences based on spacer phylogenies particularly useful for 
studying divergences within the last 50 million years [Hillis & Dixon, 1991]. Ribosomal 
DNA spacer regions are not free from constraints as are pseudogenes, as they have 
to maintain a certain degree of secondary structure, the maintenance of which 
requires compensatory mutations for stabilising stem-loop structures [Hillis & Dixon, 
5´ EST 18S 5.8S ITS1 ITS2 26S 3´ EST 
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1991]. Most eukaryotic organisms contain many, up to thousands, of copies of rDNA 
paralogues, homogenisation of the sequences occurs by concerted evolution. It is 
mainly intergenic recombination, unequal crossing over, and gene conversion that 
homogenises the sequences of the paralogous rDNA repeats [Buckler, et al., 1997]. 
Guintoli et al. has shown that Pneumocystis obtained from rats have at most 2 copies 
of rRNA [Guintoli, et al., 1994], reminiscent of Tetrahymena that contains 
exceptionally few rDNA copies [Yao, et al., 1974]. Despite the fact that ITS 
sequences have been successful for reconstructing phylogenies among taxa and 
species, discordant or unresolved results have been reported, these have been 
attributed mainly to xenology and homoplasy [O’Donnel, et al., 1997; Hijri, et al., 
1999]. Despite the widespread use of ITS sequence typing for epidemiological 
studies of P. jirovecii, no phylogenetic or population genetic analyses have been 
forthcoming. Helweg-Larsen reported that phylogenetic attempts employing 
Neighbour-Joining failed to resolve, as bootstrap values were all < 0.5 [Helweg-
Larsen, et al., 2001b]. In addition Hsueh et al. published a Maximum Likelihood tree 
of ITS sequences obtained from Pneumocystis isolated from Maccaca mulata, 
however, resolution was poor and no useful inferences could be made [Hsueh, et al., 
2001]. 
 
1.3.2.3  Intraspecific gene genealogies  
Classical phylogenetic heuristic methods were designed to infer relationships 
between genes sampled from individuals belonging to different species (phylogeny 
sensu strictu) [Posada & Crandall, 2001]. The different species are assumed to be 
hierarchical and the result of reproductive isolation and population fissions, leading to 
fixation of mutations and non-overlapping gene pools. The evolution of such systems 
is assumed to be tree like with dichotomous branching patterns since it infers 
speciation events [Posada & Crandall, 2001; Rosenberg & Nordborg, 2002]. The 
direction of evolution, although it is not always known if the tree is unrooted, is 
assumed to be linear [Allaby & Brown, 2001]. Tokogeny, however, is not hierarchical 
but the result of sexual reproduction or recombination, with resultant relatively recent 
mutations not yet fixed in the population [Posada & Crandall, 2001]. The genealogical 
outcomes of intraspecific evolution, such as recombination and homoplasies 
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generates reticulate relationships for which classical phylogenetic algorithms such as 
Maximum Likelihood, Maximum Parsimony or Minimum Evolution, do not 
compensate for, and their assumptions are violated [Posada & Crandall, 2001]. The 
results of a recent evolutionary timescale means that ancestral states still exist and 
multiple apomorphies are being fixed or lost from the population, resulting in a 
multifurcating rather than a dichotomous branching pattern [Allaby & Brown, 2001]. 
Population genetic methods that allow persistent ancestral nodes, multifurcations and 
reticulations are necessary to account for intraspecific population dynamics. The 
stochastic process known as the coalescent is an extension of classical population 
genetic models. The underlying theme is that in the absence of selection, sampled 
lineages can be viewed as randomly picking their parents as one goes back in time. 
Whenever two lineages pick the same parent they are said to coalesce. Eventually all 
lineages coalesce into the most recent common ancestor (MRCA) of the sample 
[Rosenberg & Nordborg, 2002]. Modelling population structure as a network does not 
assume reproductive isolation and enables multiple ancestry, apomorphy and extant 
ancestral states to be portrayed, and is a much more realistic description than tree 
building for intraspecific analyses [Allaby & Brown, 2001]. 
 
 
1.4 TREATMENT AND RESISTANCE DEVELOPMENT 
  
1.4.1  Standard treatment and prophylaxis 
 
The first report that trimethoprim sulphamethoxazole (TMP-SMX) (cotrimoxazole) 
may be of clinical use in treating PcP was by Hughes et al. who in 1974 
demonstrated the efficacy of cotrimoxazole in a murine PcP model [Hughes, et al., 
1974]. A follow up clinical study demonstrated the efficacy of TMP-SMX at 20/100 
mg/kg per day, administered for 14 days for treating PcP in humans [Hughes, et al., 
1975]. With the advent of the AIDS pandemic it was realised that the outcome of 
AIDS and non-AIDS associated PcP was similar with cotrimoxazole treatment, 
however, AIDS patients required longer duration of therapy to attain the same 
results. In addition, it was established that intravenous vs. oral cotrimoxazole 
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presented no statistically significant advantage to treatment outcome [PCP Therapy 
Group, 1984]. Later studies comparing aerosolised pentamidine to cotrimoxazole 
reported a greater risk (3.25 X) for recurrence of PcP if aerosolised pentamidine 
treatment was administered [Hardy, et al., 1992]. Many treatment failures or failure of 
prophylaxis using high dose cotrimoxazole were attributed to non-compliance due to 
side effects. This prompted further comparisons of cotrimoxazole, aerosolised 
pentamidine and dapsone. Ioannidis et al. reported cotrimoxazole to be superior and 
lower doses (one double strength tablet three times per week instead of daily) 
increased tolerance to this agent without losing efficacy. Low doses of dapsone had 
less toxic effects, but this was at the expense of efficacy. It was observed that 
although high doses of aerosolised pentamidine improved efficacy it failed to prevent 
toxoplasmosis, and it was concluded that the lower dose cotrimoxazole was the 
superior regimen for preventing PcP in patients with AIDS [Ioannidis, et al., 1996]. 
 
Highly active antiretroviral therapy (HAART) remains the most effective approach to 
preventing opportunistic infections in HIV-infected persons; however, some patients 
are unable to take HAART, are not ready to start therapy or have failed therapy. In 
addition to HAART, specific prophylactic regimens provide survival benefits, even for 
those receiving HAART. Primary prophylaxis for opportunistic infections in adults and 
adolescents (including pregnant woman and patients receiving HAART) is 
recommended to be initiated when CD4+ cell counts reach <200/μl, if the person has 
a history of oropharyngeal candidiasis, if the CD4+ ratio drops below 14%, or if the 
person had a history of an AIDS-defining illness. Recommended chemoprophylaxis is 
cotrimoxazole, 1 double strength tablet per day or 1 single strength tablet per day. 
Alternatively, 1 double strength tablet three times a week can be used. Alternative 
regimens include dapsone, dapsone plus pyrimethamine plus leucovorin, or 
aerosolized pentamidine. It is considered safe to discontinue primary prophylaxis in 
patients responding to HAART with a 3-6 month sustained rise in CD4+ cells from 
<200/μl to >200/μl. Patients experiencing a recurring episode should be administered 
secondary prophylaxis (long term maintenance chemoprophylaxis) with the above 
mentioned regimens. Evidence suggests it safe to suspend secondary prophylaxis 
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when a patient’s CD4+ cell count exceeds 200/μl for ≥3 months as a consequence of 
HAART [USPHS/IDSA Prevention of Opportunistic Infections Working Group, 1999].  
In children indications for initiating primary prophylaxis are: HIV-infected or HIV-
indeterminate infants aged 1-12 months; HIV-infected children 1-5 years with CD4+ 
cells <500/μl or CD4+ ratio < 15%; HIV-infected children 6-12 years with CD4+ 
<200/μl or CD4+ ratio of <15%. The following is recommended as primary prophylaxis 
in these groups: cotrimoxazole at 150/750 mg/m2/day in 2 two divided doses three 
times a week on consecutive days, or single dose three times a week on consecutive 
days, or 2 divided doses three times a week on alternate days. Alternative regimens 
include dapsone, aerosolised pentamidine or atovaquone. If PcP recurs after 
treatment of an acute infection, prophylaxis is recommended for life. The regimen is 
as above for primary prophylaxis [USPHS/IDSA Prevention of Opportunistic 
Infections Working Group, 1999]. 
 
The drug of choice for treatment of PcP in adults and paediatric patients is 
cotrimoxazole at TMP 15 mg/kg/day, SMX 75 mg/kg/day, orally or intravenously in 3 
or 4 divided doses for 14–21 days. Alternatively, pentamidine, trimetrexate, 
atovaquone or primaquine may be used. [Walzer, et al., 2000]. 
 
 
1.4.2 Mechanism of action of cotrimoxazole 
 
Folates play an essential role in metabolism where they act as cofactors. Folates are 
synthesised de novo in prokaryotes and lower eukaryotes, but higher organisms 
need preformed folates to be absorbed via the diet. In the biosynthesis of folates (Fig 
1.2) p-aminobenzoic acid (pABA) condenses with 2-amino-4-hydroxy-6-
hydroxymethyl-7,8-dihydropteridine pyrophosphate (DHPPP), a reaction catalysed by 
dihydropteroate synthase (DHPS) [E.C. 2.5.1.15], to form dihydropteroate (DHP). 
Dihydrofolate synthase (DHFS) [E.C. 6.3.2.12] then catalyzes the addition of 
glutamate to DHP to produce dihydrofolate (DHF). DHF is then reduced by 
dihydrofolate reductase (DHFR) [E.C. 1.5.1.3] to produce tetrahydrofolic acid, i.e. 
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folate, in a form available as cofactor for many essential reactions of metabolism 
[Ouellete, et al., 1998]. 
 
Trimethoprim and sulfamethoxazole are substrate analogues in folate metabolism in 
prokaryotes and lower eukaryotes and act by competitive inhibition. 
Sulphamethoxazole (SMX) targets the enzyme DHPS, which catalyzes the 
condensation of pABA, to which SMX is an analogue, with dihydropteroate 
pyrophosphokinase (DHPPP). In addition to sulphonamides competitive inhibition of 
DHPS resulting in inhibition of folate synthesis, sulpha drugs are metabolised to the 
sulpha-containing folate analogue sulpha-dihydropteroate (sulpha-DHP) that in itself 
inhibits metabolism [Patel, et al., 2003]. Trimethoprim (TMP) acts on DHFR, which 
catalyses the reduction of DHF to tetrahydrofolate. Sulphonamides and trimethoprim 
act in tandem to inhibit folate biosynthesis [Ouellette, et al., 1998]. 
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Figure 1.2 Schematic diagram of the folate synthesis pathway 
  Key enzymes and inhibitors are boxed. Based on Ouellette, et al., 1998. 
1.4.3  Development of resistance to cotrimoxazole 
 
P. carinii DHPS was characterised in 1992 as being part of a trifunctional folic acid 
synthase (fas) gene encoding dihydroneopterin aldolase, hydroxymethyldihydropterin 
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pyrophosphokinase (DHPPK) and DHPS [Volpe, et al., 1992; Volpe, et al., 1993]. 
Lane et al. compared the DHPS gene of Pneumocystis from various hosts and 
observed polymorphisms suggestive of different evolutionary pressures. The ratio of 
nonsynonymous:synonymous amino acid changes in the human (100%) was greater 
than that from the rodent isolates (36%) and the transversion:transition ratio was 
higher in human (0.54) than rodent isolates (0.07). These observations imply that 
human isolate’s DHPS genes have been under selective pressure, possibly due to 
longterm exposure to sulphonamides [Lane, et al., 1997]. Polymorphisms reported in 
P. jirovecii DHPS genes are at codon positions 23, 55, 57, 60, 111, and 248. Three of 
these, at positions 55, 57, and 60 were similar to DHPS “hotspots” of other 
organisms known to be involved in sulphonamide resistance development [Lane, et 
al., 1997]. The detection frequency of P. jirovecii DHPS genes with mutations at 
codons 55 and 57 from Europe and the USA, have been reported to be between 
20.4% - 69.5%  [Mei, et al., 1998; Helweg-Larsen, et al., 1999; Santos, et al., 1999; 
Visconti, et al., 1999; Beard, et al., 2000; Huang, et al., 2000; Takahashi, et al., 2000; 
Nahimana, et al., 2003; Kazanjian, et al., 2004; Montes-Cano, et al., 2004].   
 
The first association of DHPS mutations and prophylaxis / sulphonamide exposure 
was made by Kazanjian et al. who in 1998 observed that mutations at positions 55 
and 57 were more common in patients who received and failed sulpha or sulphone 
prophylaxis (5/7) than those who did not receive (2/13) prophylaxis [Kazanjian, et al., 
1998]. Subsequently more reports appeared that associated sulphone / sulpha 
exposure with mutations at codon 55 and 57, suggesting development of mutations 
during treatment / prophylaxis [Ma, et al., 1999; Nahimana, et al., 2003a]. DHPS 
mutations have been reported in 62% - 80.3% of patients exposed to sulpha / 
sulphone agents compared to 23% - 53.8% in patients not receiving these drugs 
[Helweg-Larsen, et al., 1999; Santos, et al., 1999; Huang, et al., 2000; Kazanjian, et 
al., 2000; Nahimana, et al., 2003a]. Mutation frequency has been reported to be 
increasing; in patients receiving sulpha prophylaxis from 46% in 1994-1995 to 88% in 
2000-2001 and in patients not exposed from 38% in 1996-1997 to 54% in 2000-2001 
[Kazanjian, et al., 2004]. 
 
CHAPTER 1  INTRODUCTION 
_________________________________________________________________ 
 
25
Geographic location has been shown to be an independent predictor for harbouring a 
mutated strain [Beard, et al., 2000; Huang, et al., 2000]. Specific geographic areas 
have been associated with a markedly increased risk of mutations occurring. The 
organisms from the West coast of the USA, including San Francisco and Seattle, 
have been shown to have a significantly higher incidence of mutations than those in 
Atlanta [Beard, et al., 2000; Huang, et al., 2000]. On a finer scale, hospitalisation in a 
specific hospital has been associated with resistance gene detection [Nahimana, et 
al., 2003a]. These studies have suggested that acquisition of mutated strains may 
occur de novo from the environment or spread from person-to-person. [Beard, et al., 
2000; Huang, et al., 2000; Nahimana, et al., 2003a].  
 
The role of DHPS mutations in clinical outcome is still controversial. DHPS mutations 
have been associated with failure of sulphonamide prophylaxis [Kazanjian, et al., 
1998; Mei, et al., 1998; Kazanjian, et al. 2000; Visconti, et al., 2001]. However, little 
evidence exists that treatment failure is associated with DHPS mutations in that a) it 
has been reported that the majority of patients with DHPS mutations respond to 
standard cotrimoxazole therapy [Kazanjian, et al., 2000], b) both DHPS wild type and 
mutation types have similar clinical responses to standard cotrimoxazole therapy 
[Visconti, et al., 2001], and c) pathophysiological factors appear to have a greater 
degree of association with treatment failure than DHPS mutations [Kazanjian, et al., 
1998]. A few reports have suggested an association of DHPS mutations with 
sulphonamide therapy failure, Kazanjian et al. reported 7% of patients with DHPS 
wild type genes failed therapy, while 28% of patients harbouring DHPS mutations 
failed therapy [Kazanjian, et al., 2000]. What has become evident is that 
sulphonamide exposure and length thereof, increases the risk of acquiring DHPS 
mutations [Ma, et al., 1999; Huang, et al., 20000; Kazanjian, et al., 2000; Nahimana, 
et al., 2003b]. Despite the lack of clinical data on treatment failure, in vitro site-
directed mutagenesis of the orthologous folic acid synthase gene of Saccharomyces 
cerevisiae have indicated that DHPS mutations at codon 55 and 57 may confer 
resistance to sulpha / sulphones. However, results indicated that a single mutation at 
codon 55 renders the enzyme resistant to sulphanilamide and a single mutation at 
codon 57 renders the enzyme resistant to sulphanilamide and sulphadoxine. The 
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paradox however, is that the double mutation 55 + 57 renders the organism 
hypersensitive to sulphamethoxazole and dapsone. In addition, the double mutant 
enzyme has a reduced affinity for the substrate (pABA) – and growth requires the 
addition of pABA [Iliades, et al., 2004; Meneau, et al., 2004]. 
 
It is well known that other pathogens, notably Escherichia coli, Streptococcus 
pneumoniae, Neisseria gonorrhoea and Plasmodium falciparum develop stepwise 
resistance to these agents by point mutations in the gene coding for the 
sulphonamide target DHPS and trimethoprim target DHFR [Lopez, et al., 1987; 
Swedberg, et al., 1993; Brooks, et al., 1994; Wang, et al., 1997; Qvarnaström & 
Swedberg, 2000]. The region at position 55 - 57 comprises Thr-Arg-Pro 
corresponding to the E. coli DHPS gene positions 62 - 64, a region known to be an 
active site involved in binding both substrate and sulphonamide. It has been found to 
be a highly conserved region in all DHPS sequences identified to date. In the E. coli 
DHPS gene, Thr62 is involved in binding the substrate (pterin) with two hydrogen 
bonds, one of which is lost if Thr is replaced by Ala. Thr62 in E. coli is homologous to 
Thr55 in P. jirovecii. The adjacent amino acid in E. coli is Arg63, its homologue in P. 
jirovecii is Arg56, which is involved in binding both pterin substrate and 
sulphonamides. Thus, the substitution of Ala55 for Thr55 in the P. jirovecii enzyme is 
likely to affect Arg56 and its ability to bind sulphonamides. In addition to this, the 
observed substitution of Ser57 for Pro57, which is also adjacent to Arg56, could affect 
binding to both substrate and drug [Kazanjian, et al., 1998]. 
 
Studies have indicated that, in contrast to the high prevalence of DHPS mutations, 
DHFR polymorphisms are rare [Ma, et al., 1999]. A lower selective pressure is 
thought to be exerted by trimethoprim on DHFR, since it has been shown from in vitro 
studies and animal models that trimethoprim contributed only marginally to the 
efficacy of cotrimoxazole [Edman, et al., 1989; Ma, et al., 1999]. On comparing 
percentages of isolates harbouring DHPS (43%) and DHFR (0%) mutations, it was 
suggested that DHPS gene mutations were not random, but indicative of selective 
pressure on DHPS and less so on DHFR [Ma, et al., 1999]. DHFR gene 
polymorphism was reported for the first time in 2002 from Japan, where DHFR genes 
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with synonymous and nonsynonymous nucleotide substitutions were observed. The 
two synonymous substitutions T540C and T312C and two amino acid substitutions 
Ala67Val and Cys116Tyr did not correlate with cotrimoxazole treatment failure. The 
authors suggested that Cys116Tyr may have been selected during therapy 
[Takahashi, et al., 2002]. It was reported that DHPS but not DHFR polymorphisms 
contributed to cotrimoxazole PcP treatment failures [Takahashi, et al., 2002]. 
 
In South Africa, Ruffini and Madhi found 28% of HIV-1 infected children that 
developed PcP, had a history of being on cotrimoxazole prophylaxis at the time of 
their illness, raising concern to the possible emergence of sulphonamide resistant 
strains in South Africa [Ruffini & Madhi, 2002]. 
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1.5 OBJECTIVES 
 
1. To compare a) different PCR primers directed at various gene targets, and b) 
PCR techniques with IF microscopy for the detection of P. jirovecii in clinical 
specimens. 
 
2. To determine the extent of co-infection associated with PcP in South Africa. 
 
3. To determine local P. jirovecii ITS1-5.8S-ITS2 rDNA strain types in Cape 
Town, and model lineage evolution employing a coalescent-theory based 
statistical parsimony network analysis. 
 
4. To investigate the possible emergence of cotrimoxazole-resistant strains of P. 
jirovecii in South Africa.  
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
_______________________________ 
 
2.1 CLINICAL SPECIMENS 
 
2.1.1  Clinical specimens for PCR performance evaluation 
 
For PCR performance evaluation, 78 sequential clinical specimens submitted to the 
Pathology Laboratories at Tygerberg Hospital, South Africa, for identification of P. 
jirovecii (June 2001 to April 2002) were collected and stored at -80°C. Specimens 
comprised: sputum (14), tracheal aspirates (TASP) (50), bronchoalveolar lavage 
fluids (BAL) (9) and fresh lung biopsy tissues (5). In addition, archived formalin-fixed, 
paraffin-wax embedded lung histology sections (12) previously confirmed (1981 - 
1999) as PcP-positive by methanamine silver staining, were obtained from the 
Department of Anatomical Pathology (1981 to 1999) and included in the study.  
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2.1.2 Sputum specimens for co-infection investigations 
 
Microbiology and virology laboratory data obtained from the 78 sequential specimens 
employed in section 2.1.1 were investigated for indications of co-infections. In 
addition to routine records, HIV data were available for 40 of the 78 patients. M. 
tuberculosis culture-confirmed sputum specimens (663) were obtained from the 
Medical Research Council (South Africa) Unit for Tuberculosis Operational and Policy 
Research. The specimens were collected from patients residing in five provinces in 
South Africa viz. KwaZulu Natal (192), Western Cape (72), Eastern Cape (148), 
North West (177) and Mpumalanga (74). HIV status for 648 of 663 patients was 
known.  
 
 
2.1.3  Specimens for ITS genotyping 
 
Clinical specimens (20) were obtained from 19 patients diagnosed with PcP, 
attending the Tygerberg Hospital. Included were three specimens from twin babies 
both of whom were HIV-positive. The babies presented with PcP simultaneously and 
were admitted together to the paediatric intensive care unit. From twin 1 two 
specimens were analysed: a tracheal aspirate and lung biopsy (collected six days 
after the tracheal aspirate), and from twin 2 a lung biopsy was obtained concurrently 
with the lung biopsy of twin 1. 
 
 
2.2 DIAGNOSTIC DATA: IMMUNOFLUORESCENCE  
AND CO-INFECTION 
 
2.2.1 Indirect immunofluorescence 
 
Indirect IF was performed as the standard diagnostic test by medical technologists at 
Tygerberg Hospital. The DETECT IF Pneumocystis carinii indirect 
immunofluorescence kit (Shield Diagnostics Ltd. Dundee, UK) was used to detect P. 
jirovecii cysts in clinical samples according to the manufacturer’s instructions.  
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2.2.2 Co-infection 
 
Microbiology and virology laboratory records of the patients diagnosed with PcP by 
indirect immunofluorescence were investigated retrospectively for reports of other 
pathogens detected during the episode of PcP. HIV status data were obtained 
concurrently where available.  
 
TB culture confirmed specimens (2000 – 2003) were obtained from the Medical 
Research Council, Unit for Tuberculosis Operational and Policy Research. HIV data 
of the patients from whom specimens were taken was available for 648 of 663 
patients. Specimens were supplied as accession numbers and no patient names 
were made available. The only demographic data provided were provinces of 
residence of the patients. 
 
 
2.3 PCR INVESTIGATIONS 
 
2.3.1  Sample treatments prior to DNA extraction 
 
2.3.1.1 BAL’s, tracheal aspirates and sputum 
Mucoid specimens of 1 to 5 ml were treated with an equal volume of 0.1 M 1,4-
dithiothreitol (DTT) (Roche Molecular Biochemicals, Mannheim, Germany), vortexed 
and incubated at 37°C for 30 min until liquefied. The suspension was centrifuged at 
3 000xg for 15 min and the supernatant discarded. The pellet was resuspended in 
500 μl sterile deionised water (dH2O). DNA extraction was performed using the High 
Pure Template Preparation Kit (Roche) as for isolation of nucleic acids from whole 
blood, buffy coat, or cultured cells according to the manufacturer’s instructions with a 
few modifications. Briefly, Tissue Lysis Buffer (4 M urea, 200 mM Tris, 20 mM NaCl, 
200 mM EDTA, pH 7.4) and 20 µl Proteinase K (20 mg/ml) was added to 200 µl 
sample, vortexed and incubated overnight until a clear homogeneous liquid was 
obtained. DNA was then extracted employing the Roche system as described in 
section 2.3.2.1. 
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2.3.1.2 Fresh biopsy tissue 
Extraction from fresh biopsy tissue was performed using the High Pure Template 
Preparation Kit (Roche) as for isolation of nucleic acids from mammalian tissue. 
Briefly, 25 – 50 mg of tissue was mechanically disrupted with a sterile pestle. Tissue 
Lysis Buffer (4 M urea, 200 mM Tris, 20 mM NaCl, 200 mM EDTA, pH 7.4) and 40 μl 
Proteinase K (20 mg/ml) was added to the sample, vortexed and incubated at 37°C 
overnight until liquefied. After the overnight incubation an additional 40 µl Proteinase 
K (20 mg/ml) was added, and incubated at 56°C for 2 h.  Remaining insoluble tissue 
was carefully removed by drawing up with a 200 µl pipette tip. DNA was then 
extracted from the solution employing the Roche system as described in section 
2.3.2.1.  
 
2.3.1.3 Formalin-fixed paraffin wax-embedded tissue 
Extraction from formalin-fixed paraffin wax-embedded tissue was performed using 
the High Pure Template Preparation Kit (Roche) as for isolation of nucleic acids from 
formalin-fixed paraffin wax-embedded tissue sections, according to the 
manufacturer’s instructions. To deparaffinize tissue sections 3 – 4 microtome slices 
were soaked in xylene (Sigma-Aldrich, Missouri, USA) for 30 min. The sample was 
centrifuged at 6 000xg for 10 sec and the supernatant discarded. The sections were 
then incubated for 10 sec in the following series of ethanol concentrations to 
rehydrate the tissue: 100 % ethanol, 80 %, 60 %, 40 % and lastly in dH2O. The 
sample was centrifuged at 6 000xg for 10 sec and the supernatant was discarded. Of 
the remaining tissue, 25 – 50 mg was used and processed as follows: Tissue Lysis 
Buffer (4 M urea, 200 mM Tris, 20 mM NaCl, 200 mM EDTA, pH 7.4) and 40 μl 
Proteinase K (20 mg/ml) was added to the sample, vortexed and incubated overnight 
at 37°C until liquefied. After the overnight incubation an additional 40 µl Proteinase K 
(20 mg/ml) was added and incubated at 56°C for 2 h. Remaining insoluble tissue was 
removed by carefully drawing up with a 200 µl pipette tip. DNA was then extracted 
from the solution employing the Roche system as described in section 2.3.2.1. 
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2.3.1.4 TB-positive sputum specimens (663 specimens, section 2.1.2) 
Specimens (200 μl) were treated with an equal volume of 1N NaOH, 0.1N sodium 
citrate and N-acetyl-L-cysteine. The suspension was vortexed and incubated at 37°C 
for 30 min until liquefied. After centrifugation at 3 000xg for 15 min the supernatant 
was discarded and DNA extracted from the pellet employing the Promega system as 
described in section 2.3.2.2. 
 
 
2.3.2 DNA extraction 
 
2.3.2.1 DNA extraction: Roche system 
To 200 μl treated specimen an equal volume binding Buffer (6 M guanidine-HCl, 10 
mM urea, 10 mM Tris-HCl, 20% Triton X-100 (v/v), pH 4.4) was added and the 
solution was incubated at 72°C for 10 min. Isopropanol (Sigma) was added and 
mixed. The mix was then transferred to the upper reservoir of a combined High Pure 
filter tube-collection tube assembly and centrifuged at 6 000xg for 1 min. The elute 
and collection tube was discarded and the filter combined with a new collection tube. 
Inhibitor Removal Buffer (ethanol, 5 M guanidine HCl and 20 mM Tris-HCl at pH 6.6) 
was added and the assembly centrifuged at 6 000xg for 1 min. The elute and 
collection tube was discarded. The filter was then combined with a new collection 
tube; Wash buffer (ethanol, 20 mM NaCl and 2 mM Tris-HCl, at pH 7.5) was added 
and centrifuged at 6 000xg for 1 min. The elute and collection tube was discarded 
and the filter combined with a new collection tube. This step was repeated once. The 
assembly was then centrifuged at maximum speed (16 000xg) for 10 sec to remove 
any residual Wash Buffer. The collection tube was discarded and the filter combined 
with a 1.5 ml sterile reaction tube. Prewarmed (70ºC) Elution Buffer (10 mM Tris at 
pH 8.5) was added and the assembly centrifuged at 6 000xg for 1 min. Aliquots of 
the extracted DNA were stored at – 80ºC and a working aliquot kept at 4 – 8ºC. 
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2.3.2.2 DNA extraction: Promega system 
DNA extraction was performed employing the Wizard® SV Genomic DNA Purification 
System (Promega, Madison, USA) as for purification of genomic DNA from mouse-
tail clippings or animal tissue using a microcentrifuge. To the pellet obtained in 
section 2.3.1.4 200 μl Nuclei Lysis Buffer, 450 μl 0.5M EDTA ph 8.0, 20 μl Proteinase 
K (20 mg/ml), and 5 μl Rnase A Solution (4 mg/ml) was added and incubated at 55°C 
overnight. Wizard® SV Lysis Buffer (250 μl) was added and vortexed. The lysate was 
transferred to a minicolumn assembly and centrifuged at 13 000xg for 3 min. The 
elute was discarded and the sample subjected to washing: 650 μl Wizard® Wash 
solution was added and centrifuged at 13 000xg for 1 min after which the elute was 
discarded. The washing step was repeated for a total of 4 washes. The elute was 
discarded and the minicolumn was reassembled and centrifuged at 13 000xg for 2 
min to dry the binding matrix. Nuclease free water (250 μl) was added and incubated 
at room temperature for 2 min. The assembly was centrifuged at 13 000xg for 2 min. 
Aliquots of the eluted purified DNA were stored at – 80ºC and a working aliquot kept 
at 4 – 8ºC. 
 
2.3.2.3 Gel electrophoresis for determining DNA integrity and PCR product 
 detection and sizing 
Electrophoresis was performed on a 0.5% for DNA integrity and 1.4% UltraPure 
(GibcoBRL®) agarose gel for PCR product detection. Gels were run for 45 min at 80 
V using Tris-acetate EDTA buffer. Ethidium bromide was used to stain DNA bands 
and captured by UV transillumination. The 100 bp DNA molecular weight marker XIV 
(Roche) was used to estimate expected PCR products. 
 
 
2.3.3 PCR PROCEDURES 
 
A summary of primers employed and resultant PCR product sizes are given in Table 
2.1. Details of PCR mixtures and cycling conditions (Applied Biosystems GeneAmp® 
PCR System 9700, PE Biosystems, Ca, USA) are described in the following sections 
(2.3.3.1 – 2.3.3.7). 
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TABLE 1 PCR primers employed 
 
 
Primers 
 
Sequences 5′ - 3′ Size (bp) Reference 
ITS     
First 1724F ITS2R 
AAGTTGATCAAATTTGGTC 
CTCGGACGAGGATCCTCGCC 
Nested ITS1F 
ITS2R1 
CGTAGGTGAACCTGCGGAAGGATC 
GTTCAGCGGGTGATCCTGCCTG 
550 
Lu, et al., 
1995 
DHPS     
First F1 B45 
CCTGGTATTAAACCAGTTTTGCC 
CAATTTAATAAATTTCTTTCCAAATAGCATC 
Nested A HUM BN 
GCGCCTACACATATTATGGCCATTTTAAATC 
GGAACTTTCAACTTGGCAACCAC 
300 
Lane, et 
al., 1997 
DHPS 
Single 
A HUM 
B HUM 
GCGCCTACACATATTATGGCCATTTTAAATC 
CATAAACATCATGAACCCG 750 
Takahashi, 
et al., 2000 
DHFR     
First FR208 FR1038 
GCAGAAAGTAGGTACATTATTACGAGA 
AACCAGTTACCTAATCAAACTATATTGC 
Nested FR242 FR1018 
GTTTGGAATAGATTATGTTCATGGTGTACG 
GCTTCAAACCTTGTGTAACGCG 
798 
Ma, et al., 
1999 
MSG     
Heminested 
JKK14 
JKK15 
JKK17 
GAATGCAAATCCTTACAGACAACAG 
GAATGCAAATCTTTACAGACAACAG 
AAATCATGAACGAAATAACCATTGC 
249 
Huang, et 
al., 1999 
MtLSUrRNA    
Single 
 
pAZ102-E 
pAZ102-H 
GATGGCTGTTTCCAAGCCCA 
GTGTACGTTGCAAAGTACTC 
Nested pAZ102-X PAZ102-Y 
GTGAAATACAAATCGGACTAGG 
TCACTTAATATTAATTGGGGAGC 
346 
 
 
260 
 
 
Wakefield, 
et al., 1996 
18S rRNA      
One-tube - 
nested 
Pc1 
Pc2 
Pc5 
Pc6 
CCAGATTAGCTTTTGCTGATCGCGGG 
TTTACTTCCTCTAAATGACCAAATTTGATC 
CAGAGCCAGCAAGTTCATTTC 
CCAAATTTGATCAACTTTCCAG 
265 Mathis, et al., 1997 
Real-time 
5S rRNA 
5S F 
5S R 
AGTTACGGCCATACCTCAGA 
AAAGCTACAGCACGTCGTAT 
Tm = 
82.5°C 
+/- 
2.0°C 
Larsen, et 
al., 2002 
Single 5S F 5S R 
AGTTACGGCCATACCTCAGA 
AAAGCTACAGCACGTCGTAT 120 
Kitada, et 
al., 1991 
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2.3.3.1  Internal transcribed spacer (ITS) 
Nested PCR. Nested PCR of the internal transcribed spacer (ITS) region was 
performed according to the method of Lu et al. [Lu, et al., 1995]. For the first PCR the 
forward primer 1724F: 5′ – AAGTTGATCAAATTTGGTC and reverse primer ITS2R: 
5′ – CTCGGACGAGGATCCTCGCC was used. The primers for the nested (second 
round amplification) consisted of the forward ITS1F: 5′ – 
CGTAGGTGAACCTGCGGAAGGATC and reverse ITS2R1: 5′ – 
GTTCAGCGGGTGATCCTGCCTG. Amplification was performed in a total volume of 
25 µl. The reaction mix comprised: 2 µl of DNA template, 2 mM MgCl2, 0.2 µM of 
each primer, 0.2 mM of each dNTP, 0.625 units Taq DNA polymerase in a PCR 
buffer (20 mM Tris-HCl pH 8.0, 0.1 mM EDTA, 1 mM DTT, 50% (v/v) glycerol and 
stabilizers) (Invitrogen, UK). For the second round of amplification 1 µl of the first-
round product was used as template and the concentration of each primer was 0.4 
µM. 
 
Temperature cycling: A three step initial phase comprising 94°C for 10 min followed 
by 47°C for 5 min (while Taq DNA polymerase was added as a hot start) and 72°C 
for 5 min. Amplification: 35 cycles comprising 94°C for 1 min; 47°C for 1 min; and 
72°C for 2 min followed by a final extension period of 10 min at 72°C. For the second 
round of amplification an initial 94°C for 10 min was followed by 35 cycles comprising 
94°C for 1 min; 47°C for 1 min; and 72°C for 2 min followed by a final extension 
period of 10 min at 72°C. 
 
2.3.3.2  Dihydropteroate synthase (DHPS) 
Nested PCR. Nested PCR of the DHPS gene was performed as previously described 
[Lane, et al., 1997]. It consisted of a first round PCR with forward primer DHPS F1: 5′ 
– CCTGGTATTAAACCAGTTTTGCC and reverse primer DHPS B45: 5′ – 
CAATTTAATAAATTTCTTTCCAAATAGCATC. The primers for the second round 
PCR consisted of the forward primer DHPS AHUM: 5′ – 
GCGCCTACACATATTATGGCCATTTTAAATC and reverse DHPS BN: 5′ – 
GGAACTTTCAACTTGGCAACCAC. Amplification was performed in a total volume of 
25 µl. The reaction mix comprised: 2 µl of DNA template, 2 mM MgCl2, 0.4 µM of 
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each primer, 0.2 mM of each dNTP, 0.625 units Taq DNA polymerase in a PCR 
buffer (20 mM Tris-HCl pH 8.0, 0.1 mM EDTA, 1 mM DTT, 50% (v/v) glycerol and 
stabilizers) (Invitrogen). For the second round of amplification 1 µl of the first-round 
product was used as template. Temperature cycling: A three step initial phase 
comprising 94°C for 5 min followed by 52°C for 5 min (while Taq DNA polymerase 
was added as a hot start) and 72°C for 5 min. Amplification: 35 cycles comprising 
92°C for 30 sec; 52°C for 30 sec; and 72°C for 1 min followed by a final extension 
period of 5 min at 72°C. For the second round of amplification an initial 94°C for 5 
min was followed by 35 cycles comprising 92°C for 30 sec; 55°C for 30 sec; and 
72°C for 1 min followed by a final extension period of 5 min at 72°C. 
 
2.3.3.3  Dihydropteroate synthase single  
A single step PCR was performed as previously published [Takahashi, et al., 2000] 
with the forward primer DHPS AHUM: 5′ - 
GCGCCTACACATATTATGGCCATTTTAAATC and reverse primer DHPS BHUM: 5′ – 
CATAAACATCATGAACCCG. Amplification was performed in a total volume of 25 µl. 
The reaction mix comprised: 2 µl of DNA template, 2 mM MgCl2, 0.4 µM of each 
primer, 0.2 mM of each dNTP, 0.625 units Taq DNA polymerase in a PCR buffer (20 
mM Tris-HCl pH 8.0, 0.1 mM EDTA, 1 mM DTT, 50% (v/v) glycerol and stabilizers) 
(Invitrogen). Temperature cycling: A three step initial phase comprising 94°C for 5 
min followed by 45°C for 5 min (while Taq DNA polymerase was added as a hot 
start) and 72°C for 5 min. Amplification: 35 cycles comprising 94°C for 1 min; 45°C 
for 1 min; and 72°C for 2 min followed by a final extension period of 10 min at 72°C.  
 
2.3.3.4  Dihydrofolate reductase (DHFR) 
Nested PCR. A nested PCR was performed as described by Ma et al. [Ma, et al., 
1999]. For the first round of amplification the forward primer FR208: 5′ – 
GCAGAAAGTAGGTACATTATTACGAGA and the reverse primer FR1038: 5′ – 
AACCAGTTACCTAATCAAACTATATTGC was used. For the second round PCR the 
forward primer FR242: 5′- GTTTGGAATAGATTATGTTCATGGTGTACG and reverse 
primer FR1018: 5′ – GCTTCAAACCTTGTGTAACGCG was used. Amplification was 
performed in a total volume of 25 µl. The reaction mix comprised: 2 µl of DNA 
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template, 2 mM MgCl2, 0.25 µM of each primer, 0.2 mM of each dNTP, 0.625 units 
Taq DNA polymerase in a PCR buffer (20 mM Tris-HCl pH 8.0, 0.1 mM EDTA, 1 mM 
DTT, 50% (v/v) glycerol and stabilizers) (Invitrogen). For the second round of 
amplification 1 µl of the first-round product was used as template. Temperature 
cycling: A three step initial phase comprising 95°C for 5 min followed by 60°C for 5 
min (while Taq DNA polymerase was added as a hot start) and 72°C for 5 min. 
Amplification: 35 cycles comprising 94°C for 1 min; 60°C for 2 min; and 72°C for 3 
min followed by a final extension period of 10 min at 72°C. For the second round of 
amplification an initial 94°C for 5 min was followed by 35 cycles comprising 94°C for 
1 min; 60°C for 2 min; and 72°C for 3 min followed by a final extension period of 10 
min at 72°C. 
 
2.3.3.5  Major surface glycoprotein (MSG) 
Hemi-nested PCR. The MSG PCR was performed according to the method of 
Huang et al. [Huang, et al., 1999] with the forward primer JKK14: 5′ – 
GAATGCAAATCCTTACAGACAACAG and a combination of the two reverse primers 
JKK15: 5′ – GAATGCAAATCTTTACAGACAACAG and JKK17: 5′ – 
AAATCATGAACGAAATAACCATTGC. Amplification was performed in a total volume 
of 25 µl. The reaction mix comprised: 2 µl of DNA template, 3 mM MgCl2, 1 µM final 
concentration of the 3 primers (in eqimolar ratio), 0.4 mM of each dNTP, 0.625 units 
Taq DNA polymerase in a PCR buffer (20 mM Tris-HCl pH 8.0, 0.1 mM EDTA, 1 mM 
DTT, 50% (v/v) glycerol and stabilizers) (Invitrogen). Temperature cycling: A three 
step initial phase comprising 96°C for 1 min followed by 65°C for 5 min (while Taq 
DNA polymerase was added as a hot start) and 72°C for 5 min. Amplification: 43 
cycles comprising 95°C for 1 min; 65°C for 1 min; and 72°C for 1 min followed by a 
final extension period of 10 min at 72°C.  
 
2.3.3.6 Mitochondrial large subunit rRNA (mtlsurRNA) 
Nested PCR. The nested PCR was performed according to Wakefield et al. 
[Wakefield, et al., 1996]. It consisted of the forward primer pAZ102-E: 5′ – 
GATGGCTGTTTCCAAGCCCA and reverse primer pAZ102-H: 5′ – 
GTGTACGTTGCAAAGTACTC. For the nested reaction the forward primer pAZ102-
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X: 5′ – GTGAAATACAAATCGGACTAGG and reverse primer pAZ102-Y: 5′ - 
TCACTTAATATTAATTGGGGAGC was used. Amplification was performed in a total 
volume of 25 µl. The reaction mix comprised: 2 µl of DNA template, 3 mM MgCl2, 1 
µM of each primer, 0.4 mM of each dNTP, 0.625 units Taq DNA polymerase in a 
PCR buffer (20 mM Tris-HCl pH 8.0, 0.1 mM EDTA, 1 mM DTT, 50% (v/v) glycerol 
and stabilizers) (Invitrogen). For the second round of amplification 1 µl of the first-
round product was used as template. Temperature cycling: A three step initial phase 
comprising 94°C for 2 min followed by 50°C for 5 min (while Taq DNA polymerase 
was added as a hot start) and 72°C for 5 min. Amplification: 40 cycles comprising 
94°C for 1.5 min; 50°C for 1.5 min; and 72°C for 2 min followed by a final extension 
period of 10 min at 72°C. The nested second round PCR was performed on 
specimens that did not amplify after the first round PCR and consisted of 94°C for 1.5 
min and amplification of 40 cycles comprising 94°C for 1.5 min; 50°C for 1.5 min; and 
72°C for 2 min followed by a final extension period of 10 min at 72°C. 
 
2.3.3.7 Small subunit ribosomal RNA (18s rRNA) 
One-tube nested PCR: The nested PCR was performed according to Mathis et al. 
[Mathis, et al., 1997]. It consisted of the forward outer primer PC1: 5′ –
CCAGATTAGCTTTTGCTGATCGCGGG and reverse outer primer PC2: 5′ – 
TTTACTTCCTCTAAATGACCAAATTTGATC. The inner forward primer PC5: 5′ – 
CAGAGCCAGCAAGTTCATTTC and reverse primer PC6: 5′ - 
CCAAATTTGATCAACTTTCCAG was used. Amplification was performed in a total 
volume of 25 µl. The reaction mix comprised: 2 µl of DNA template, 4 mM MgCl2, 3 
nM of each of the outer primers (PC1 and PC2), 1.5 μM of each of the inner primers 
(PC5 and PC6), 0.2 mM of each dNTP and 0.625 units Taq DNA polymerase in a 
PCR buffer (20 mM Tris-HCl pH 8.0, 0.1 mM EDTA, 1 mM DTT, 50% (v/v) glycerol 
and stabilizers) (Invitrogen). Temperature cycling: A three step initial phase 
comprising 94°C for 5 min followed by 50°C for 5 min (while Taq DNA polymerase 
was added as a hot start) and 72°C for 5 min. Amplification: 20 cycles comprising 
94°C for 30 sec; 72°C for 30 sec; and 30 cycles comprising 94°C for 30 sec, 55°C for 
30 sec and 72°C for 30 sec followed by a final extension period of 5 min at 72°C.  
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2.3.4 REAL-TIME 5S RIBOSOMAL RNA PCR 
 
2.3.4.1  Real-time amplification  
PCR was performed according to Palladino et al. [Palladino, et al., 2001]. It consisted 
of the forward primer 5S sense: 5′ – AGTTACGGCCATACCTCAGA and reverse 
primer 5S antisense: 5′ – AAAGCTACAGCACGTCGTAT. Amplification was 
performed in a total volume of 20 µl. The reaction mix comprised 10 µl of DNA 
template, 1.5 mM MgCl2, 0.5 μM of each primer and 2 μl FastStart SYBR Green I in 
LightCycler glass capillary tubes (Roche). Temperature cycling: the real-time PCR 
was performed in a LightCycler I System (Roche). Amplification: denaturation and 
FastStart Taq activation at 95°C for 10 min followed by 38 cycles comprising heating 
at 20°C/sec to 95°C with a 15 sec hold; cooling at 20°C/sec to 55°C with a 10 sec 
hold and heating at 20°C/sec to 72°C with a 10 sec hold. This was immediately 
followed by a melting curve analysis to determine the melting temperature (Tm) of the 
dsDNA product. This consisted of heating at 20°C/sec to 95°C with no hold, cooling 
at 20°C/sec to 40°C with a 15 sec hold, and then heating at 0.2°C/sec to 95°C during 
which fluorescence (F1) was measured at 530 nm. A Tm of 82.5°C +/- 2.0°C was 
indicative of P. jirovecii [Palladino, 2001]. 
 
2.3.4.2  Standard curve  
For creating a standard curve for absolute quantitative analysis a conventional PCR 
was performed according to Kitada et al. [Kitada, et al., 1991], employing the same 
primers as for the real-time PCR reaction with a positive control specimen. It 
consisted of a forward primer 5S sense: 5′ – AGTTACGGCCATACCTCAGA and 
reverse primer 5S antisense: 5′ – AAAGCTACAGCACGTCGTAT. Amplification was 
performed in a total volume of 50 µl. The reaction mix comprised 5 µl of DNA 
template, 1.5 mM MgCl2, 0.5 μM of each primers, 0.2 mM of each dNTP and 1.25 
units Taq DNA polymerase in a PCR buffer (20 mM Tris-HCl pH 8.0, 0.1 mM EDTA, 
1 mM DTT, 50% (v/v) glycerol and stabilizers) (Invitrogen). Temperature cycling: the 
PCR was performed in a thermocycler (Applied Biosystems GeneAmp® PCR System 
9700) with a three step initial phase comprising 95°C for 9 min followed by 50°C for 5 
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min (while Taq DNA polymerase was added as a hot start) and 72°C for 5 min. 
Amplification: 35 cycles comprising 94°C for 30 sec; 55°C for 60 sec; and 72°C for 60 
sec followed by a final extension period of 5 min at 72°C.  
 
PCR products were separated by electrophoresis in a 1.4% UltraPure (GibcoBRL®) 
agarose gel for 45 min at 80V using Tris-acetate EDTA buffer. Ethidium bromide was 
used to stain the DNA products and was examined and captured by UV 
transillumination. The 100 bp DNA molecular weight marker XIV (Roche) was used to 
estimate the expected 120 bp PCR product. The PCR product was purified (Wizard® 
SV gel and PCR clean-up system, Promega) and amplicon concentration was 
obtained by measuring absorbance at 260 nm from which tenfold dilutions were 
prepared. In addition, a known positive clinical specimen was serially diluted and 
incorporated in the standard curve estimation. The final standard curve contained: 1 
X 10-1; 1 X 101 and 1 X 103; 1 X 106 and 1 X 1012 copies/μl. All standard curve 
reactions were performed in duplicate.  The standard curve was calculated 
employing the second derivative maximum analysis method incorporated in the 
LightCycler quantification software package (Roche). 
 
 
2.4 GENOTYPING AND COALESCENT PHYLOGENETIC 
ANALYSIS 
 
2.4.1  Specimens 
 
Clinical specimens (20) submitted to the Pathology Laboratories at Tygerberg 
Hospital, South Africa, for identification of P. jirovecii were investigated (section 
2.1.1.). 
 
2.4.2  ITS gene amplification 
 
Sample preparation and DNA extraction was performed as described in sections 
2.3.1 and 2.3.2. Amplification of the ITS gene regions was performed as per section 
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2.3.3.1. In addition, high fidelity nested PCR of the internal transcribed spacer (ITS) 
region was performed as described by Lu et al. [Lu, et al., 1995] employing Pwo DNA 
polymerase (Roche) according to the manufacturer’s instructions. The high fidelity 
PCR was included to confirm Taq generated genotype sequences. Pwo is a highly 
processive 5’–3’ DNA polymerase and possesses a 3’–5’ exonuclease activity 
(proofreading). Employing this polymerase increases fidelity to >10-fold that of Taq 
DNA polymerase. The same primers as for the Taq polymerase reactions (Table 2.1) 
were employed. Amplification was performed in a total volume of 50 µl. The reaction 
mix comprised 4 µl of DNA template, 2 mM MgSO4, 0.2 µM of each primer, 0.2 mM 
of each dNTP, 1.25 units Pwo DNA polymerase in a PCR buffer (20 mM Tris-HCl pH 
7.5, 100 mM KCl, 1 mM DTT, 0.1 mM EDTA, 0.5% Nonidet P40 (v/v), 0.5% Tween 
20 (v/v), and 50% (v/v) glycerol) (Roche). For the second round of amplification 2 µl 
of the first-round product was used as template and the concentration of each primer 
was 0.4 µM. Temperature cycling: the PCR was performed in a thermocycler 
(Applied Biosystems GeneAmp® PCR System 9700). Initial denaturation of 94°C for 
2 min. Amplification: 10 cycles comprising 94°C for 15 sec; 55°C for 30 sec; and 
72°C for 45 sec followed by 15 cycles comprising 94°C for 15 sec; 55°C for 30 sec; 
72°C for 45 sec (+ 5 sec for each cycle); and a final extension at 72°C for 7 min. For 
the second round of amplification cycling conditions were the same. PCR products of 
expected size (550 bp) were separated by electrophoresis as described in section 
2.3.2.3. 
 
 
2.4.3  Subcloning 
 
Subcloning of purified ITS PCR products was undertaken employing pGEM® -T 
Vector System (Promega) according to the manufacturer’s instructions. The pGEM®  
-T vector contains 3′ terminal thymidine at both ends that assist ligation of PCR 
products into plasmid by preventing recircularisation of the vector, and providing 
compatible T overhangs for PCR products generated by Taq DNA polymerases. Taq 
DNA polymerases add a single deoxyadenosine, in a template-independent fashion, 
to the 3′ -ends of the amplified fragment. The vector contains a multiple cloning 
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region within the α - peptide coding region of β-galactosidase. Insertional inactivation 
of the α-peptide allows recombinant clones to be directly identified by colour 
screening on indicator plates. 
 
2.4.3.1  PCR product preparation  
Purified PCR product (from section 2.4.2) concentration was estimated by 
comparison to the DNA molecular weight marker XIV (Roche) and diluted to 10 ng/μl 
with nuclease free water. PCR products generated by Taq DNA polymerase contains 
A overhangs (required for cloning), however, PCR products generated by Pwo DNA 
polymerase are blunt ended and require a A-tailing procedure. Briefly: to five 
microliters Pwo PCR product 1 μl Taq DNA polymerase 10X reaction buffer with 
MgCl2 (Promega), dATP to a final concentration of 0.2 mM, and 5 units Taq DNA 
polymerase (Invitrogen) was added to a final reaction volume of 10 μl, and incubated 
at 70°C for 20 min. 
 
2.4.3.2  Ligation 
Ligation was performed according to the manufacturer’s instructions. Briefly: The 
pGEM® -T vector and control insert DNA was centrifuged at 4 000xg for 30 sec to 
collect the contents at the bottom of the tubes. The ligation reaction was set up as in 
Table 2.2 in 0.5 ml tubes with low DNA-binding capacity (Promega).  
 
2.4.3.3  Transformation 
The ligated products from section 2.4.3.2 were introduced into high efficiency (1 X 
108cfu/μg DNA) competent JM 109 cells (Promega Corporation, Madison, WI, USA). 
The genotype of JM 109 is recA1, endA1, gyrA96, thi, hsdR17 (rK-,mK+), relA1, 
supE44, Δ(lac-proAB), [F′, traD36, proAB, laclqZΔM15]. 
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TABLE 2.2  Ligation reactions 
 Standard 
Reaction 
Volume (μl) 
Positive 
Control* 
Volume (μl) 
2X rapid Ligation Buffer, T4 DNA Ligase 5 5 
pGEM®-T Easy vector (50 ng/μl) 1 1 
PCR Product  1 - 
Control insert DNA - 2 
T4 DNA Ligase (3 Weiss units/μl) 1 1 
Deionised water 2 1 
Final volume 10 10 
* Positive control was run with every batch   
The reactions were mixed by pipetting and incubated at 4°C overnight. 
 
 
Transformation was performed according to the manufacturer’s instructions. Briefly: 
The ligation reaction tubes were centrifuged at 4 000xg for 20 sec. Two microliters of 
the ligation solution was transferred to a new reaction tube on ice. JM 109 cells 
(Promega) were thawed for 5 min in an ice bath, and mixed by gentle flicking. To the 
ligation solution 50 μl of cells was added and mixed by gentle flicking. The tubes 
were left on ice for 20 min and subsequently heat-shocked at 42°C for 45 – 50 sec in 
a water bath and returned to ice for 2 min. Room temperature SOC medium (950 μl) 
was added to the tubes containing cells transformed with the ligation reaction and 
incubated for 1.5 h in a shaking (150 rpm) water bath at 37°C. The cells were 
subsequently pelleted by centrifugation at 1 000xg for 10 min, and the pellet 
resuspended in 200 μl SOC medium. Two Luria-Bertanie (LB) medium agar plates 
containing 100 μg/ml ampicillin, 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG), 
and 80 μg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) 
(LB/ampicillin/IPTG/X-Gal plates) were equilibrated to room temperature for each 
reaction and 100 μl of the SOC reaction mixture was plated on each plate. The plates 
were then incubated at 37°C overnight. 
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2.4.3.4 Selecting transformants 
From two LB/ampicillin/IPTG/X-Gal plates, ten white colonies, labelled clones a – j, 
were picked and streaked onto LB/ampicillin plates and incubated at 37°C overnight. 
From the resulting growth, half of a single, well isolated colony from each of five 
clones (a – e) was suspended in 50 μl nuclease free water and subjected to PCR as 
described below (2.4.3.5). The rest of the confluent growth of the 10 clones (a – j) 
were resuspended in Mueller-Hinton broth with 10% glycerol and stored at - 80°C.  
 
2.4.3.5  Insert amplification 
Amplification was performed employing vector specific forward primer M13F (5’ – 
GTTTTCCCAGTCACGAC – 3’) and reverse primer M13R (5’ – 
CAGGAAACAGCTATGAC –3’) in a total volume of 25 µl. The reaction mix 
comprised 2 µl of DNA template, 2 mM MgCl2, 0.5 µM of each primer, 0.2 mM of 
each dNTP, 0.625 units Taq DNA polymerase (Invitrogen) in a PCR buffer (20 mM 
Tris-HCl pH 8.0, 0.1 mM EDTA, 1 mM DTT, 50% (v/v) glycerol and stabilizers) 
(Invitrogen). The cycling conditions were 95°C for 2 min followed by 25 cycles of 
95°C for 30s; 45°C for 30s and 72°C for 30s, with a final extension at 72°C for 5 min 
in a thermocycler (Applied Biosystems GeneAmp® PCR System 9700). PCR 
products were separated by electrophoresis (section 2.3.2.3). A PCR product of the 
expected size (806 bp) confirmed the presence of the correct insert and was 
prepared for direct sequencing using ExoSAP-IT (USB Corporation, Cleveland, 
USA). Sequencing was performed employing vector specific primers M13F and 
M13R, according to the manufacturer’s instructions as described in section 2.4.4.  
 
 
2.4.4  Sequencing 
 
The PCR product concentrations were estimated by comparison to the DNA 
molecular weight marker XIV (Roche) concentration standards incorporated in the 
molecular weight markers. The PCR products were diluted to 10 ng/μl with nuclease-
free water. PCR products were prepared for direct sequencing using the ExoSAP-IT 
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(USB Corporation) enzyme digestion. The enzyme combination of shrimp alkaline 
phosphatase and exonuclease 1 hydrolyses any remaining dNTP’s and degrades 
any residual single-stranded primers or extraneous single-stranded DNA, preparing 
the PCR product for dideoxy cycle sequencing. The procedure was performed 
according to the manufacturer’s instructions. Briefly, 2 µl of ExoSAP-IT was added to 
5 µl diluted PCR product. The mix was incubated, using a thermocycler (Applied 
Biosystems GeneAmp® PCR System 9700) at 37°C for 15 min and then at 80°C for 
15 min to irreversibly inactivate the enzymes. A final concentration of 5 ng/µl DNA 
was used for sequencing. 
 
Sequencing reactions were performed using the ABI Prism® BigDyeTM Terminator 
Ready Reaction v3.1 Cycle Sequencing Kit (Applied Biosystems) according to the 
manufacturer’s instructions. Briefly, half reactions were performed as follows: 4 μl 
ready Reaction Premix, 2 μl BigDye Sequencing Buffer, 3.2 pmol primer (M13 F 
and/or M13 R), 3 – 10 ng template DNA, and nuclease free water was added for a 
final volume of 20 μl.  
 
Temperature cycling: the PCR was performed in a thermocycler (Applied Biosystems 
GeneAmp® PCR System 9700) with an initial denaturation at 96°C for 1 min, followed 
by 25 cycles comprising 96°C for 10 sec; 50°C for 5 sec; and 60°C for 4 min. 
Capillary electrophoresis was performed on an ABI Prism® 3100 Genetic Analyser 
(Applied Biosystems) according to the manufacturer’s instructions, by the Central 
Analytical Facility, University of Stellenbosch.  
 
 
2.4.5  Coalescent statistical parsimony network analysis 
 
ITS1 and ITS2 sequences were aligned with all previously published ITS sequences 
employing Clustal W, incorporated in the BioEdit software package (version 5.06; 
Tom Hall, Department of Microbiology North Carolina State University 
[http://www.mbio.ncsu.edu/BioEdit/page2.html]), with subsequent visual inspection 
and optimisation. ITS genotypes were assigned and named according to Lee et al. 
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[Lee, et al., 1998]. An area within the ITS1 contains a homopolymeric tract (located 
between positions 62 – 71 that has 10 T bases in tandem) that has been shown to 
yield variable nucleotide numbers when sequenced repeatedly and was omitted from 
genotyping [Lee, et al., 1998]. New types were only assigned if found in more than 
one patient specimen.  
 
Statistical parsimony was applied using the computer program TCS (version 1.13; 
Clement, M., J. Derington, and D. Posada. Brigham Young University. 
[http://inbio.byu.edu/Faculty/kac/crandall_lab/] [Clement, et al., 2000]. ITS1 and ITS2 
sequences were concatenated. Gaps were treated as missing characters, but 
subsequent to coalescence network analysis, included to reveal haplotype 
subdivisions within the obtained haplotypes. Unresolved loops were optimised by 
applying coalescence theory to obtain the most parsimonous network [Rosenberg, et 
al., 2002]. 
 
 
2.5 DHPS AND DHFR GENE SCREENING AND SEQUENCING 
 
2.5.1  Specimens 
 
One hundred and seventy eight sequential specimens, that included the 78 described 
in section 2.1.1, submitted to the Pathology Laboratories at Tygerberg Hospital, 
South Africa, for identification of P. jirovecii (June 2001 to February 2003) were 
collected and stored at -80°C. In addition, 23 of 663 TB-positive specimens that 
produced an amplicon by mtLSUrRNA nested PCR (section 4.2.2) were included. 
 
 
2.5.2 Amplification and sequencing 
 
Sample preparation (section 2.3.1) and DNA extraction (section 2.3.2) was 
undertaken and amplification of DHPS and DHFR genes were performed as 
described in sections 2.3.3.2 and 2.3.3.4, respectively. PCR products were 
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sequenced as described in section 2.4.4 employing DHPS forward and reverse 
primers Ahum and Bnest, and DHFR forward and reverse primers FR242 and 
FR1018. 
 
 
2.5.3  DHPS and DHFR sequence alignment 
 
DNA sequences were analysed using the computer program Chromas Version 1.45 
[C. McCarthy, Griffith University, Australia]. The deduced DNA sequences were 
converted to FASTA format and compared to published wild type sequences, 
deposited in the GenBank repository, using the multiple sequence alignment 
computer program BioEdit (version 5.06; Tom Hall, Department of Microbiology, 
North Carolina State University [http://www.mbio.ncsu.edu/BioEdit/page2.html]). The 
P. jirovecii sequences obtained were compared to the P. jirovecii wild type genes 
with the following GenBank accession numbers: DHPS U66279 [Lane, et al., 1997] 
and DHFR AF090368.1 [Ma, 1999]. Sequences producing double peaks indicative of 
mixed strain types were submitted to subcloning as described in section 2.4.3, and 
resequenced. 
 
 
2.5.4  Genome walking 
 
The Universal GenomeWalker™ kit (BD Bioscience Clontech, Palo Alto, CA) was 
employed for exploring upstream sequences of currently employed DHPS primer 
annealing sites according to the manufacturer’s recommendations. Genome walking 
is performed by construction of a pool of adaptor-ligated genomic DNA fragments 
(libraries). Genomic DNA is digested with various restriction enzymes to create blunt-
ended genomic fragments and is ligated to adapter sequences. A primary PCR is 
performed using an outer adaptor primer (AP1) and an outer gene specific primer 
(GSP1). A nested PCR is performed on the product of the primary PCR employing a 
nested adaptor primer (AP2) and a nested gene specific primer (GSP2). Each of the 
DNA fragments – which begin in a known sequence at the 5´ end of GSP2 and 
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extend into unknown adjacent genomic DNA – can then be cloned and further 
analysed. 
 
2.5.4.1 Library construction 
An open-lung biopsy confirmed by methanamine silver staining and PCR for the 
presence of P. jirovecii, as well as a BAL specimen confirmed by IF and PCR for the 
presence of P. jirovecii were investigated. DNA extraction was performed as 
described in section 2.3.1 and 2.3.2. The quality of genomic DNA was evaluated by 
running 1 μl of extracted DNA on 0.5% agarose gel. In addition, the purity of the 
extracted DNA was evaluated by subjecting the DNA to digestion by Dra I. The 
digestion reaction was performed as follows: Briefly, 5 μl DNA was digested with 16 
U Dra I in Dra I restriction buffer (BD Bioscience Clontech) in a total volume of 20 μl. 
Digestion occurred at 37°C overnight. The digested DNA was evaluated on 0.5% 
agarose gel by electrophoresis. 
 
For each library construction three blunt end digestions were performed, a positive 
human genomic DNA control was included with each library construction. Each 
reaction consisted of 25 μl genomic DNA, 8 μl restriction enzyme (Dra I, EcoR V, Pvu 
II), 10 μl restriction enzyme buffer, and dH2O to a final volume of 100 μl. The 
reactions were incubated at 37°C for 2 h, vortexed at slow speed and returned to 
37°C for overnight digestion. From each reaction 5 μl was subjected to 0.5% agarose 
gel electrophoresis.  
 
Digested DNA was purified by phenol / chloroform ethanol precipitation. Briefly, 95 μl 
phenol (Sigma) was added to each tube, vortexed at slow speed, and centrifuged at 
6 000xg for 30 sec. The aqueous phase was aspirated, to which 95 μl chloroform 
(Sigma) was added, vortexed at slow speed and centrifuged at 6 000xg for 30 sec. 
The aqueous phase was aspirated to which 190 μl ice cold 95% ethanol (Sigma), 9.5 
μl 3 M NaOAc (pH 4.5), and 20 μg glycogen (Fermentas, Vilnius, Lithuania) was 
added and vortexed at slow speed. The solution was then centrifuged at 14 000xg for 
10 min and the pellet washed in 100 μl ice-cold 80% ethanol (Sigma). After 
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centrifugation at 14 000xg for 15 min the pellet was air dried and resuspended in 20 
μl TE (10/01, pH 7.5) (Sigma). One microliter of digest solutions were 
electrophoresed on 0.5% agarose gels and DNA quantified by visual inspection. 
 
Four microliters of digested DNA (50 pg/μl) was ligated to adaptors by the addition of 
1.9 μl GenomeWalker adaptor, 1.6 μl 10X ligation buffer, and 0.5 μl T4 DNA ligase. 
The reaction was incubated at 4°C overnight in an Applied Biosystems 9700 
Thermalcycler. The ligation reaction was terminated after overnight incubation by 
heat inactivation at 70°C for 5 min. To the reaction 72 μl TE (10/1, pH 7.4) (Sigma) 
was added and vortexed at slow speed. 
 
2.5.4.2 DNA walking 
A PCR was undertaken employing the BD Advantage™ II PCR enzyme system (BD 
Bioscience Clontech) with primers GSP1 (DHPS B45 – see Table 2.1) and AP1. 
Amplification was performed in a total volume of 50 µl. The reaction mix comprised: 
1 µl of DNA template, 2.5 mM Mg(Oac)2, 10 μM of each primer, 0.2 mM of each 
dNTP, Advantage II Genomic Polymerase buffer and 1μl Advantage II polymerase 
mix. Temperature cycling consisted of a two step cycle: 7 cycles comprising 94°C for 
2 sec and 72°C 3 min, followed by 32 cycles of 94°C, 2 sec and 67°C, 3 min. Final 
extension was at 67°C for 4 min.  
 
A nested reaction was performed with primers GSP2 (DHPS Bn, see table 2.1) and 
AP2. Amplification was performed in a total volume of 50 µl. The reaction mix 
comprised: 1 µl of primary PCR product, 2.5 mM Mg(OAc)2, 10 μM of each primer, 
0.2 mM of each dNTP, Advantage II Genomic Polymerase buffer and 1μl Advantage 
II polymerase mix. Temperature cycling consisted of a two step cycle: 5 cycles 
comprising 94°C for 2 sec and 72°C for 3 min, followed by 20 cycles of 94°C for 2 
sec and 67°C for 3 min. Final extension was at 67°C for 4 min.  PCR products (5 μl) 
were analysed on 1.5% agarose gels by electrophoresis. Products were subjected to 
DNA sequencing as described in section 2.4.4 employing GSP2. 
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2.5.5  Extended DHPS and DHFR primer investigations 
 
2.5.5.1 Specimens 
Specimens employed consisted of two categories: four specimens that had yielded a 
DHPS or DHFR PCR product using previously employed primers (section 2.3.3), and 
five specimens that displayed discordant DHPS/DHFR-negative vs. mtLSUrRNA 
nested PCR-positive results. 
 
2.5.5.2 DHPS primer design 
New primers were designed employing the computer program GeneFisher 
[Geigerich, et al., 1996] according to software recommendations. For DHPS primer 
searches the published P. jirovecii hydroxymethyl-dihydropterin pyrophosphokinase / 
dihydropteroate synthase (Genbank AF139132) [Ma, et al., 1999] was employed as 
the input sequence. The following parameters were specified: Primer size 18 –31; 
primer GC content 45% – 65%; melting temperature (Tm) 55°C - 65°C; PCR distance 
500 – 1000 bp; 3´ clamp GC content 45% – 55%; Maximum GC clamp size 4. 
Primers PSGF1 and PSGF2 derived. One set of primers was empirically designed in 
order to include all previously employed primer annealing sites and assigned as 
primers LR1 and LR2. In addition, the previously published primer B45 was modified 
subsequent to detection of errors of the published primer sequence [Lane, et al., 
1997] and redesigned as B45b.  
 
Reaction mixture and cycling parameters as described in section 2.3.3.2 were used 
but with appropriate annealing temperatures. Forward primer PSGF1 5´ 
TTTATAAATGCAGGGGCGACGA and reverse primer PSGF2 5´ 
CCCGTATAATATCACAGCCTCCTA. Annealing temperature 52ºC, PCR product 
size 628 bp. Forward primer LR1 5´ CAAATTAGCGTATCGAATGACCT and reverse 
primer LR2 5´ TGCAAAATTACAATCAATCAACCAAAG. Annealing temperature 
62ºC, PCR product size 1030 bp. Forward primer F1b 5´ 
GTTAATCCTGGTATTAAACAGTTTTGCCAT and reverse primer B45b 5´ 
CAATTCAATAAACTCCTTTCCAAATAGCATC. Annealing temperature 52ºC, PCR 
product size 911 bp. 
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2.5.5.3 DHPS primer combinations 
Reaction mixture and cycling parameters as described in section 2.3.3.2 were used 
but with an appropriate annealing temperature. Forward primer DHPS F1: 5′ – 
CCTGGTATTAAACCAGTTTTGCC and reverse primer DHPS BHUM: 5′ – 
CATAAACATCATGAACCCG. Annealing temperature 52ºC, PCR product size 838 
bp.  
 
2.5.5.4 DHFR primer design 
New primers were designed employing the computer program GeneFisher 
[Geigerich, et al., 1996] according to software recommendations. For DHFR primer 
searches the published P. jirovecii dihydrofolate reductase gene (Genbank 
AF090368) [Ma, et al., 1999] was employed as the input sequence. The following 
parameters were specified: Primer size 18 –31; primer GC content 45% – 65%; 
melting temperature (Tm) 55°C - 65°C; PCR distance 500 – 1200 bp; 3´ clamp GC 
content 45% – 55%; Maximum GC clamp size 4. Primer pair FRGF1 and FRGF2 was 
derived. 
 
Reaction mixture and cycling parameters as described in section 2.3.3.4 were used 
but with an appropriate annealing temperature and extension time. Forward primer 
FRGF1 5´ AGATTCCTGTACTGTGGCTTCTGA and reverse primer FRGF2 5´ 
ACCCTGAGGAACTTTACTTCCA. Annealing temperature 65ºC, extension time 1 
min. PCR product size 1167 bp. 
 
2.5.5.5 Gene sequencing 
PCR products obtained in 2.5.5.2 – 2.5.5.4 were subjected to DNA sequencing as 
described in section 2.4.4 employing primers used for amplification. 
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2.6 ETHICAL APPROVAL 
 
Approval to perform this study was obtained from the Stellenbosch University 
Division of Research Development and Support, Subcommittee C (Protocol Numbers 
2001/C081 and 2002/C085). Work on M. tuberculosis sputum specimens obtained 
from the Unit for Tuberculosis Operational and Policy Research had received 
approval from the Medical Research Council Bioethics committee as part of the TB 
surveillance protocol. 
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CHAPTER 3 
 
PCR DETECTION 
 
 
_______________________________ 
 
3.1 INTRODUCTION 
 
Culture of P. jirovecii is still elusive and diagnostic investigations have in the past 
relied on the microscopic detection of cysts or trophic forms of the fungus in 
respiratory fluids obtained by BAL, TASP, induced sputum or from tissues obtained 
from transbronchial or open lung biopsies. The problems are that a single stain 
cannot detect all the P. jirovecii life cycle stages, variable observer skill and 
interpretational differences. Early diagnosis of PcP in immunocompromised patients, 
a life threatening complication if not treated correctly, may lower the morbidity and 
mortality associated with it. The PCR has been reported to be superior to staining 
techniques for the detection, as it is more sensitive and specific [Leign, et al., 1993]. 
The major advantages of PCR are the ability to detect low numbers of organisms 
(sensitivity) and the very specific nature of PCR methods. The first report of PCR for 
clinical detection of P. jirovecii in BAL was by Wakefield et al., employing primers 
directed at the mtLSUrRNA [Wakefield, et al., 1990a]. Subsequently a number of 
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reports have been published on PCR for the detection of P. jirovecii in clinical 
samples employing various chromosomal loci [Wakefield, et al., 1990a; Kitada, et al., 
1991; Tamburrini, et al., 1993; Honda, et al., 1994; Lee, et al., 1994; Chouaid, et al., 
1995; De Luca, et al., 1995; Moonens, et al., 1995; Lu, et al., 1995; Skøt, et al., 1995; 
Lane, et al., 1997; Mathis, et al., 1997; Rabodonirina, et al., 1997; Ribes, et al., 1997; 
Huang, et al., 1999; Sandhu, et al., 1999; Sing, et al., 2000; Torres, et al., 2000; 
Helweg-Larsen, et al., 2002; Kasolo, et al., 2002; Lishimpi, et al., 2002]. The 
sensitivity and specificity of PCR methods using these different targets varies [De 
Luca, et al., 1995; Lu, et al., 1995]. More recently real-time PCR has been described 
as being a sensitive and specific technique with the potential for quantitative analysis 
to differentiate colonisation from infection [Kaiser, et al., 2001; Palladino, et al., 2001; 
Larsen, et al., 2002a; Larsen, et al., 2002b; Larsen, et al., 2004]. Discrepant results 
have been reported when comparing IF staining techniques with PCR. Factors that 
could lead to discordant results include the observation that PCR can rapidly convert 
from positive to negative following initiation of specific treatment for PcP, whereas 
cyst wall specific stains can detect empty cysts subsequent to successful treatment / 
clearance [Armbruster, et al., 1995]. 
 
The perception by clinicians at Tygerberg Hospital that the P. jirovecii IF method 
appears to produce both false-positive and false-negative results prompted 
evaluation- and comparison of IF and recent molecular detection techniques. 
However, primer selection plays a significant role in the diagnosis of PcP by PCR 
and various primers and PCR techniques should be evaluated for local strains / 
conditions [De Luca, et al., 1995]. 
 
 
3.2 RESULTS 
 
3.2.1 PCR evaluation 
 
A study to evaluate the detection of P. jirovecii from various clinical specimens by 
nine PCR assays was undertaken. PCR amplification was performed with 
CHAPER 3 PCR DETECTION 
___________________________________________________________________ 
55
mtLSUrRNA nested, mtLSUrRNA single-round, DHPS nested, MSG hemi-nested, 
ITS nested, 18S one-tube nested, DHPS single, and DHFR nested primers. 
Amplification products are shown in Figures 3.1 – 3.8. 5S Real-time PCR products 
detected by SYBR Green fluorescence are shown in Figure 3.9. Real-time PCR 
products, characterised as melting at 82.5ºC, were confirmed as 120 bp (Figure 
3.10).  
 
Of 90 specimens processed, depending on the primers employed, an amplification 
product indicative of P. jirovecii was obtained in 9 to 62 specimens (Table 3.1). The 
highest detection rate was observed for the mtLSUrRNA nested (69%), followed by 
real-time 5S (54%), mtLSUrRNA single (47%), DHPS nested (42%), MSG 
heminested (27%), ITS nested (24%), 18S nested (20%), DHPS single (10%), and 
DHFR nested (10%). Concordances between the PCR reactions varied from 41.9% 
to 94.9% (Table 3.2). Least concordance was seen for DHPS single vs. mtLSUrRNA 
nested PCR (41.9%). The highest degree of concordance among the PCR methods 
was mtLSUrRNA nested vs. real-time 5S (88.9%), DHPS single vs. 18S (90.5%), and 
18S vs. DHPS nested PCR (94.9%). The mtLSUrRNA single and nested reactions 
(same primers employed for first round) displayed a concordance of 64.9% with the 
nested reaction detecting 20 additional specimens to the single-round PCR. DHPS 
nested and DHPS single PCR (different primers employed) displayed a concordance 
of 82.4%. The highest detection rate was obtained with mtLSUrRNA nested and 5S 
real-time PCR for which discordant results are shown and further analysed in Table 
3.3. By considering a positive PCR targeting another gene, other than mtLSUrRNA 
and / or staining as confirmation, results suggested two false-negative mtLSUrRNA 
nested PCR results (specimens 4 and 5, Table 3.3), and 12 false-negative real-time 
5S rRNA PCR results (specimens 6 – 17, Table 3.3).  
 
P. jirovecii strain typing which involved sequencing of ITS PCR products was 
performed as described in Chapter 5. It is of interest that of six specimens, which 
were ITS PCR positive, the products on sequencing contained the amplified 
homologous region of Candida albicans in five specimens and Cryptococcus magnus 
in one specimen. For two of these specimens all other PCR products were negative.  
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Figure 3.1 P. jirovecii detection employing mtLSUrRNA single-round PCR 
Positive PCR fragment: 346 bp. Lane 1: 100 bp DNA ladder; Lane 19: Negative 
control; Lane 20: Positive control. 
 
 
 
 
 
 
 
 
 
Figure 3.2 P. jirovecii detection employing mtLSUrRNA nested PCR  
Positive PCR fragment: 260 bp. Lane 1: 100 bp DNA ladder; Lane 19: Negative 
control; Lane 20: Positive control. 
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Figure 3.3 P. jirovecii detection employing DHPS nested PCR  
Positive PCR fragment: 300 bp. Lane 1: 100 bp DNA ladder; Lane 19: Negative 
control; Lane 20: Positive control. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 P. jirovecii detection employing DHPS single PCR  
Positive PCR fragment: 750 bp. Lane 1: 100 bp DNA ladder; Lane 19: Negative 
control; Lane 20: Positive control. 
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Figure 3.5 P. jirovecii detection employing ITS nested PCR  
Positive PCR fragment: 550 bp. Lane 1: 100 bp DNA ladder; Lane 19: Negative 
control; Lane 20: Positive control. 
 
 
 
 
 
 
 
 
 
Figure 3.6 P. jirovecii detection employing MSG hemi-nested PCR 
Positive PCR fragment: 249 bp. Lane 1: 100 bp DNA ladder; Lane 19: Negative 
control; Lane 20: Positive control. 
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Figure 3.7 P. jirovecii detection employing 18S one-tube nested PCR 
Positive PCR fragment: 265 bp. Lane 1: 100 bp DNA ladder; Lane 19: Negative 
control; Lane 20: Positive control. 
 
 
 
 
 
 
 
 
 
Figure 3.8 P. jirovecii detection employing DHFR nested PCR 
Positive PCR fragment: 798 bp. Lane 1: 100 bp DNA ladder; Lane 19: Negative 
control; Lane 20: Positive control. 
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Figure 3.9 Real-time 5S rRNA PCR melting curve analysis 
Positive signal at Tm 82.5°C +/- 2.0°C. 
 
 
 
 
 
 
Figure 3.10 Real-time 5S PCR products  
Lane 1: 100 bp DNA ladder; Lane 6: Negative Control 
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Table 3.1  PCR detection results 
 
  BAL TASP Sputum Bx PET Total (%) 
  n = 9 n = 50 n = 14 n = 5 n = 12 n = 90 
        
mtLSUrRNA 
nested 6 31 8 5 12 
62  
(69) 
       
Real-time 5S 2 26 6 4 11 49 (54) 
        
mtLSUrRNA1 4 27 3 3 5 42  (47) 
        
DHPS nested 2 23 5 3 5 38  (42) 
        
MSG heminested 0 9 3 3 9 24  (27) 
        
ITS nested 1 15 2 2 2 22  (24) 
        
18S one-tube 
nested 0 8 3 4 3 
18 
(20) 
        
DHPS single 1 4 2 2 0 9 (10) 
        
DHFR nested 0 3 0 3 3 9 (10) 
BAL = Bronchoalveolar lavage fluid; TASP = Tracheal aspirate fluid; Bx = fresh lung biopsy;  
PET = Paraffin wax-embedded lung tissue 
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Table 3.2  Concordance (%) among PCR techniques evaluated 
 
  
Real-
time 
5S 
Mt 
LSU 
rRNAn 
Mt LSU 
rRNA1 
DHPSn MSGn ITSn 18S DHPSs DHFRn 
           
Real-time 5S -         
Mt LSU rRNAn 88.9 -        
Mt LSU rRNA1 56.6 64.9 -       
DHPSn 52.2 56.1 54.1 -      
MSGn 73.3 69.1 51.1 72.3 -     
ITSn 62.2 60.2 58.2 74.5 74.5 -    
18S 61.1 62.2 54.1 94.9 87.2 87.2 -   
DHPSs 52.2 41.9 54.0 82.4 77.0 78.4 90.5 -  
DHFRn 56.5 49.3 61.6 83.6 79.5 78.1 87.7 87.7 - 
           
Percent concordance between PCR methods = (concordant positives + concordant negatives) / all 
tests X 100. n = nested; s = single round; hn = heminested; 1-tn = one-tube nested 
 
 
 
 
_____________________________________________________________________ 
Table 3.3  Real-time and mtLSUrRNA nested discordant PCR results  
(Following page) 
a DETECT IF Pneumocystis carinii indirect immunofluorescense kit (Shield Diagnostics) 
b Tracheal aspirate 
c Paraffin wax-embedded lung biopsy 
d Methanamine silver histological staining 
e Bronchoalveolar lavage 
Dark grey shading = false mtLSUrRNA nested – negative results 
Light grey shading = false 5S real-time PCR results 
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Table 3.3  Real-time and mtLSUrRNA nested discordant PCR results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. Specimen type 
mtLSUrRNA
nested 
Real-
time 
Other PCR 
positive 
Supporting 
tests 
1 Sputum - + None IFa - 
      
2 TASPb - + None IF - 
      
3 TASP - + None None 
      
4 TASP - + DHPS nested IF - 
      
5 TASP - + MSG None 
      
6 TASP + - MtLSUrRNAs, DHPS nested IF + 
      
7 TASP + - MtLSUrRNAs, DHPS nested IF + 
      
8 TASP + - MtLSUrRNAs, DHPS nested IF + 
      
9 TASP + - ITS nested, DHPS nested IF + 
      
10 TASP + - MtLSUrRNAs, DHPS nested IF - 
      
11 TASP + - MtLSUrRNAs, DHPS nested IF - 
      
12 TASP + - mtLSUrRNAs, DHPS nested IF - 
      
13 Sputum + - mtLSUrRNAs, DHPS nested IF - 
      
14 PET lungc + - MtLSUrRNAs MSd + 
      
15 Biopsy + - MtLSUrRNAs IF + 
      
16 BALe + - MtLSUrRNAs IF + 
      
17 TASP + - MtLSUrRNAs IF + 
      
18 BAL + - MtLSUrRNAs IF - 
      
19 BAL + - MtLSUrRNAs Not done 
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3.2.2 Real-time quantitative analysis 
 
Quantitative analysis was performed on discordant 5S real-time, mtLSUrRNA nested 
and DHPS nested PCR specimens to determine whether a correlation existed 
between organism concentration and method performance. The standard curve 
employed for quantitative analysis (Figure 3.11) had the following characteristics 
(employing the second derivative maximum analysis method incorporated in the 
LightCycler software suite): Slope = -0.658, Intercept = 33.5, Error = 0.155, and r = -
0.96. The quantitative data obtained on the discordant results are shown in Table 
3.4. No correlation was observed between target copy number and performance of a 
PCR method. 
 
 
 
 
 
Figure 3.11 Standard curve obtained for quantitative real-time 5S rRNA PCR 
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Table 3.4 Quantitative analysis of discordant mtLSUrRNA, DHPS and 5S real-
time PCR results 
 
Specimen No. PCR Profile Target copy number (targets/μl)# 
1 mtLSUrRNA n - DHPS n - 1.06 X 10
-1 
2 mtLSUrRNA n - DHPS n - 2.43 X 10
7 
3 mtLSUrRNA n - DHPS n - 7.37 X 10
1 
4 mtLSUrRNA n + DHPS n + 2.96 X 10
8 
5 mtLSUrRNA n + DHPS n - 1.82 X 10
-1 
6 mtLSUrRNA n + DHPS n - 1.44 X 10
3 
7 mtLSUrRNA n + DHPS n - 4.56 X 10
5 
8 mtLSUrRNA n + DHPS n - 7.09 X 10
4 
9 mtLSUrRNA n + DHPS n - 4.94 X 10
3 
10 
mtLSUrRNA s + 
mtLSUrRNA n + 
DHPS n - 
1.05 X 103 
11 
mtLSUrRNA s + 
mtLSUrRNA n + 
DHPS n - 
3.96 X 1010 
12 
mtLSUrRNA s + 
mtLSUrRNA n + 
DHPS n - 
4.59 X 10-1 
13 
mtLSUrRNA s + 
mtLSUrRNA n + 
DHPS n - 
2.85 X 10-1 
14 
mtLSUrRNA s + 
mtLSUrRNA n + 
DHPS n - 
3.13 X 10-1 
 
# As determined by quantitative PCR employing 5S rRNA real-time PCR with 10 μl DNA template.  
n = nested; s = single-round 
Shading depicts the four PCR profile groups 
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3.2.3  PCR vs. standard staining techniques 
 
PCR results were compared to IF and histological staining (methenamine silver) by 
specimen type (Table 3.5). Concordances were calculated among the results 
obtained (Table 3.6). Agreement of PCR and IF on TASP ranged from 16% - 48%, 
for BAL from 22% - 44%, and for sputum from 36% - 57%. PCR agreement with fresh 
biopsies ranged from 40% - 100% and that on formalin-fixed paraffin wax-embedded 
lung biopsy specimens from 0% - 100% (Table 3.6). It is of note that, compared to 
histological techniques (methanamine silver staining), PCR on respiratory fluid 
specimens subjected to IF displayed remarkable discordances. The two most 
sensitive PCR assays (mtLSUrRNA nested and 5S real-time PCR) produced 
concordance to IF on TASP of 46 – 48%, BAL of 44%, and sputum of 43% - 50%, 
whilst compared to methanamine silver histology (often regarded as gold standard) 
concordance of 80 – 100% was obtained. This alludes to questioning the reliability of 
IF on respiratory fluids. When compared to IF mtLSUrRNA nested PCR appeared the 
most concordant PCR method (48%), followed by 5S real-time PCR (45%). Similarly, 
on methanamine silver stained histology sections, mtLSUrRNA nested PCR was 
most sensitive (100%), followed by 5S real-time PCR (88%). 
 
3.2.3.1  Comparison of mtLSUrRNA PCR to IF 
Since the mtLSUrRNA nested PCR demonstrated the highest detection rate among 
the primer combinations (Table 3.1) and the highest degree of concordance to 
staining (Table 3.6), 74 mtLSUrRNA nested PCR results were evaluated against IF 
(Table 3.7). MtLSUrRNA PCR detected P. jirovecii in 42 / 74 whilst IF reported a 
positive signal from 56 / 74 specimens (Tables 3.7 and 3.8). Direct comparison of 
mtLSUrRNA nested PCR to IF yielded a sensitivity and specificity of 55.4% and 
38.9%, respectively (Table 3.7), whilst comparison of IF to mtLSUrRNA yielded a 
sensitivity of 73.8% and specificity of 21.9% (Table 3.8). 
CHAPER 3 PCR DETECTION 
___________________________________________________________________ 
67 
 Table 3.5  PCR technique results vs. IF and histology staining by specimen type in 2X2 format 
 
  Staining Results 
  IF Histology 
  TASP BAL Sputum PET Biopsy 
  Positive Negative Positive Negative Positive Negative Positive Negative Positive Negative 
                
Positive 19 6 2 0 3 3 11 0 4 0 Real-
time 5S Negative 21 4 5 2 5 3 1 0 1 0 
n = 90                
Positive 18 4 3 1 3 2 12 0 5 0 Mt LSU 
rRNAn Negative 22 6 4 1 5 4 0 0 0 0 
n = 90            
Positive 19 8 3 1 1 2 5 0 3 0 Mt LSU 
rRNAs Negative 21 2 4 1 7 4 7 0 2 0 
n = 90            
Positive 17 6 1 1 3 2 5 0 3 0 DHPSn Negative 23 4 6 1 5 4 7 0 2 0 
n = 90            
Positive 9 0 0 0 2 1 9 0 3 0 MSGn Negative 28 9 7 2 6 5 3 0 2 0 
n = 86            
Positive 12 3 1 0 2 0 2 0 2 0 ITSn Negative 28 7 6 2 6 6 10 0 3 0 
n = 90            
Positive 7 1 0 0 2 1 3 0 4 0 18S Negative 33 9 7 2 6 5 9 0 1 0 
n = 90            
Positive 3 1 1 0 2 0 0 0 2 0 DHPSs Negative 26 2 6 2 5 4 12 0 3 0 
n = 69            
Positive 3 0 0 0 0 0 3 0 3 0 DHFRn Negative 27 2 6 2 7 4 9 0 2 0 
n = 68            
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Table 3.6  Concordance (%) of PCR techniques to staining by specimen type # 
 IF Histology 
 TASP 
n = 50 
BAL 
n = 9 
Sputum 
n = 14 
Total 
n = 73 
Biopsy 
n = 5 
PET* 
n = 12 
Total 
n = 17 
Real-time 5S  46 44 43 45 80 92 88 
MtLSUrRNA n 48 44 50 48 100 100 100 
mtLSUrRNA s 42 44 36 41 60 42 47 
DHPS nested 42 22 50 41 60 42 47 
MSG hn 39 22 50 39 60 75 71 
ITS n 38 33 57 41 40 17 24 
18S n 32 22 50 34 80 25 41 
DHPS s 16 33 55 27 40 0 12 
DHFR n 16 25 36 22 60 25 35 
# Calculated from Table 3.6. 
* Formalin-fixed paraffin-wax embedded lung biopsy specimens 
CHAPER 3 PCR DETECTION 
___________________________________________________________________ 
69
 
 
Table 3.7 Sensitivity and specificity of mtLSUrRNA PCR vs IF 
 
  IF  
  Positive Negative Total 
Positive 31 a 11 c 42 
mtLSUrRNA PCR { Negative 25 b 7 d 32 
Total 56 a + b 18 c + d 74 
 
Sensitivity: 55.4% 
Specificity: 38.9% 
Sensitivity = a / (a + b) x 100; Specificity = d / (c + d) x 100 
 
 
 
 
Table 3.8 Sensitivity and specificity of IF vs mtLSUrRNA 
 
  MtLSUrRNA nested  
  Positive Negative Total 
Positive 31 25 56 
            IF           { 
Negative 11 7 18 
Total 42 32 74 
 
Sensitivity: 73.8% 
Specificity: 21.9% 
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3.2.4  Analysis of discrepant PCR and IF results 
 
Discrepancies between results obtained from mtLSUrRNA nested PCR and IF were 
seen with 36 / 74 specimens (Tables 3.7 and 3.8). This high degree of discrepancy 
prompted investigations of clinical data by review of hospital records and histology 
and / or cytology results. The findings are summarised in sections 3.2.4.1 and 
3.2.4.2. 
 
3.2.4.1 PCR-negative IF-positive 
PCR-negative IF-positive discrepant results were seen in 25 specimens. Following 
review of hospital records, histology and/or cytology results and DHPS nested PCR 
(confirmed by sequencing), specimen results were as follows: (Summarised in Table 
3.9a.) 
 
False IF positive (7 / 25 specimens) 
• One specimen, clinically the patient was considered not to have PcP and the 
histology result was negative. 
• Three specimens, clinically the patients were considered not to have PcP, one 
of these was negative by cytology and the other two patients recovered 
without specific PcP treatment. 
• Two patients were negative by cytology and/or histology. 
• One patient was diagnosed and successfully treated for M. tuberculosis. 
 
False mtLSUrRNA PCR negative (9 / 25 specimens) 
• Eight specimens produced a DHPS nested PCR amplicon that was confirmed 
by sequencing. 
• One specimen on re-amplification was mtLSUrRNA nested PCR positive. 
 
Unresolved (9 / 25 specimens) 
• On six specimens no other laboratory tests were performed to exclude PcP, 
and patients received cotrimoxazole. 
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• Three specimens failed to produce an amplification product with a template 
preparation control employing a universal bacterial PCR (Template quality 
suspected). 
 
 
Table 3.9a Analysis of discrepant mtLSUrRNA PCR-negative IF-positive   
results by incorporating clinical records and cytology/histology 
findings and additional PCR results where available 
 
Discrepancy 
Number of 
specimens 
Clinical records and cytology, 
histology and DHPS PCR 
results where available 
Consideration 
1 
Clinically not considered PcP 
and histology negative 
3 
Clinically not considered PcP, 
one patient cytology negative, 
and two patients improved 
without treatment 
2 
Cytology and/or histology 
negative 
1 
Diagnosed with TB and 
successfully treated for TB 
7 PCR negative, 
thus false IF-positive
6 
No other laboratory tests 
performed to exclude PcP, 
received cotrimoxazole. 
3 
Suspect template DNA, possible 
PCR-negative 
9 Unresolved 
 
8 DHPS PCR positive 
 
PCR – 
IF + 
1 Repeat PCR-positive 
9 False PCR 
negative 
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3.2.4.2 PCR-positive IF-negative 
PCR-positive IF-negative discrepant results were seen in 11 specimens. The 
discrepant results are summarised in Table 3.9b. Following review of hospital 
records, histology and/or cytology results and DHPS nested PCR (confirmed by 
sequencing) results, specimen results were as follows: 
 
False IF negative (1 / 11 specimens) 
• One patient on repeat sampling was IF positive. 
 
Unresolved (10 / 11 specimens) 
• Four patients were clinically considered to have PcP and received 
cotrimoxazole. 
• Of six patients insufficient clinical data was recorded. 
 
 
Table 3.9b Analysis of discrepant mtLSUrRNA PCR-positive IF-negative 
results by incorporating clinical records and cytology/histology 
findings and additional PCR results where available 
 
Discrepancy 
Number of 
specimens 
Clinical records and 
cytology, histology and 
DHPS PCR results where 
available 
Consideration 
1 Repeat IF-positive False IF-negative 
4 
Clinically considered PcP and 
received cotrimoxazole 
PCR + 
IF - 
6 No clinical records available 
10 Unresolved 
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Of the 36 specimens that produced discrepant results, 19 could not be resolved due 
to insufficient data although for 10 specimens false negative IF results are indicated 
(Tables 3.9a and 3.9b). The unresolved cases included: a) template DNA suspect (3 
specimens); b) No laboratory investigations or clinical records that supported or 
excluded PcP (10 specimens); c) insufficient clinical evidence to exclude PcP (6 
specimens).  
 
Including the review of hospital records, histology and/or cytology results and DHPS 
nested PCR (confirmed by sequencing), mtLSUrRNA yielded a sensitivity and 
specificity of 77.5% and 93.3%, respectively. The resultant positive and negative 
predictive values were 96.9% and 60.9% (Table 3.10). Comparing IF to reviewed 
results the sensitivity and specificity was 96.9% and 60.9%, and the positive and 
negative predicted values were 77.5% and 93.3%, respectively (Table 3.11). From 
Table 3.10 and 3.11 the derived prevalence of P. jirovecii in the sampled population 
was 69.9% based on mtLSUrRNA nested PCR results, and 74% based on IF results. 
 
 
Table 3.10  Sensitivity and specificity of mtLSUrRNA PCR vs IF with 
clinical review 
 
  Reviewed data  
  Positive Negative Total 
Positive 31 a 1 c 32 a + c 
mtLSUrRNA PCR { 
Negative 9 b 14 d 23 b + d 
Total 40 15 55 
 
Sensitivity: 77.5% 
Specificity: 93.3% 
Positive predictive value: 96.9% 
Negative predictive value: 60.9% 
Prevalence: 69.9% 
Positive predictive value = a / (a + c); Negative predictive value = d / (b + d);  
Prevalence = a + b / (a + b + c) 
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Table 3.11  Sensitivity and specificity of IF vs mtLSUrRNA PCR with 
clinical review 
 
  Reviewed data  
  Positive Negative Total 
Positive 31 9 40 
           IF             { 
Negative 1 14 15 
Total 32 23 55 
 
Sensitivity: 96.9% 
Specificity: 60.9% 
Positive predictive value: 77.5% 
Negative predictive value: 93.3% 
Prevalence: 74% 
 
 
3.3 DISCUSSION 
 
The perception by clinicians at Tygerberg Hospital that the P. jirovecii IF method 
appears to produce both false-positive and false-negative results prompted 
evaluation and comparison of IF and PCR techniques. 
 
3.3.1  PCR evaluation 
 
The mtLSUrRNA nested PCR employed against the South African clinical specimens 
yielded the highest level of sensitivity, followed by 5S rRNA real-time PCR. 
MtLSUrRNA is a nested reaction targeting a multicopy gene and lends itself to the 
detection of very low numbers of organisms, as reported in other studies 
[Rabodonirina, et al., 1997; Ribes, et al., 1997; Sing, et al., 2000; Torres, et al., 
2000]. MtLSUrRNA nested PCR detected considerably more P. jirovecii than the 
single-round PCR, 62 vs. 42 positive specimens. 5S Real-time PCR performed sub-
optimally, since utilisation of a sensitive amplicon detection technique (real-time 
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fluorescence detection) targeting a multicopy gene present at > 103 copies per 
haploid genome [Kitada, et al., 1991] one would expect a higher detection rate than 
conventional mtLSUrRNA nested PCR. However, 5S real-time PCR detection was 
similar to mtLSUrRNA single-round PCR. The detection limit for conventional 
mtLSUrRNA single PCR and 5S PCR have been suggested to be 10 nuclei / μl and 
160 nuclei / μl (as tested on rat isolates), respectively [De Luca, et al., 1995]. This 
implies that mtLSUrRNA should be more sensitive than conventional 5S PCR. The 
concordance of conventional 5S and mtLSUrRNA single PCR has been reported to 
be 93.6% [De Luca, et al., 1995]. However, in the current study, the use of real-time 
PCR has shifted the concordance of conventional mtLSUrRNA single and 5S real-
time PCR to 56.6%. The employment of fluorescent detection chemistry has 
improved the sensitivity of the 5S PCR technique, which was more sensitive in the 
current study than conventional mtLSUrRNA single-round PCR. Both 5S and 
mtLSUrRNA single PCR primers have been tested in previous studies for specificity: 
mtLSUrRNA single primers have been tested against Aspergillus nidulans, A. 
fumigatus, Cryptococcus neoformans, Candida albicans and non-albicans strains, 
Mycobacterium tuberculosis, Saccharomyces cerevisiae, and Histoplasma 
capsulatum [Wakefield, et al., 1990b; Lu, et al., 1995], and 5S primers against 
Corynebacterium kutshceri, Pasteurella pneumotropica, C. albicans, C. glabrata, 
Aspergillus fumigatus, C. neoformans and M. tuberculosis [Kitada, et al., 1991]. 
Although many clinically more relevant organisms could have been included for 
testing specificity, 5S real-time PCR has the advantage of melting curve analysis to 
confirm the sequence identity of the amplicon, and mtLSUrRNA products are verified 
by employing nested primers. It is widely assumed that real-time PCR is more 
sensitive than conventional amplification systems. Careful analysis of published 
reports reveals that real-time PCR has equal sensitivity to conventional amplification 
formats [Palladino, et al., 2001; Flori, et al., 2004]. In the current study analysis of 
discordant mtLSUrRNA nested and 5S real-time PCR indicates that mtLSUrRNA 
nested PCR produced two false-negative results, whilst 5S real-time PCR produced 
12 false-negative reports. This reinforces the value of conventional mtLSUrRNA 
nested PCR for the epidemiological detection of P. jirovecii from clinical specimens. 
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The inability to amplify the DHPS gene from all P. jirovecii PCR-positive specimens 
(38 vs. 62 for mtLSUrRNA nested) has been reported by other investigators in the 
USA [Beard, et al., 2000; Huang, et al., 2000]. A plausible explanation as to why 
DHPS fails to amplify all mtLSUrRNA positive specimens is that DHPS is a single 
nuclear encoded gene whereas mtLSUrRNA is a mitochondrial encoded gene and 
many mitochondria may be present at any one time within the cytoplasm. This may 
also be the reason for the poor performance of the DHPS single-round PCR as one 
would expect a lower yield than with the nested reaction.  
 
DHFR detected only 9 specimens, compared to 62 by mtLSUrRNA nested PCR. 
These findings are similar to those reported by Lu et al. (Indiana, USA) who obtained 
detection rates of 23% employing DHFR [Lu, et al., 1995]. However, in contrast, De 
Luca et al. reported similar sensitivities on comparing the two techniques 
(mtLSUrRNA: 72.7% and DHFR: 71%) [De Luca, et al., 1995]. Similar to the reported 
DHFR 5S concordance of 56.8% by De Luca et al. [De Luca, et al., 1995], the current 
study yielded a concordance of 61.6%. In support of similar sensitivities obtained, a 
detection limit of 160 nuclei / μl was reported for rat isolates on DHFR and 5S PCR 
[De Luca, et al., 1995].  
 
The poor performances of the MSG (24 MSG positive vs. 42 mtLSUrRNA single 
positive) seen in this study is in contrast to that reported by Huang et al. Working on 
specimens obtained from patients in the USA in 1999, they found that MSG PCR 
sensitivity exceeded that of mtLSUrRNA single PCR, and that MSG PCR yielded a 
positive signal from as little as 16 fg total DNA as compared to 1.6 pg by mtLSUrRNA 
single PCR [Huang, et al., 1999]. A reason for the observed low sensitivity and 
concordance is unclear, but speculation as to why MSG primers were seen not to be 
as efficient as the mtLSUrRNA primers on these recent specimens from South Africa 
is that the MSG gene (involved in antigenicity) is known to undergo constant 
rearrangement and such events may have resulted in modified primer annealing site 
[Garbe & Stringer, 1994; Kutty, et al., 2001]. 
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The lack of sensitivity of the ITS PCR (24% detection vs. 47% detection by 
mtLSUrRNA single-round PCR) is in contrast to previous studies reported in the 
literature. ITS PCR has been shown to be more sensitive (100% sensitivity) than 
mtLSUrRNA single PCR (87% sensitive), with an apparent detection limit of 3 
organisms per reaction [Lu, et al., 1995]. It is of importance to note that while Lu et al. 
reported that ITS PCR did not amplify DNA from various other organisms including C. 
albicans and C. neoformans [Lu, et al., 1995], in the present study, on subcloning 
and sequencing of the P. jirovecii indicative 550 bp amplicons, the homologous 
region of C. albicans (five specimens) and Cryptococcus magnus (one specimen) 
was demonstrated. For two of these specimens all other PCR reactions were 
negative. 
 
Previous reports of the high sensitivity of 18S rRNA nested PCR (100% detection 
compared to 87% detection by mtLSUrRNA single PCR) [Lu, 1995], is in 
contradiction to what was obtained from the current study (20% 18S detection vs. 
47% mtLSUrRNA single PCR detection). In addition, Mathis et al. reported that by 
omitting the nested reaction of 18S PCR a detection rate similar to that of single-
round mtLSUrRNA PCR is obtained, but when performing a nested reaction, up to a 
100 fold increase in sensitivity was obtained compared to a single step 18S and 
mtLSUrRNA PCR. A detection limit of 3 cysts per reaction was reported for the 
nested 18S PCR [Mathis, et al., 1997].  
 
 
3.3.2  Real-time quantitative analysis 
 
Quantitative analysis of discordant 5S real-time, mtLSUrRNA nested and DHPS 
nested PCR was performed to determine if a correlation exists between target copy 
number and PCR method performance. From the data obtained no correlation to 
target copy number could be observed, indicating that factors other than organism 
concentration play a role in the variable efficacy of these three PCR methods. 
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3.3.3  Analysis of PCR vs. IF 
 
It should always be borne in mind, that when comparing techniques sampling can 
influence result outcomes e.g. one PCR-negative specimen, on re-amplification was 
seen to be positive, and on repeat staining of an IF-negative specimen cysts were 
subsequently demonstrated. Direct comparison of mtLSUrRNA to IF yielded a poor 
sensitivity and specificity, 55.4% and 41.2%, respectively. When IF was compared to 
mtLSUrRNA nested PCR results a sensitivity- and specificity of 73.8% and 21.9% 
was obtained. The apparent lack of sensitivity of PCR compared to IF was due to IF 
reporting a positive signal from 56 specimens and PCR from 42 (∆ 14 specimens). 
Where discrepancies (36 specimens) were observed, clinical information, 
cytology/histology and additional DHPS PCR (sequence confirmed) findings were 
taken into consideration. Seven false IF-positive results were uncovered that could 
be substantiated by good clinical and laboratory findings to exclude PcP. False IF 
signals could be due to the inability of fluorescence microscopy to differentiate true 
positives from non-specific background fluorescence as morphology is not weighted 
to the same extent as in conventional non-fluorescent stains. In addition, empty 
cysts, which will be detected by IF but not by PCR, have been shown to persist in 
lung tissue for 4 – 6 weeks after successful treatment [Armbruster, et al., 1995]. One 
specimen was considered a false IF-negative (true PCR-positive). This could be due 
to the inability of IF to accurately detect trophic forms of P. jirovecii that can often 
outnumber cysts in clinical specimens [El-Sadr & Gidhu, 1986]. Nine specimens 
failed to produce an amplification product on mtLSUrRNA PCR. These were 
considered false negative results due to amplification (and sequence confirmation) by 
DHPS nested primers. The reasons for these results are unclear as it defies the 
target copy number hypothesis, and alternative factors should be considered. It is of 
interest that when compared to the gold standard of methenamine silver histology-
staining, mtLSUrRNA, and in fact most other PCR assays, performed much better 
than when compared to IF.  
 
CHAPER 3 PCR DETECTION 
___________________________________________________________________ 
79
Subsequent to the review of clinical records and additional staining and PCR results, 
the IF method was seen to exhibit high sensitivity (96.9%) but low specificity (60.8%), 
evidence suggests false-positive (9/23) results. MtLSUrRNA PCR displayed a 
sensitivity of 77.5% and specificity of 93.3%. The positive predictive value obtained 
by PCR (96.9%) exceeds that of IF (77.5%), indicating that with a population of low 
prevalence of disease PCR is most effective. However, the negative predictive value 
of IF (93.3%) exceeds that of PCR (60.9%), and would be a more appropriate choice 
of test for populations with a high prevalence of disease. Prevalence seen in the 
population studied (specimens submitted specifically on suspicion of PcP, or 
performed to exclude PcP) was 69.9% - 74%. Exact conclusions as to the most 
suitable diagnostic method for this population are confounded by the high number of 
unresolved clinical cases (19 / 74 = 25.7%).  
 
Similar studies employing mtLSUrRNA primers found a higher sensitivity of PCR 
compared to staining techniques and a reduced specificity, owing to the detection of 
very low numbers of organisms [Moonens, et al., 1995; Ribes, et al., 1997]. This is 
frequently encountered when a nested PCR is employed and has been suggested to 
indicate colonisation or subclinical infection [Rabodonirina, et al., 1997; Ribes, et al., 
1997; Sing, et al., 2000; Torres, et al., 2000]. However, comparable sensitivities and 
specificities of PCR to IF have been reported [Moonens, et al., 1995; Mathis, et al., 
1997]. After review of clinical data Mathis et al. reported sensitivities and specificities 
of 18S PCR and IF to be 94.8% and 99.1%, and 93.8% and 100%, respectively. 
However, it was noted that PCR seemed more sensitive on sputum samples and IF 
on BAL samples [Mathis, et al., 1997]. This could be due to the higher incidence of 
background non-specific fluorescence occurring in sputum as opposed to BAL.  
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CHAPTER 4 
 
CO-INFECTION 
 
 
_______________________________ 
 
4.1 INTRODUCTION 
 
Worldwide, PcP and pulmonary tuberculosis (TB), caused by Mycobacterium 
tuberculosis, are the primary lung infections associated with HIV. Their respective 
prevalence, however, varies geographically. P. jirovecii is the most frequent cause of 
opportunistic pneumonia in the USA and Europe, while M. tuberculosis seems to be 
the main pulmonary pathogen in African HIV-positive patients [Orlovic, et al., 2001]. 
In the developing world M. tuberculosis appears to be the most commonly 
encountered co-infecting pathogen associated with PcP, occurring in up to 66% of 
PcP cases [MacLeod, et al., 1989; Abouya, et al., 1992; Machiels, et al., 1992; Atzori, 
et al., 1993; Weinberg & Duarte, 1993; Malin, et al., 1995; Mahomed, et al., 1999]. 
Pathogens, other than M. tuberculosis, commonly encountered include S. 
pneumoniae, S. aureus and CMV [MacLeod, et al., 1989; Hsiao, et al., 1997]. Rates 
of co-infection associated with PcP and any other pathogen, range from 20% - 70% 
[Fisk, et al., 2003]. Paediatric patients with PcP seem particularly at risk for co-
infection with CMV as rates of up to 68% among African patients [Jeena, et al., 1996; 
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Graham, et al., 2000], and 58% among Thai patients have been reported [Bhoopat, 
et al., 1994]. 
 
It has been suggested that a surprisingly high frequency of P. jirovecii and M. 
tuberculosis co-infections may occur in TB hyperendemic areas [Orlovic, et al., 2001].  
Orlovic et al. reported the co-existence of PcP and TB in 9.9% of induced sputum 
specimens obtained from HIV-positive patients [Orlovic, et al., 2001]. Similarly 
Aderaye et al. reported the detection of P. jirovecii in Ethiopian patients with proven 
TB in 13.5% of HIV-positive and 4.3% of HIV-negative patients respectively. These 
investigators reported a prevalence of PcP in 30.3% of HIV-positive patients with 
suspected TB [Aderaye, et al., 2003]. 
 
To investigate the rate of co-infections associated with PcP a retrospective review of 
laboratory data was undertaken to identify pulmonary pathogens commonly 
encountered in association with PcP. In addition, to investigate the possible 
contribution that P. jirovecii may have on patients in South Africa with pulmonary 
tuberculosis, P. jirovecii directed PCR was performed on a sputum bank created from 
a TB surveillance study. 
 
 
4.1 RESULTS 
 
4.2.1 Retrospective laboratory investigation for co-infections 
 
Of 78 sequential specimens submitted to the microbiology laboratory at Tygerberg 
Hospital for routine diagnosis of PcP, 62 produced an amplicon indicative of the 
presence of P. jirovecii by mtLSUrRNA nested PCR (section 3.2.1, Table 3.1). 
Twenty (32.2%) of these specimens were collected from patients with co-existing 
pulmonary infections (Table 4.1). The pathogenic organisms were: Gram-negative 
bacilli (Klebsiella pneumoniae, Acinetobacter spp., and Pseudomonas aeruginosa) in 
9 / 62 (14.5%) patients, CMV in four patients (6.5%), M. tuberculosis in three (4.8%), 
and respiratory syncytial virus (RSV) in two (3.2%) patients. The Acinetobacter spp. 
and Pseudomonas aeruginosa might not have been significant isolates. Co-infection 
with three pathogens was not uncommon.  P. jirovecii, M. tuberculosis and Candida 
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albicans were observed in two patients, P. jirovecii, C. albicans and S. pneumoniae 
in one patient, and P. jirovecii with two different Gram-negative bacilli in one patient. 
The significance of the C. albicans was not known. Co-infections occurred with 
higher frequency in HIV-positive patients (6 / 18) than HIV-negative patients (2 / 18), 
however, 10 / 18 patients with co-infections had an unknown HIV status. Of the 
patients with laboratory demonstrated P. jirovecii infection, as detected with 
mtLSUrRNA nested PCR (section 3.1), and record of HIV-status (40 patients), 45% 
were HIV-negative, 45% HIV-positive, and 10% were immunocompromised due to 
cytotoxic chemotherapy or systemic lupus erythaematosis. 
 
Table 4.1 PcP patients with pulmonary co-infections 
 
* Organ transplant recipients and systemic lupus erythaematosis 
# Klebsiella pneumoniae, Acinetobacter spp, Pseudomonas aeruginosa. 
 
4.2.2 P. jirovecii M. tuberculosis co-infections 
 
HIV status 
Co-infecting pathogen Total 
Immuno-
suppressed* 
Positive Negative Unknown 
Cytomegalovirus 4 1 2 0 1 
Respiratory cyncytial 
virus 
2 0 1 0 1 
Gram negative bacteria# 9 0 1 2 6 
M. tuberculosis 2 0 1 0 1 
M. tuberculosis and  
C. albicans 
1 1 0 0 0 
S. pneumoniae and  
C. albicans 
1 0 1 0 0 
Two different Gram 
negative bacteria 
1 0 0 0 1 
Total 20 2 6 2 10 
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Sputum specimens, collected from patients residing in five provinces of South Africa, 
for a TB surveillance study, were screened by PCR for the presence of P. jirovecii 
(Figure 4.1).  MtLSUrRNA nested PCR detected P. jirovecii DNA in 23 / 663 M. 
tuberculosis culture-positive sputum specimens (Table 4.2). Of HIV-positive patients 
with confirmed TB 4.3% had P. jirovecii DNA detectable in sputum. Of HIV-negative 
patients with confirmed TB 2.5% had P. jirovecii DNA detectable in sputum. 
Detection was highest in patients from the Western Cape (3 / 72) (4.2%), followed by 
those from North West Province (7 / 177) (4.0%), KwaZulu Natal (7 / 192) (3.7%), 
Eastern Cape (5 / 148) (3.4%), with the lowest detection in Mpumalanga (1 / 74) 
(1.4%). The prevalence of HIV in the sampled population was 45.4% and the 
prevalence of P. jirovecii 3.5%. Of the TB patients co-infected/colonised with P. 
jirovecii 13 / 23 were HIV-positive, 9 / 23 were HIV-negative and one patient had an 
unknown HIV status. P. jirovecii was detected more frequently in HIV-positive vs. 
HIV-negative patients residing in KwaZulu Natal (6 / 7 vs. 1 / 7), Western Cape (3 / 3 
vs. 0 / 3) and North West (5 / 7 vs. 2 / 7); however, in the Eastern Cape P. jirovecii 
was detected more frequently in HIV-negative patients (5 / 5 vs. 0 / 0). The single 
case of P. jirovecii detected from Mpumalanga was from an individual whose HIV 
status was unknown. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Provinces from which sputum specimens were obtained for 
screened co-existing P. jirovecii and M. tuberculosis# 
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  # Numbers of specimens screened are indicated. 
 
Table 4.2 Detection of P. jirovecii by mtLSUrRNA nested PCR in sputum  
  from M. tuberculosis culture-positive specimens 
 
   PcP detection by HIV status 
 
n 
HIV-
positive 
(%) 
PcP 
detection 
(%) Positive Negative Unknown
       
KwaZulu Natal 192 55.7 7 (3.7) 6 1 0 
       
Western Cape 72 30.6 3 (4.2) 2 1 0 
       
Eastern Cape 148 23.0 5 (3.4) 0 5 0 
       
North West 177 52.0 7 (4.0) 5 2 0 
       
Mpumalanga 74 62.2 1 (1.4) 0 0 1 
       
5 Provinces 
Total 663 45.4 23 (3.5) 13 9 1 
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4.3 DISCUSSION 
 
Of 78 sequential specimens submitted to Tygerberg Hospital for routine PcP 
diagnosis 62 were positive for P. jirovecii by mtLSUrRNA nested PCR. Of these 
patients who were initially suspected of having PcP on clinical grounds, 32.2% 
harboured co-infecting pathogens in the respiratory tract. The most frequent co-
infections seen in the patient population tested were Gram-negative bacilli (14.5%), 
followed by CMV (6.2%). The significance of the Gram-negative bacilli is unknown. 
Previous reports have indicated high co-infection rates of P. jirovecii and CMV, 
particularly in the paediatric population where rates between 5% and 100% in HIV-
positive patients have been reported [Michalany, et al., 1987; Weinberg, et al., 1993; 
Bhoopat, et al., 1994; Graham, et al., 1995; Jeena, et al., 1996; Mootsikapun, et al., 
1996; Hsiao, et al., 1997]. In South Africa Jeena et al. reported 68% co-infection of 
CMV and P. jirovecii in HIV-positive paediatric cases [Jeena, et al., 1996]. In contrast 
to a study in Zimbabwe, in which S. pneumoniae was the co-infecting pathogen in up 
to 50% of HIV-positive adults [McLeod, et al., 1989], our data suggest a low co-
infection rate (1 / 62) with S. pneumoniae.  
 
The high rate of detection of P. jirovecii by molecular techniques in 
immunocompetent patients (45% of specimens submitted for routine PcP diagnosis) 
is worrisome. Sing et al. reported detecting P. jirovecii in 17% - 20% of 
immunocompetent patients not presenting with PcP [Sing, et al., 2000]. In our study 
population one cannot assume a high false positive rate, as argued by Sing et al. 
since the obtained positive predicted value for mtLSUrRNA nested PCR is 96.9% 
(section 3.3.4.2, Table 3.10). This implies that a real problem exists in that PcP in 
South Africa may be occurring in immunocompetent patients more frequently than 
expected. 
 
The detection of P. jirovecii in 3.5% of sputum samples from patients with culture 
confirmed pulmonary TB is of concern. The diagnostic yield of sputum samples for 
detection of P. jirovecii is very low [Masur, et al., 1988], suggesting that this figure is 
possibly an underestimate. Orlovic et al. reported the detection of M. tuberculosis in 
9.9% of South African patients who were on treatment for PcP [Orlovic, et al., 2001]. 
Higher prevalence of co-infection has been reported throughout the developing 
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world. In Brazil and Tanzania induced sputum specimens stained with Toluidine-blue 
have diagnosed co-infection in 25% and 66% of HIV-positive patients respectively 
[Atzori, et al., 1993; Pitchenik, et al., 1983]. Studies employing BAL and 
transbronchial biopsy specimens with standard staining have shown co-infection in 
HIV-positive patients ranging from 5% to 40% [McLeod, et al., 1989; Abouya, et al., 
1992; Machiels & Urban, 1992; Bhoopat, et al., 1994; Malin, et al., 1995; Mahomed, 
et al., 1999]. Geographic variations in the frequency of co-infecting pathogens have 
been noted. From Mexico reports of M. tuberculosis P. jirovecii co-infections in HIV-
positive patients have reached 24%, whereas lower rates have been reported in the 
USA (6%) and Italy (5%) [Mohar, et al., 1992].  
 
The clinical and radiographic presentation of TB can mimic that of PcP, particularly in 
immunocompromised individuals. Orlovic et al. reported that the most common 
symptoms in patients co-infected with P. jirovecii and M. tuberculosis was a 
productive or dry cough, night sweats, dyspnoea, and fever. In addition, radiographic 
presentation of bilateral patchy infiltrates or reticulonodular patterns, focal 
consolidation, hilar / paratracheal lymphadenopathy, pleural effusion, and necrotizing 
or cavitation were seen in co-infected patients, exemplifying the difficulties in 
differentiating co-existence of the two pathogens [Orlovic, et al., 2001]. Aderaye et al. 
reported that 13.5% of patients diagnosed with TB on chest radiography tested 
positive for P. jirovecii employing nested PCR, with no microbiological evidence of TB 
[Aderaye, et al., 2003].  
 
In the current study, 3.5% of patients diagnosed initially as having TB were co-
infected / colonised with P. jirovecii.  In addition, of patients diagnosed initially as 
having PcP 4.8% were co-infected with M. tuberculosis. Although the data sets were 
vastly different in terms of statistical power, it would seem evident that when 
encountering TB or PcP, clinicians in South Africa can expect co-infection in 3.5% - 
4.8% of patients.  
 
Although the clinical outcome and relevance of P. jirovecii co-infection with M. 
tuberculosis is unknown from our study design, Orlovic et al. reported from South 
Africa that clinical response was only seen once the second infection was adequately 
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treated [Orlovic, et al., 2001]. In patients with dual infection, M. tuberculosis appears 
to exert a more dominant role in the disease process [Orlovic, et al., 2001]. P. 
jirovecii is generally regarded as a pathogen of low virulence, which in HIV-positive 
patients emerges later during the progressive loss of cell mediated immunity, and 
appears initially as a more subtle disease with symptoms absent for weeks to months 
prior to the requirement for hospitalisation [Lucas, et al., 1990; Orlovic, et al., 2001]. 
In many cases more virulent pathogens such as M. tuberculosis may trigger an acute 
disease, with detection of subclinical P. jirovecii. However, ignoring laboratory 
detection of P. jirovecii could lead to unresponsiveness to TB treatment regimes, or 
the infection may remain subclinical for a latent period, but emerge as a serious 
pneumonia when cellular immunity has diminished. 
 
On analysis of the value of nested PCR for different immunological groups of patients 
Sing et al. reported that nested PCR and IF displayed good correlation in the HIV-
positive group. In the other patient groups (transplant recipients, malignancy, 
otherwise immunosuppressed, immunocompetent) nested PCR and IF yielded a poor 
correlation, mainly with BAL but also with sputum and TASP [Sing, et al., 2000]. The 
poor concordance of mtLSUrRNA nested PCR and IF from the present study 
(Chapter 3) may be due to the high representation of HIV-negative, non-
immunocompromised individuals diagnosed with PcP (45%). This suggests that other 
immunosuppressive factors such as nutrition or co-infections may predispose our 
study population to the development of PcP. In support of this suggestion, nutrition 
was the first condition recognised as predisposing to PcP in children [Burke & Good, 
1973]. The detection of P. jirovecii in HIV-positive patients by nested PCR should 
alert clinicians to possible early developmental stages of disease as colonisation 
rarely occurs in HIV-infected patients without leading to overt PcP [Sing, et al., 2000]. 
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CHAPTER 5 
 
GENOTYPING AND COALESCENT 
PHYLOGENETIC ANALYSIS  
 
 
_______________________________ 
 
5.1 INTRODUCTION 
 
Pneumocystis pneumonia (PcP) is a major contributor to morbidity and mortality in 
immunocompromised individuals [Rimland, et al., 2002; Ruffini, et al., 2002]. Many 
molecular epidemiological techniques are not applicable for typing of Pneumocystis, 
as it cannot readily be propagated in vitro. Regions that have been investigated for 
designing a typing method include the mitochondrial large subunit rRNA 
(mtLSUrRNA), mitochondrial small subunit rRNA (mtSSUrRNA), arom locus, and 
internal transcribed spacer regions (ITS) [Tsolaki, et al., 1998]. Sequence diversity of 
P. jirovecii ITS1 and ITS2 regions made these regions suitable for typing of P. 
jirovecii [Lu, et al., 1994]. Ribosomal DNA of P. jirovecii is present as a single copy in 
the cell and is transcribed as a single transcript, with 18S rRNA, 5.8S rRNA and 26S 
rRNA occurring in tandem [Guintoli, et al., 1994]. The rRNA genes are separated by 
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ITS1 between 18S rRNA and 5.8S rRNA, and ITS2 between 5.8S rRNA and 26S 
rRNA [Edman, et al., 1989].  
 
Globally the most frequently encountered genotypes are Eg and Ne [Tsolaki, et al., 
1996; Lee, et al., 1998; Tsolaki, et al., 1998]. Latouche et al. proposed that as a 
specific type was seen to persist during the same episode of PcP, genotype 
switching did not occur [Latouche, et al., 1997]. However, in a study conducted on 19 
patients, within the same episode of PcP, genotype changes were observed in 53% 
of the patients [Helweg-Larsen, et al., 2001]. In addition co-infection with more than 
one genotype has been reported in a high proportion of PcP episodes [Lu, et al., 
1994; Tsolaki, et al., 1996; Tsolaki, et al., 1998; Tsolaki, et al., 1999; Nahimana, et 
al., 2000; Nimri, et al., 2002]. The current understanding is that P. jirovecii infection is 
not clonal, and that repeated de novo acquisition of ITS types is likely to occur 
[Tsolaki, et al., 1996; Latouche, et al., 1997]. 
   
Conventional molecular phylogenetic analysis of tree building is based on 
homologous characters between species that are assumed reproductively isolated 
with ascendance based on linear, dichotomous speciation events [Rosenberg, et al., 
2002]. These assumptions do not hold when analysing intraspecific nucleotide 
evolution at the population level. Focus is shifted to a recent evolutionary timescale, 
which implies that ancestral states may still exist, multiple apomorphies may be 
present, sexual reproduction may take place and recombination may be involved 
[Rosenberg, et al., 2002]. Coalescent theory addresses these issues as it models 
genealogical processes of selectively neutral genes from a population, looking 
backward in time whereby all lineages will eventually coalesce into a single lineage 
termed the most recent common ancestor of the sample [Rosenberg, et al., 2002].  
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5.2 RESULTS 
 
5.2.1  ITS1 and ITS2 genotypes 
 
From the 20 clinical specimens (19 patients) 83 clones were sequenced and ITS 
types assigned. Twelve new ITS1 sequences (Roman numerals Fig. 5.1) and 13 new 
ITS2 sequences (Arabic numerals Fig. 5.2) were found. A novel ITS2 type was 
identified in three patients and designated u (Table 5.1; Fig.5.2). Four new 
combinations of previously reported ITS1 and ITS2 sequences were demonstrated: 
Eo, Je, Ge and No.  
 
PCR employing DNA polymerase Pwo demonstrated a reduced specificity when 
compared to Taq DNA polymerase reactions. Although Pwo polymerase produced 
amplicons of the expected size, upon cloning and sequencing 35 clones, most PCR 
products were shown to be human DNA and/or the homologues ITS regions of 
Candida albicans. However, successful amplification of four new types employing 
Pwo confirmed the sequences of Eu, Ⅹg, E12 and Ⅺ11 (Table 5.1 and Figs. 5.1 and 
5.2). A single ITS type was detected in 3 specimens; 5 specimens contained 2 types; 
8 specimens 3 types; 2 specimens 4 types; 1 specimen 5 types and 1 specimen 6 
types. Sequencing of two specimens, a tracheal aspirate and a biopsy, collected from 
one patient yielded nine different types  (specimens 2 and 3 Table 5.1). The most 
frequent type detected in the population studies was Eg (14/19 patients, 33/83 
clones), followed by Gg (4/19, 7/83), Eu (3/19, 5/83) and Gh (2/19, 2/83) (Table 5.1).   
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Figure 5.1  Alignment of new ITS1 sequences  
 GenBank accession numbers Ⅰ - Ⅺ: AY328043 – AY328053 
 
 
 
 
 
 
 
Figure 5.2  Alignment of new ITS2 sequences  
 GenBank accession numbers u: AY328054 and 1 –12: AY328055 – AY328066 
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Table 5.1  ITS types demonstrated from 20 specimens (83 clones) 
 
 
 * Specimen 2 and 3 from same patient – tracheal aspirate and biopsy, respectively.  
 #  Specimens from twins – twin 1 specimens 2 & 3, twin 2 specimen 4.  
 Novel ITS2 type u designated as it was demonstrated from three patients.  
New ITS1 and ITS2 sequences that were only detected once are indicated by Roman and 
Arabic  numerals respectively. 
 
 
The 95% parsimony distance matrix and resultant statistical parsimony network are 
shown in Table 5.2 and Figure 5.3. Coalescence suggests the major ancestral 
haplotype is Eg that radiates microevolutionary minor haplotypes. Unresolved loops 
are indicated between types Eo, Ge, Ne and No, as well as for Eo, No and Ng, and 
Ng, Ⅰg and ⅨE. There appears to be several haplotypes that can be considered as 
“missing” from the sampling performed. Of major interest was specimens received 
from baby twins who presented with PcP simultaneously (Table 5.1). The tracheal 
aspirate of twin 1 revealed ITS types Je, Ne, Eg, Eo, Ⅰg and Ⅱg, and the biopsy types 
Eg, Ne, Ⅲg and Ⅳ1. In total, twin 1 presented with nine types obtained from 14 
clones with only type Eg common to both specimens. From the biopsy of twin 2, 3 
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types Eg, Ge and No were identified from six clones. The only type common to both 
twins was Eg (Fig. 5.4). 
 
 
Table 5.2  Real (observed among sequences) distance matrix analysis on the 
33 different ITS1 - ITS2 sequences obtained 
 
 
 
Produced with program TCS (version 1.13; Clement, M., J. Derington, and D. Posada. Brigham Young 
University). ITS1 and ITS2 sequences concatenated. Gaps treated as missing data. Parsimony limit: 
95%. 
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Figure 5.3  ITS haplotype network  
 Derived from Table 5.2 employing coalescent theory [Posada & Crandall, 2001]. Lines 
connecting haplotypes are equivalent to one mutational difference with empty nodes 
representing haplotypes not found in the population. Haplotype subdivisions 
incorporating indel information (one indel depicted by a connecting line) are shown in 
the boxed haplotypes Eg and Ge.  
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Figure 5.4  ITS haplotype network focusing on twins that presented 
concurrently with PcP.  
 Lines connecting haplotypes are equivalent to one mutational difference with empty 
nodes representing haplotypes not found in the population. 
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5.2.2  5.8S rRNA genotypes 
 
From the 83 clones analysed thirteen different 5.8S rDNA sequences were detected 
(Fig. 5.5). Eighty-two clones contained a CG at position 115 – 116. Of the 20 clinical 
specimens examined, 13 contained a single 5.8S rDNA type; three contained 2 
types; three contained 3 types and 1 contained 4 different types. From the twins, the 
tracheal aspirate of twin 1 possessed four different 5.8S rRNA types and the biopsy 2 
types, with only one type common to both the biopsy and the tracheal aspirate. Twin 
2 harboured two 5.8S rDNA types. One type associated with ITS types Eg and Ge 
was also present in both tracheal aspirate and biopsy specimens from twin 1, but the 
second type exhibited a genotype that was demonstrated in twin 2 only (linked to ITS 
type No, Fig. 5.4). No linkage association could be demonstrated between the ITS 
and 5.8S rDNA types obtained. 
 
 
 
Figure 5.5  Alignment of new 5.8S rDNA sequences 
 GenBank accession numbers A – M: AY328067 – AY328078 and AY330724. P. ratti: 
L27658; P. macaca:  AF 288848; P. jirovecii (P. carinii f. sp . hominis): AF013954 
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5.3 DISCUSSION 
 
The most prevalent ITS1 and ITS2 types demonstrated were Eg (14/19 patients), 
similar to studies from other continents [Tsolaki, et al., 1996; Tsolaki, et al., 1998; 
Totet, et al., 2003], followed by Gg (4/19), Eu (3/19) and Gh (2/19). Coalescent 
theory proposes that haplotypes of low frequency occupy tips and those of high 
frequency internal nodes [Golding, et al., 1987; Excoffier, et al., 1989]. Older alleles 
have a greater probability of having produced mutated derivatives, and therefore a 
greater probability of becoming interior haplotypes than do younger alleles, with the 
result that haplotypes of greater antiquity occur at internal nodes and haplotypes of 
recent evolutionary origin occur preferentially at the tips of a cladogram [Crandall & 
Templeton, 1993]. Since Eg is the most frequently isolated local and global allele and 
as an internal haplotype positioned at the centre of the cladogram, it can be 
postulated that Eg is the major ancestral haplotype with radiated recent evolutionary 
lineages occurring at the tips. 
 
The ITS type combinations Eo, Je, Ge and No were unique to the South African 
samples and in addition 12 new ITS1 and 13 new ITS2 sequences were 
demonstrated. A novel ITS2 type that was detected in three different temporally 
separated patients was designated u (GenBank accession number AY328054). It 
was observed that all the new ITS1 and ITS2 sequences (singletons) detected in 
South Africa were connected to the cladogram network with 0.95 confidence (95% 
parsimony limit), a finding in accordance with the prediction that in a geographically 
subdivided population with limited gene flow, a singleton is more likely to be 
connected to an allele in the same population than an allele in a different population 
[Watterson, 1985].  
 
Homoplasy and / or recombination was evident from unresolved loops in the 
cladogram. An internal ambiguity was seen within the major haplotype Eg. Eg, Gg, 
G8 and E8 were interconnected in the cladogram forming a closed loop that could be 
broken at any connection point. Since the subdivision within Eg was created by the 
incorporation of indel occurrences, and since indels are mutations evolving in a 
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completely parsimonous fashion [Crandall & Templeton, 1993], recombination is 
strongly supported by the analysis. External ambiguities, with tip halpotypes having 
alternative connections to a number of haplotypes, seem to have occurred frequently. 
This is indicative of a homoplasious fashion of evolution [Crandall & Templeton, 
1993]. The occurrence of an internal ambiguity observed in the haplotype network 
from the twin could be the result of either recombination or homoplasies. Since the 
connections are due to nucleotide mutations and not indels, and nucleotide mutations 
do not necessarily evolve in a completely parsimonous fashion, one cannot exclude 
either explanation. 
 
Co-infection with different P. jirovecii strain types appeared common in the patient 
population investigated, with 15/19 patients (79%) harbouring more than one 
genotype. Two specimens from one patient, taken only six days apart revealed the 
presence of nine different genotypes. In a study conducted by Lee et al. it was 
suggested that samples containing six or more genotypes resulted from cross 
contamination during processing [Lee, et al., 1998]. However, in the present study 
cross contamination could be excluded as types Je, Ne, Ⅰg, Eo and Ⅱg found in one 
specimen were not detected in any other specimens analysed. Other studies, on 
sequencing up to 5 clones/specimen have reported the presence of 3 – 5 types from 
a specimen [Lu, et al., 1994; Helweg-Larsen, et al., 2001; Nimri, et al., 2002; Nevez, 
et al., 2003]. 
 
ITS analysis of P. macacae employing classical phylogenetic approaches, as 
performed by Hsueh et al. [Hsueh, et al., 2001], does not appear to provide for 
adequate intraspecies resolution. If Pneumocystis ITS regions undergo 
recombination or if there is a high rate of homoplasies, classic analysis would in 
effect be unresolved due to a saturation effect. On applying coalescence based 
statistical parsimony analysis on ITS regions from P. jirovecii, the parsimony network 
clearly shows linkage loops between haplotypes, indicative of homoplasies or 
recombination. Morphological investigations on Pneumocystis conducted in 1984 
certainly support recombination in that synaptonemal complexes, indicative of 
meiosis in the “early precyst” stage, were reported [Matsumoto, et al., 1984].  
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Based on sequence information and haplotype frequency data, genotype Eg was 
identified as the outgroup and most probable major ancestral haplotype within the 
population group.  In support of the coalescence approach adopted, genotyping 
conducted worldwide has shown that the most frequently encountered ITS type is Eg 
[Tsolaki, et al., 1996; Latouche, et al., 1997; Lee, et al., 1998; Tsolaki, et al., 1998; 
Nimri, et al., 2002; Nevez, et al., 2003; Totet, et al., 2003]. As certain genotypes, 
most notably type Eg are over represented, dissemination of specific ITS types, 
appears to be the major mode of propagation.  
 
Linkage of 5.8S rDNA types with ITS types was not evident, indicating that different 
parental strains may harbour very similar ITS types or recombination may occur. 
Although the relevance of 5.8S rDNA sequence polymorphisms necessitates further 
investigations, as an adjunct to ITS regions they may assist in distinguishing strain 
types within populations with similar ITS genotypes. When considering the number of 
different ITS1 and ITS2 genotype combinations reported, recombinational events 
could well contribute to the degree of heterogeneity observed worldwide. 
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CHAPTER SIX 
 
COTRIMOXAZOLE RESISTANCE 
 
  
_______________________________ 
 
6.1 INTRODUCTION 
 
The long-term use of trimethoprim and sulphonamides, for prophylaxis and treatment 
of PcP, has prompted investigations into the possibility that resistance could be 
emerging and result in breakthrough cases and treatment failures [Helweg-Larsen, et 
al., 1999; Huang, et al., 2000; Kazanjian, et al., 1998; Visconti, et al., 2001]. Point 
mutations in the P. jirovecii DHPS gene have been reported and have been 
associated with prophylactic failures [Kazanjian, et al., 1998; Mei, et al., 1998; 
Kazanjian, et al., 2000; Visconti, et al., 2001]. It is well known that other pathogens, 
notably Escherichia coli, Streptococcus pneumoniae, Neisseria gonorrhoea and 
Plasmodium falciparum develop resistance to sulphonamides by point mutations in 
DHPS genes [Lopez, et al., 1987; Swedberg, et al., 1993; Brooks, et al., 1994; Wang, 
1997; Qvarnaström & Swedberg, 2000].  
 
Studies have shown that mutations detected in P. jirovecii DHPS arise during 
therapy, suggesting selection for resistance [Ma, et al., 1999; Huang, et al., 20000; 
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Kazanjian, et al., 2000; Nahimana, et al., 2003b]. DHPS mutations have been 
reported in up to 68.5% of specimens screened in the USA [Huang, et al., 2000], 
40% in Paris [Santos, et al., 1999], 35.5% in Spain [Montes-Cano, et al., 2004], 35% 
in Italy [Visconti, et al., 1999], 25% in Japan [Takahashi, et al., 2000], 20.4% in 
Denmark [Helweg-Larsen, et al., 1999], and 7% in China [Kazanjian, et al., 2004]. A 
significantly higher proportion of mutations have been detected from patients recently 
exposed to sulphonamides [Kazanjian, et al., 1998]. In the USA up to 80.3% of 
mutations in P. jirovecii DHPS have been detected in patients with recent exposure 
to sulphonamides, whereas up to 47.5% have been recovered from patients without 
sulphonamide exposure [Huang, et al., 2000]. Similarly, in Denmark 62% of 
mutations have been detected in patients with exposure vs. 10.5% without [Helweg-
Larsen, et al., 1999]. De novo acquisition of mutated strains in patients without prior 
exposure to cotrimoxazole has also been demonstrated in certain geographic areas, 
notably San Francisco and Seattle in the USA [Beard, et al., 2000; Huang, et al., 
2000], and Lyon [Nahimana, et al., 2003a] as well as Paris [Latouche, et al., 2003] in 
France, suggesting geographic area as an independent predictor for harbouring P. 
jirovecii containing a DHPS mutation. However, there is little supportive clinical 
evidence that DHPS gene mutations effect strain responses to standard 
sulphonamide therapy [Kazanjian, et al., 2000].  
 
Dihydrofolate reductase (DHFR), the target of trimethoprim, has been investigated for 
mutations that could play an additional role in resistance to cotrimoxazole. However, 
animal models have suggested a minimal role of trimethoprim in the action of 
cotrimoxazole [Edman, et al., 1989]. Polymorphisms in the DHFR gene have been 
detected, but no mutation has been associated with known DHFR enzymatic active 
sites or with treatment / prophylaxis failure [Takahashi, et al., 2002]. 
 
A major limitation to the screening of DHPS and DHFR gene mutations is the inability 
of currently recommended primers to amplify DHPS and DHFR genes [Lu, 1995; 
Beard, et al., 2000; Huang, et al., 2000]. In Chapter 3 we report the lack of sensitivity 
of DHPS nested PCR vs. mtLSUrRNA nested PCR, in that only 38 / 81 mtLSUrRNA-
positive specimens produced a DHPS amplicon. Even more problematic were DHFR 
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primers, with only 9 / 81 mtLSUrRNA-positive specimens giving DHFR gene 
products.  
 
In order to investigate this apparent lack of sensitivity and ensure primer annealing 
sites were fully compatible both genome walking as well as different primer 
combinations and newly designed primers were employed (Fig. 6.1). In addition, on 
comparing the sequence of the DHPS primer B45, published by   Lane et al. [Lane, 
et al., 1997] with the DHPS sequence (GenBank AF139132), primer – target 
mismatches of three nucleotides were evident (Figure 6.2).  
 
 
 
 
 
 
Figure 6.1PCR primer annealing sites to DHPS and DHFR genes 
 DHPS nucleotide positions according to GenBank AF139132.  
 DHPS primers: 1, LR1; 2, LR2; 3, F1; 4, B45; 5, Ahum; 6, Bhum; 7, Bnest 
 DHFR nucleotide positions according to GenBank AF090368 
 DHFR primers: 1, FRGF1; 2, DHFR1038; 3, DHFR208; 4, DHFR1018; 5,  DHFR242; 
 6, FRGF2 
 
 
 DHPS 
1 
3 4 
5 
2 
6
7
 
52 75 
130 152 
202 232 
1082 1060 
1024 994 
967 949 
572 550 
DHFR 
5 
3 
1 264 287 
724 750 
757 787 
6
4 
2 15811555 
1554 1534 
1443 1431 
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Genomic target# : 5´ GATGCTATTTGGAAAGGAGTTTATTGAATTG 
DHPS B45 * : 5´ GATGCTATTTGGAAAGAAATTTATTAAATTG 
Corrected  * : 5´ GATGCTATTTGGAAAGGAGTTTATTGAATTG 
 
 
Figure 6.2DHPS Primer mismatch 
 # DHPS GenBank AF139132 
 * Sequence of reverse complement to reverse primer  
 
 
6.2 RESULTS 
 
6.2.1 DHPS gene investigations 
 
6.2.1.1 Genome walking 
DNA extracted from the P. jirovecii-positive lung biopsy and BAL specimens was 
successfully digested employing Dra I, EcoR V, Pvu II (Figure 6.3). Genomic libraries 
were constructed by ligating digests to adapters. Primary and nested PCR yielded 
PCR products (Figure 6.4). However, subsequent DNA sequence analysis indicated 
that PCR products obtained were of human chromosomal origin.  
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Figure 6.3  DraI digested genomic DNA 
 Lane 1, 10Kb Molecular weight marker; Lane 2, Clinical specimen 1;  
 Lane 3, Clinical specimen 2. Clinical specimen 2 was subsequently employed. 
 
 
 
 
 
Figure 6.4  Genome walking nested PCR products 
Lane 1, 1Kb molecular weight marker; Lane 2 – 6, nested PCR products; Lane 7, negative control; 
Lane 8, positive (kit) control 
1 2 3
1       2      3       4      5       6        7      8 
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6.2.1.2 Optimisation of DHPS amplification 
The corrected B45 primer (Figure 6.2) was employed on eight mtLSUrRNA-positive 
specimens that failed to produce an amplification product with the original B45 
reaction. No additional DHPS genes were demonstrated on using the corrected 
primer sequence.  
 
Optimisation of the new primer combination LR1 and LR2 was performed. The 
concentration of MgCl2 that produced the strongest PCR product (1030 bp) was 2.5 
mM. Due to the large LR1 + LR2 PCR product size, dNTP concentrations and PCR 
extension time were also assessed. To investigate the possible role that DNA 
template concentration may have on amplification attempts, template preparation 
dilutions (1:10 and 1:50) were incorporated. No increase in sensitivity was noted.  
A proofreading enzyme with a chemical hotstart modification (Proofstart®) was 
evaluated. A range of MgCl2 concentrations (1.5 mM, 2 mM, 2.5 mM) was attempted 
as well as the addition of Q-solution® which enables amplification of targets with high 
GC content or stable secondary structure. No increase in sensitivity was noted.  
 
Amplification employing LR1 and LR2 with optimised conditions was successful in 
detecting 3 / 28 discordant specimens previously amplified by mtLSUrRNA PCR but 
not by previously reported DHPS PCR primers (Table 6.1). Similarly, of the 28 
discordant specimens DHPS genes were amplified with the new primer combination 
F1 and Bhum from the same three samples (Table 6.1).  
 
The DHPS PCR products obtained with primers LR1 and LR2 (1030 bp) from 
specimens failing to produce amplification products with previously published primers 
(three specimens) were sequenced. On comparison to the wild type DHPS gene, no 
mutations were detected.   
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Table 6.1 DHPS PCR amplification analysis 
No. Specimens 
Primer strategy 
Positive Negative 
   
MtLSUrRNA 28 0 
Ahum + Bhum 0 28 
LR1 + LR2 3 25 
F1 + Bhum 3 25 
   
 
 
6.2.2 DHFR gene investigations 
 
The four FRGF1 and FRGF2 PCR products (1189 bp) were sequenced in order to 
determine the possible existence of mutations located at primer annealing sites. No 
mutations in the obtained sequences were identified when compared to the DHFR 
wild type sequence.   
 
6.2.2.1 Optimisation of DHFR amplification 
The new primer combination FRGF1 and FRGF2 successfully amplified four 
specimens that were DHFR positive with previously employed primers. However, on 
applying FRGF1 and FRGF2 primers to 23 specimens previously amplified by 
mtLSUrRNA but negative by previous DHFR primers (discordant), no further DHFR 
gene products were demonstrated. 
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6.2.3 DHPS mutations 
 
DHPS nucleotide positions according to Ma et al. [Ma, et al., 1999]. Of 56 DHPS 
genes amplified and sequenced, 54 contained the wild type sequence. Strains from 
one patient, obtained from a tracheal aspirate and post-mortem lung biopsy 
specimens, contained DHPS genes with the double mutation A346G and C352T 
(Thr55Ala; Pro57Ser). The tracheal aspirate was collected one day after initiation of 
cotrimoxazole therapy. Review of clinical records indicated that the patient had no 
previous exposure to sulphonamides in the recent past. The lung biopsy specimen 
was obtained 18 days after the tracheal aspirate. The mutation was detected in 1 / 5 
clones from the tracheal aspirate, while only wild type sequences were detected in 
five clones from the post-mortem lung biopsy. All viral, bacterial and fungal cultures 
performed on the specimens were negative. The post-mortem finding attributed the 
cause of death to ventilation damage. Sequencing of ITS gene regions (5 clones 
from each specimen) revealed only type Eg - present in both tracheal aspirate and 
post-mortem lung biopsy specimens. The effect of DHPS mutations on the enzyme 
active site is depicted in Figure 6.5. A specimen collected from a second patient 
yielded DHPS with a synonymous substitution: T432C.  
 
 
6.2.4 DHFR mutations 
 
DHFR nucleotide positions referred to are according to Takahashi et al. [Takahashi, 
2002]. Of 27 DHFR genes amplified and sequenced 3 genotypes were detected 
(Figure 6.6). The wild type gene sequence (genotype 1) was detected in 23 
specimens. Three specimens contained a C1046T (nucleotide positions according to) 
transition mutation (amino acid substitution Ala67Val) (genotype 2). A further 
specimen contained two nucleotide substitutions: a transversion C1022G (amino acid 
substitution Arg59Gly) and a nucleotide transition C1126T, located in the intron 
region of DHFR (genotype 3). Genotypes 2 and 3 were obtained from patients within 
3 days of initiation of cotrimoxazole therapy. None of the patients had prior exposure 
to cotrimoxazole. Sequencing the ITS gene regions from 5 clones / specimen 
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demonstrated that both patients’ P. jirovecii harbouring genotype 2 contained ITS 
genotypes Eg and Eu.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5a Wild type DHPS active site 
  Wild type: Thr55Arg56Pro57 
  Hydrogen bonds to substrate (red) are shown in green 
  Produced with the program Deep View from the      
  published P. carnii DHPS amino acid sequence (GenBank M86602) [Volpe, 1992] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5b Mutation modified DHPS active site 
  Double mutation: Thr55Ala, Arg56, Pro57Ser   
  Hydrogen bonds to substrate (red) are shown in green 
  Produced with the program Deep View from the      
  published P. carnii DHPS amino acid sequence (GenBank M86602) [Volpe, 1992] 
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  Deep View – The Swiss-PdbViewer is available from [http://www.expasy.org/spdv/] 
                                     .180                .200                .220           
1 170:TGGGTCGTAAGACATGGGAAAGTCTTCCTGCTCATTCTAGGCCTCTTAAGAATCGAATTA 
2 170:TGGGTCGTAAGACATGGGAAAGTCTTCCTGTTCATTCTAGGCCTCTTAAGAATCGAATTA 
3 170:TGGGTGGTAAGACATGGGAAAGTCTTCCTGCTCATTCTAGGCCTCTTAAGAATCGAATTA 
                                                                                     a               .240                .260                .280 
1 230:ATGTTGTTATTAGTCGTCAAGAGGTTCTTGATTTAGGGTAAATAATGTCAATTGAATTGC 
2 230:ATGTTGTTATTAGTCGTCAAGAGGTTCTTGATTTAGGGTAAATAATGTCAATTGAATTGC 
3 230:ATGTTGTTATTAGTCGTCAAGAGGTTCTTGATTTAGGGTAAATAATGTTAATTGAATTGC 
            Intron 
 
Figure 6.6  DHFR genotypes identified 
 1: wild type genotype 1; 2: genotype 2; 3: genotype 3. 
 Polymorphic sites: 175, 200, 278 
 Nucleotide positions according to Takahashi et al. [Takahashi, 2002]. 
 
 
6.3 DISCUSSION 
 
Currently the greatest impediment to genetic research on P. jirovecii is the lack of an 
in vitro culture system. The inability to obtain isolated Pneumocystis genetic material, 
free from human (host) DNA contamination, in any significant amount, is a serious 
obstacle as was evident from the failure of genome walking attempts.  
 
A serious limitation to screening DHPS and DHFR genes for mutations is the inability 
to obtain amplification products from specimens that had amplified by employing 
other primers, especially mtLSUrRNA. The corrected DHPS B45 primer did not 
resolve DHPS detection. The DHPS primer combination of F1 and Bhum and new 
primers LR1 and LR2 amplified 3 / 28 previously discordant specimens. Investigation 
into the possible existence of mutations at primer annealing sites indicated 1) that for 
the three previously discordant DHPS specimens analysed and 2) for four 1189 bp 
fragments of the DHFR gene, annealing mismatches were not present. These data 
suggest that factors other than primer sequence mismatches, such as internal 
secondary structure or dimerisation could occur and prevent the F1 B45 primer 
combination from amplifying target sequences optimally. The observation that the 
addition of Q-solution did not improve amplification suggests that target secondary 
structure or high CG content does not appear to be responsible. The only other 
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explanation is that both DHPS and DHFR genes are single copy and thus provide 
fewer target copies for PCR amplification when compared to multicopy genes such 
as mtLSUrRNA or MSG. An additional point of note is that LR1 + LR2; and F1 + 
Bhum primers did amplify three further DHPS genes, perhaps emphasising that to 
decrease annealing temperatures and primer base numbers could be detrimental to 
product recovery.  
 
Despite the application of new primers and primer combinations, a serious lack of 
sensitivity was still evident for amplifying DHPS and DHFR genes. Many studies have 
reported on the lack of sensitivity of DHPS primers: Totet et al. and Beard et al. 
reported the amplification of DHPS genes by nested PCR from 73.3% and 85.7% of 
specimens producing amplicons by mtLSUrRNA single round PCR [Beard, et al., 
2000; Totet, et al., 2004]. On reporting amplification of specimens obtained from 
patients clinically diagnosed with PcP, DHPS nested PCR amplified between 43.5% 
[Lane, et al., 1997] and 71.9% - 94% of specimens [Huang, et al., 2000; Helweg-
Larsen, et al., 1999; Kazanjian, et al., 2000; Kazanjian, et al., 1998]. Although few 
studies have investigated DHFR gene polymorphisms, discrepant reports have 
emerged on the amplification success. De Luca et al. and Takahashi et al. have 
reported a 71% - 100% success rate employing single round PCR whereas Lu et al, 
in comparison to five other PCR techniques reported successful amplification of 
DHFR genes by single round PCR in 23% of specimens detected by 18S and ITS 
nested PCR reactions [Lu, et al., 1995]. Perhaps when more studies emerge on 
investigations of DHFR gene polymorphisms discrepancies will become apparent.  
 
On sequencing 56 DHPS genes one patient from the Western Cape (2001) was 
found to harbour P. jirovecii that contained DHPS genes with the double mutation 
Thr55Ala; Pro57Ser. This suggests a DHPS mutation prevalence of <2% in the 
Western Cape population sampled in South Africa. The double mutation is thought to 
signify the emergence of resistance to sulphonamides, as the mutations occur in a 
region of the DHPS gene involved in binding both substrate and sulphonamides 
[Kazanjian, et al., 1998]. Although the mutations do not appear to be associated with 
therapy, they were recently reported as the first description of indicative 
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sulphonamide resistance development in P. jirovecii from South Africa [Robberts, et 
al., 2004]. Studies from other countries have shown the presence of DHPS mutations 
in specimens obtained both from patients with (up to 80.3%) and without (up to 
53.8%), prior exposure to sulphonamides [Helweg-Larsen, et al., 1999; Santos, et al., 
1999; Huang, et al., 2000; Kazanjian, et al., 2000; Nahimana, et al., 2003a]. It has 
been suggested that the geographic area of residence is an independent predictor for 
harbouring P. jirovecii with DHPS mutations, possibly related to local sulphonamide 
prescribing practices [Beard, et al., 2000]. This was evident in a recent study 
contrasting the high prevalence of mutations in the USA with a very low prevalence in 
China, where cotrimoxazole is not used as extensively [Kazanjian, et al., 2004]. 
Mechanisms other than point mutations in the DHPS active site may be responsible 
for resistance to sulphonamides as has been suggested to be the case for S. 
cerevisiae and P. falciparum. Bayly et al. reported the selection of S. cerevisiae 
strains with decreased sensitivities to sulphamethoxazole in the presence of pABA or 
folic acid, and have proposed that a physiological response involving gene or 
transported activation may be responsible [Bayly, et al., 2001]. In addition, Wang et 
al. have demonstrated that for P. falciparum an exogenous source of folate may have 
a major role in determining resistance levels, and that this characteristic seems to be 
linked to DHFR alleles [Wang, et al., 1997b]. An alternative hypothesis is that sulpha 
drug uptake may simply be inhibited by competitive transport of folic acid into cells 
[Bayly, et al., 2001].  
 
The DHFR mutation Ala67Val has recently been reported from Japan [Takahashi, et 
al., 2002]. The occurrence of the same mutation in the Western Cape could either be 
indicative of spread of a particular strain, or more significantly may indicate selective 
pressure on the enzyme by the widespread use of trimethoprim. It was, however 
suggested that DHFR Ala67Val from P. jirovecii should not influence patient 
management as the mutation is not located in conserved gene regions and is not 
close to the active site [Takahashi, et al., 2002]. The detection of the novel DHFR 
mutation Arg59Gly located in the structural region of the enzyme may support the 
suggestion that the enzyme appears to be under selective pressure; however, the 
substitution is not located at a highly conserved position. Although the mutation 
CHAPTER 6           COTRIMOXAZOLE RESISTANCE DEVELOPMENT 
___________________________________________________________________ 
112
detected in the intron region of DHFR is not expected to have an influence on the 
enzymatic functions of DHFR, it may be of use in enhancing multilocus sequence 
typing. 
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CHAPTER 7 
 
CONCLUSIONS 
 
 
_______________________________ 
 
Laboratory diagnosis of PcP is difficult as there is currently no technique available for 
culturing the organism. In South Africa IF is presently the standard laboratory 
technique for diagnosis of PcP. However, there is a perception that the P. jirovecii IF 
method produces both false-positive and false-negative results. In this study 
molecular detection employing the PCR was evaluated and compared to IF. PCR 
primer selection has been shown to play a significant role in the diagnosis of PcP and 
therefore various primers and PCR techniques were evaluated for local strains / 
conditions [De Luca, et al., 1995]. Results obtained confirmed major discrepancies 
exist between primer / target combinations. Concordance between the nine PCR 
techniques evaluated ranged from 41.2% to 94.4%. Detection rates of the techniques 
differed substantially. Of the standard PCR techniques compared, detection was 
highest employing primers directed at the mtLSUrRNA gene in a nested reaction. 
The mtLSUrRNA gene target, on employing single-round PCR, remained the most 
readily detectable even in comparison to nested reactions directed at other genes.  
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Real-time PCR, with its sophisticated chemistry and detection platforms has been 
reported as having superior sensitivity and specificity when compared to standard 
techniques. However, the present study showed that mtLSUrRNA nested PCR 
detected P. jirovecii in 15% more clinical specimens than 5S real-time PCR, 
suggesting that real-time PCR may not be superior universally. While the practical 
advantages of shorter cycling times and the automated detection of PCR products do 
assist in rapid diagnosis, when employing nuclear 5S rRNA as gene target, it is at the 
expense of sensitivity.  
 
On analysis of quantitative data obtained with real-time PCR, no apparent factor 
related to organism / target concentration per specimen, explained the discrepant 
standard PCR (DHPS nested and mtLSUrRNA nested) and real-time (5S rRNA) 
results. This suggests that factors other than target copy number play a role in the 
detection limit of genes as targets in PCR techniques. The mtLSUrRNA nested PCR 
employed against local strains was the most sensitive technique, followed by 5S 
rRNA real-time PCR. The testing of known positive lung biopsies, although few in 
number, confirmed the value of mtLSUrRNA primers in the South African setting. The 
study emphasises the requirements for correct primer selection for the detection of P. 
jirovecii. 
 
As mtLSUrRNA nested PCR demonstrated the highest level of detection, results 
were compared to those obtained from routine IF staining. The correlation obtained 
was poor and prompted review of clinical records for discordant results. Both PCR 
and IF have the potential of producing false-positive and –negative results. It is 
therefore recommended they be performed in parallel and discrepant results 
assessed following investigation of further specimens together with the clinical 
presentation. 
 
Due to the perceived increase in incidence of PcP infections in Africa, and the recent 
provision of antiretroviral therapy, P. jirovecii should be monitored nationally 
employing complementary sensitive techniques that are suitable to South African 
strains. 
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Contrary to reports that identified S. pneumoniae, M. tuberculosis and CMV as the 
most prevalent co-infections associated with PcP, a higher than expected proportion 
of local patients were co-colonised with Gram-negative bacilli in the respiratory tract. 
The clinical significance of some of the gram-negative bacilli isolated was not known.  
 
With the high burden of TB in South Africa, and particularly the Western Cape, 
clinicians should be alerted to the possibility of M. tuberculosis and P. jirovecii co-
infection. Patients presenting with diffuse pneumonia should be investigated for both 
infections. In addition, when encountering TB patients unresponsive to therapy 
clinicians should be aware of the possibility of concurrent PcP, and it is 
recommended that both infections be treated when P. jirovecii can be demonstrated 
in the laboratory. If P. jirovecii is left untreated fulminant PcP may occur later as cell 
mediated immunity wanes in HIV-infected patients. 
 
Local patient populations may be predisposed to PcP due to factors other than HIV 
as it was seen that 45% of patients diagnosed with PcP by PCR were HIV-negative. 
Similarly, of TB patients with detectable P. jirovecii 9 / 23 were HIV-negative.  The 
high prevalence of PcP in HIV-negative non-immunosuppressed patients in the 
Western Cape region is of concern. It warrants further investigation into physiological 
and/or co-infection states that may predispose to P. jirovecii infection. It is clear that 
against a backdrop of the high prevalence of HIV and under-nourished communities, 
South Africa has not placed sufficient emphasis on detecting P. jirovecii, a situation 
that should be addressed with provision of funding for the necessary investigations. 
 
Based on sequence information and haplotype frequency data, genotype Eg was 
identified as the outgroup and most probable major ancestral haplotype and MRCA 
within the population group.  In support of the coalescence approach adopted, 
genotyping conducted worldwide has shown that the most frequently encountered 
ITS type is Eg. As certain genotypes, most notably type Eg are over represented, 
dissemination of specific ITS types, appears to be the major mode of propagation.  
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Linkage of 5.8S rDNA types with ITS types was not evident, indicating that different 
parental strains may harbour very similar ITS types or recombination may occur. 
Although the relevance of 5.8S rDNA sequence polymorphisms necessitates further 
investigations, as an adjunct to ITS regions they may assist in distinguishing strain 
types within populations with similar ITS genotypes. When considering the number of 
different ITS1 and ITS2 genotype combinations reported, recombination could well 
contribute to the degree of heterogeneity observed worldwide. 
 
Investigation into pathogen population dynamics should consider employing a 
coalescent approach to resolve molecular epidemiological questions as it provides a 
more realistic approach to intraspecies relatedness. 
 
A patient in the Western Cape was found to be infected with a strain of P.jirovecii 
with a double mutation Thr55Ala; Pro57Ser mutation in the DHPS gene. The double 
mutation is thought to signify the emergence of resistance to sulphonamides, as the 
mutations occur in a region of the DHPS gene involved in binding both substrate and 
sulphonamides. Although the mutations do not appear to be associated with therapy, 
they were recently reported as the first description of indicative sulphonamide 
resistance development in P. jirovecii from South Africa [Robberts, 2004a; Robberts, 
In Press]. Subsequently Zar et al. have reported similar mutations and frequencies in 
the DHPS gene of P. jirovecii from the Western Cape [Zar, et al., 2004]. The low rate 
of mutations in the Western Cape suggests that selective pressure on local strains 
may not as yet have reached levels as found in the USA or Europe, but rather 
resemble those of China [Kazanjian, et al., 2004]. To date there remains little 
evidence that such mutated strains impair clinical response to standard 
sulphonamide therapy. The detection of DHFR Ala67Val should not influence patient 
management as the mutation is not located in conserved gene regions and is not 
close to the active site.  
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Interestingly ITS type Eu, which to date has only been identified in South Africa 
[Robberts, et al., 2004b] was associated with the DHFR mutation Ala67Val. 
Furthermore, the DHFR genotype Arg59Gly and C278T (located in the intron) has 
not been previously described. The occurrence of these DHFR genotypes could have 
potential in the development of multilocus sequence typing of P. jirovecii. It is 
inappropriate when investigating clinical specimens, to link DHPS/DHFR types with 
ITS genotypes since more than one ITS genotype can be obtained from a patient 
with a single DHPS/DHFR type. 
 
Due to the perceived increase in incidence of PcP infections in Africa, and the recent 
provision of antiretroviral therapy, P. jirovecii should be monitored nationally for 
prevalence and susceptibility to co-trimoxazole employing appropriate techniques 
that are suitable to the South African strains. 
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